

Final Program
The International Society for Heart and Lung Transplantation
Twenty-Fifth Anniversary Meeting and Scientific Sessions
Philadelphia Marriott, Philadelphia, PA
April 6-9, 2005

**INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
BOARD OF DIRECTORS**

PRESIDENT

Alec Patterson, MD, St. Louis, MO

PAST PRESIDENT

Jon Kobashigawa, MD, Los Angeles, CA

PRESIDENT-ELECT

Mark L. Barr, MD, Los Angeles, CA

SECRETARY-TREASURER

Robert C. Bourge, MD, Birmingham, AL

DIRECTORS

Katherine J. Hoercher, RN, Cleveland, OH
Ronald H. Kerman, PhD, Houston, TX
Walter Klepetko, MD, Vienna, Austria
Stephen R. Large, FRCS, Cambridge, United Kingdom
Keith McNeil, FRACP, Brisbane, Australia
Mandeep R. Mehra, MD, New Orleans, LA
Soon J. Park, MD, San Francisco, CA
Hermann Reichenspurner, MD, PhD, Hamburg, Germany
Bruce R. Rosengard, MD, FRCS, Cambridge, United Kingdom
Heather J. Ross, MD, Toronto, ON, Canada
Steven A. Webber, MD, Pittsburgh, PA

EDITOR - JHLT

James K. Kirklin, MD, Birmingham, AL

TRANSPLANT REGISTRY DIRECTOR

Marshall I. Hertz, MD, Minneapolis, MN

MCSDB DATABASE DIRECTOR

Mario C. Deng, MD, New York, NY

STAFF

Amanda W. Rowe, Executive Director
Phyllis Glenn, Director of Membership Services
Lisa Edwards, Director of Meetings
LeeAnn Mills, Director of Operations

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

www.ishlt.org

ishlt@ishlt.org

SCIENTIFIC PROGRAM COMMITTEE

Shaf Keshavjee, MD, FRCSC, Toronto, ON, Canada, Program Chair
Alec Patterson, MD, St. Louis, MO, President
Mark L. Barr, MD, Los Angeles, CA
Gerald J. Berry, MD, Stanford, CA
Annette Boehler, MD, Zurich, Switzerland
Susan M. Chernenko, MN, Toronto, Canada
Maryann R. Chrisant, MD, Philadelphia, PA
John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom
Duane Davis, MD, Durham, NC
Thomas J. Dengler, MD, Heidelberg, Germany
Fabienne Dobbels, MSc, Leuven, Belgium
Howard J. Eisen, MD, Philadelphia, PA
Marc Estenne, MD, Brussels, Belgium
Marshall I. Hertz, MD, Minneapolis, MN
James K. Kirklin, MD, Birmingham, AL
Robert L. Kormos, MD, Pittsburgh, PA
Kenneth R. McCurry, MD, Pittsburgh, PA
Mandeep R. Mehra, MD, New Orleans, LA
Jonathan B. Orens, MD, Baltimore, MD
Robert C. Robbins, MD, Stanford, CA
Joseph G. Rogers, MD, Durham, NC
Bruce L. Rosengard, MD, FRCS, Cambridge, United Kingdom
Gregory I. Snell, FRACP, MBBS, Prahran, Australia
Martin Struber, MD, Hannover, Germany
Thomas K. Waddell, MD, Toronto, ON, Canada
Lori J. West, MD, DPhil, Toronto, ON, Canada

ABSTRACT REVIEWERS

Nancy M. Albert, MSN, Chesterland, OH
Selim M. Arcasoy, MD, New York, NY
Abbas Ardehali, MD, Los Angeles, CA
Robert M. Aris, MD, Chapel Hill, NC
Carla C. Baan, MD, Rotterdam, The Netherlands
Wayne D. Babcock, MD, Modesto, CA
Peter Bergin, MBBS, FRAC, Melbourne, Australia
Sangeeta M. Bhorade, MD, Chicago IL
Roberta C. Bogaev, MD, San Antonio, TX
Dominic C. Borie, MD, PhD, Stanford, CA
Robert J. Boucek, Jr., MD, St. Petersburg, FL
Robert C. Bourge, MD, Birmingham, AL
Caron L. Burch, RN, MSN, FNP, Manhattan Beach, CA
Michael Burch, MD, London, United Kingdom
Margaret Burke, MB, MRCPPath, Harefield, Middlesex, United Kingdom
Clifford Chin, MD, Palo Alto, CA
Jason D. Christie, MD, Philadelphia, PA
David K.C. Cooper, MD, PhD, FRCS, Pittsburgh, PA
Paul A. Corris, MD, Newcastle Upon Tyne, United Kingdom
Maria G. Crespo-Leiro, MD, La Coruna, Spain
Hiroshi Date, MD, Okayama, Japan
G. William Dec, MD, Boston, MA
Sabine M. DeGeest, RN, PhD, NFESC, Basel, Switzerland
Marc DePerrot, MD, Le Plessis-Robinson, France
Mary Amanda Dew, PhD, Pittsburgh, PA

Debi H. Dumas-Hicks, RN, BS, CCTC, Metairie, LA
Niloo M. Edwards, MD, Madison, WI
Jim J. Egan, MD, Dublin, Ireland
Gregory A. Ewald, MD, St. Louis, MO
Albert Faro, MD, Gainesville, FL
David S. Feldman, MD, Columbus, OH
Roberto Fiocchi, MD, PhD, Bergamo, Italy
Stefan Fischer, MD, Hannover, Germany
Michael C. Fishbein, MD, Los Angeles, CA
Eli Gabbay, FRACP, Perth, Australia
Edward R. Garrity, Jr., MD, Maywood, IL
James F. George, PhD, Birmingham, AL
Allan R. Glanville, MD, FRACP, Sydney, Australia
Martin J. Goddard, MD, Cambridge, United Kingdom
F. Kate Gould, MB, BS, Newcastle Upon Tyne, United Kingdom
Kathleen L. Grady, RN, PhD, Chicago, IL
Eduardo G. Gronda, MD, Milan, Italy
Elizabeth Hammond, MD, Salt Lake City, UT
Paul J. Hauptman, MD, St. Louis, MO
Marshall I. Hertz, MD, Minneapolis, MN
Roland Hetzer, MD, PhD, Berlin, Germany
Stephan W. Hirt, MD, Kiel, Germany
Daphne T. Hsu, MD, New York, NY
Shahid Husain, MD, Pittsburgh, PA
Mariell Jessup, MD, Philadelphia, PA
Frances L. Johnson, MD, Baltimore, MD
Walter Klepetko, MD, Vienna, Austria
Masashi Komeda, MD, PhD, Kyoto, Japan
Robert M. Kotloff, MD, Elkins Park, PA
Tom Kotsimbos, MD, Melbourne, Australia
Christiane Kugler, MSN, RN, Hannover, Germany
Guenther Laufer, MD, Innsbruck, Austria
Robert D. Levy, MD, FRCP, Vancouver, Canada
Robert B. Love, MD, Madison, WI
Charles C. Marboe, MD, New York, NY
Bruce McManus, MD, PhD, Vancouver, BC, Canada
Bruno M. Meiser, MD, Munich, Germany
Eric N. Mendeloff, MD, Dallas, TX
Bryan F. Meyers, MD, St. Louis, MO
Nader Moazami, MD, St. Louis, MO
Michael S. Mulligan, MD, Seattle, WA
Srinivas Murali, MD, Pittsburgh, PA
Yoshifumi Naka, MD, PhD, New York, NY
Linda Ohler, RN, MSN, FAAN, Arlington, VA
Charlie G. Orosz, PhD, Columbus, OH
Francis D. Pagani, MD, PhD, Ann Arbor, MI
Scott M. Palmer, MD, Durham, NC
Francesco Parisi, MD, Rome, Italy
Soon J. Park, MD, San Francisco, CA
Si M. Pham, MD, Miami, FL
Richard N. Pierson, III, MD, Baltimore, MD
Branislav Radovancevic, MD, Houston, TX
Vivek Rao, MD, PhD, Toronto, ON, Canada
Hermann L. Reichenspurner, PhD, Hamburg, Germany
Nancy L. Reinsmoen, PhD, dip ABHI, Durham, NC
Richard J. Rodeheffer, MD, Rochester, MN

Heather J. Ross, MD, Toronto, ON, Canada
Robert E. Shaddy, MD, Salt Lake City, UT
Lianne G. Singer, MD, FRCPC, Toronto, ON, Canada
Joshua Sonett, MD, New York, NY
Randall C. Starling, MD, Cleveland, OH
Hans Ulrich Stempfle, MD, Munich, Germany
Marc Stern, MD, Suresnes, France
Thoralf M. Sundt, MD, Rochester, MN
Stuart C. Sweet, MD, PhD, St. Louis, MO
George Tellides, MD, New Haven, CT
Elbert P. Trulock, MD, St. Louis, MO
Steven S.L. Tsui, MD, Cambridge, United Kingdom
Patricia A. Uber, PharmD, New Orleans, LA
Adrian B. Van Bakel, MD, PhD, Charleston, SC
Dirk Van Raemdonck, MD, PhD, Leuven, Belgium
Andres Varela, MD, Madrid, Spain
Federico Venuta, MD, Rome, Italy
Geert M. Verleden, MD, PhD, Leuven, Belgium
Erik A.M. Verschuuren, MD, Groningen, The Netherlands
John Wallwork, MBChB, FRCS, Cambridge, United Kingdom
Richard D. Weisel, MD, Toronto, ON, Canada
George M. Wieselthaler, MD, Vienna, Austria
David S. Wilkes, MD, Indianapolis, IN
Gayle L. Winters, MD, Boston, MA
Gordon D. Wu, MD, Los Angeles, CA
James B. Young, MD, Cleveland, OH
Samuel A. Yousem, MD, Pittsburgh, PA
Adriana Zeevi, PhD, Pittsburgh, PA
Andreas O. Zuckermann, MD, Vienna, Austria

DEVELOPMENT COMMITTEE

Mandeep R. Mehra, MD, Co-Chair
Leslie W. Miller, MD, Co-Chair
Alec Patterson, MD
Jon Kobashigawa, MD
Mark L. Barr, MD

EDUCATION COMMITTEE

Mandeep R. Mehra, MD, Chair
Shaf Keshavjee, FRCSC, MD
Alec Patterson, MD
Mark L. Barr, MD
John Dark, MD, FRCS
TBD

FINANCE COMMITTEE

Robert C. Bourge, MD, Treasurer and Chair
Mark L. Barr, MD, President-Elect
James K. Kirklin, MD
Leslie W. Miller, MD

GRANTS AND AWARDS COMMITTEE

Mark L. Barr, MD, Co-Chair
Susan Stewart, FRCPath, Co-Chair

HISTORY AND ARCHIVES COMMITTEE

Hector Ventura, MD, Chair
David KC Cooper, MD, PhD
Sir Terence English, FRCS
Sharon Hunt, MD
James K. Kirklin, MD
Jon Kobashigawa, MD
Mandeep Mehra, MD
Alec Patterson, MD

NOMINATING COMMITTEE

Jon Kobashigawa, MD, Chair
Alec Patterson, MD
Stephan Schueler, MD
James Young, MD
Anne Keogh, MD

REGISTRY EXECUTIVE COMMITTEE

Marshall I. Hertz, MD, Medical Director
Mark M. Boucek, MD, Associate Director for Pediatric Transplantation
Mario C. Deng, Medical Director, Mechanical Circulatory Support Device Database
Leah B. Edwards, PhD, Associate Director for Data Analysis
Berkeley M. Keck, RN, MPH, Associate Director for Database Management
David O. Taylor, MD, Associate Director for Heart Transplantation

Elbert P. Trulock, MD, Associate Director for Lung Transplantation

SCIENTIFIC COUNCIL CHAIRS

Cell Transplantation/Tissue Engineering

Doris Taylor, PhD, Chair

Bruce Rosengard, MD, Board Liaison

Heart Failure and Transplant Medicine

Mariell Jessup, MD, Co-Chair

Edoardo Gronda, MD, Co-Chair

Mandeep Mehra, MD, Board Liaison

Infectious Diseases

F. Kate Gould, MBBS, Chair

Mechanical Circulatory Support Devices

Stephen Large, FRCS, Co-Chair

Frank Pagani, MD, Co-Chair

James K. Kirklin, MD Board Liaison

Nursing and Social Sciences

Corby D'Amico, RN, MN, Co-Chair

Michael G. Petty, MS, RN, CCNS, Co-Chair

Katherine Hoercher, RN, Board Liaison

Pathology and Basic Science

Susan Stewart, FRCPath, Co-Chair

James George, PhD, Co-Chair

Ron Kerman, PhD, Board Liaison

Pediatric Transplantation

Michael Burch, MD, Co-Chair

MaryAnne Chrisant, MD, Co-Chair

Francesco Parisi, MD, Co-Chair

Stuart Sweet, MD, PhD, Co-Chair

Lori West, MD, DPhil, Co-Chair

Steven Webber, MB, ChB, Board Liaison

Pulmonary Arterial Hypertension

Christopher McGregor, MD, FRCS, Co-Chair

Jean-Luc Vachiery, MD, Co-Chair

Keith McNeil, MD, Board Liaison

Pulmonary Transplantation

Allan Glanville, MD, FRACP, Co-Chair

Jonathan Orens, MD, Co-Chair

Keith McNeil, MD, Board Liaison

ISHLT PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schuler, MD
2003-2004	Jon Kobashigawa, MD

PAST PROGRAM CHAIRS

1988 Los Angeles, CA
John C. Baldwin, MD

1990 San Diego, CA
D. Glenn Pennington, MD

1991 Paris, France
John B. O'Connell, MD

1992 San Diego, CA
Eric A. Rose, MD

1993 Boca Raton, FL
Maria Rosa Costanzo, MD

1994 Venice, Italy
John Wallwork, MBChB, FRCS

1995 San Francisco, CA
Leslie W. Miller, MD

1996 New York, NY
William A. Baumgartner, MD

1997 London, England
Stephan Schueler, MD

1997 Chicago, IL
James B. Young, MD

1998 San Francisco, CA
Mark L. Barr, MD

1999 Osaka, Japan
Jon Kobashigawa, MD

2000 Vancouver, Canada
David O. Taylor, MD

2001 Washington, DC
Robert C. Robbins, MD

2002 Vienna, Austria
Bruce R. Rosengard, MD

2003 San Francisco, CA
Mandeep Mehra, MD

ISHLT AWARD RECIPIENTS

LIFETIME ACHIEVEMENT AWARD

2004 Sir Magdi Yacoub, MD
1999 Keith Reemtsma, MD
1996 Norman Shumway, MD

LIFETIME SERVICE AWARD

1997 Jacques Losman
1996 Michael Kaye

ISHLT/ROCHE TRANSPLANT CAREER DEVELOPMENT AWARD

2002 Anthony Azakie, MD
2000 Gordon D. Wu, MD

ISHLT/NOVARTIS TRANSPLANT CAREER DEVELOPMENT AWARD

2004 Allan M. Ramirez, MD

ISHLT/ROCHE TRANSPLANT RESEARCH FELLOWSHIP GRANT

2004 Kendra N. Taylor, PhD
2003 Felix Fernandez, MD
2002 Ruediger Hoebelt, MD
2001 Matteo Vatta, PhD
2001 Arnar Geirsson, MD
2000 Christopher H. Wigfield, FRCS
1999 Donald Wong, PhD
Sivasai Krovvidi, PhD
1998 Kelly S.A. Blair, MD
A.M. El Gamel, MD
1997 Jonathen Chen, MD
Anne K. Raisanen-Sokolowski, MD
1996 Tuija S. Ikonen, MD

ISHLT/NOVARTIS TRANSPLANT RESEARCH FELLOWSHIP GRANT

2000 Richard S. Lee, MD
1999 George Juang, MD
Satoshi Saito, MD
1998 Margaret L. Schwarze, MD

ISHLT/FUJISAWA TRANSPLANT RESEARCH FELLOWSHIP GRANT

2004 Christian A. Gleissner, MD
2003 Ewout J. van den Bos, MD
2004 Alyssa M. Krasinskas, MD

ISHLT/ACTELION TRANSPLANT RESEARCH DEVELOPMENT AWARD

2004 Tsuyoshi Shoji, MD, PhD

ISHLT/XDX TRANSPLANT RESEARCH DEVELOPMENT AWARD

2004 Monica Zwierzchoniewska, MD

ISHLT/WYETH-AYERST TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Christine L. Lau, MD

ISHLT/ORTHO BIOTECH TRANSPLANT RESEARCH FELLOWSHIP GRANT

1997 Owen T. Lawrence, MD
1996 Andrew F. Pierre, MD
1995 Frances L. Johnson, MD

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Scott D. Ross, MD

ISHLT NURSING RESEARCH GRANT

2004 Deidre E. Logan, PhD
2003 Diane H. Leloudis, RN, MSN
2003 Janet E. Madill, PhD
2002 Annette J. De Vito Dabbs, RN, MN, PhD
2001 Lynn Doering, RN, DNSc
2000 Nancy M. Albert, MSN, RN
1999 Jeanne Salyer, PhD
1998 Katherine St. Clair, RN, MSN
1997 Eileen Collins, RN, PhD

CAVES AWARD

2004 M.D. Peterson, MD
2003 Sigrid Sandner, MD
2002 Peter Blaha, MD
2001 Alexander S. Krupnick, MD
2000 Michael P. Fischbein, MD
1999 Joerg Koglin, MD
1998 Carla C. Baan, MD
1997 Simon D. Eiref, MD
1996 Moninder S. Bhabra, MD
1995 Elizabeth A. Davis, MD
1994 Jobst Winter, MD
1994 Alain Chapelier, MD
1993 David Marshman, MD
1992 David P. Kapelanski, MD
1991 A. Jiminez, MD
1990 Andres J. Duncan, MD
1989 A.M. Wood, MD
1988 Charles D. Fraser, Jr., MD
1987 Wim Van Der Bij, MD
1986 Stuart J. Knechtle, MD
1985 Michael A. Breda, MD
1984 Hermann Reichenspurner, MD
1983 Robbin G. Cohen, MD

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 31.25 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This program has been approved for 33 Category 1 Continuing Education Points for Transplant Coordinators (CEPTs) by the American Board of Transplant Coordinators (ABTC).

This program has been approved for ___ contact hours; CERP Category A by the American Association of Critical Care Nurses (AACN).

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their need.

Goals

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives

At the conclusion of this meeting, participants should be able to:

- * understand emerging developments in transplantation, including the latest in the role of tolerance and the innate immune system
- * understand the potential of molecular diagnostic tools in the detection of transplant related injury and the diagnosis of rejection
- * understand, identify, prevent, and treat post-transplant complications of immunosuppression including infections, renal dysfunction, and post-transplant malignancy
- * compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
- * understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
- * compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
- * describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of

patients for transplant therapy

- * understand current animal models of basic science immunology and their application to the transplant setting

- * evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation

- * understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection

- * identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation

- * evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, cell and tissue transplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation

- * evaluate and implement the use of alternative methods of monitoring and treating rejection

- * identify, prevent, and treat donor-transmitted diseases

Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers declaring such affiliations are shown below. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

FACULTY/PRESENTATION	COMPANY AFFILIATION	RELATIONSHIP
Vincent Armenti	Novartis, Fujisawa, Roche, Wyeth	Grant Research
Robin Avery	Roche, MedImmune, Schemy Plough	Co-Investigator
Daniel Bernstein	XDx	Consultant
John Boehmer	Arrow International	Consultant
Sangeeta M. Bhorade	Fujisawa	Research Grant Support
Steven Bolling	Orois	Financial Interest
Charles B. Canter	Novartis	Research Support
John V. Conte	Chase Medical Co.	Consultant
Jack Copeland	SynCardia Inc.	Financial Interest
Jacqueline Cornelissen	Novartis	Unrestricted Educational Grant
Paul Corris	Novartis, Roche, Chiron	Research Support
Lisa A. Coscia	Novartis, Fujisawa, Roche, Wyeth	Research Support
Sekhar Dharmarajan	Dompe	Consultant
David B. Dyke	Thoratec	Training Course Lecturer
Howard J. Eisen	Novartis, XDx	Consultant, Grant Support
Alex Farivar	Roche	Subsidized Research
Ronald Freudenberger	Medtronic	Research/Speaker/Consultant
Allan Glanville	Roche, Novartis, Mayre, Fujisawa	Advisory Board/Grant Support
Roland Hetzer	Berlin Heart	Consultant
Renee Howser	World Heart	Employee
Mariell Jessup	Acorn	Advisory Board
Shaf Keshavjee	XDx	Investigator, Scientific Advisory Committee
Jon Kobashigawa	Fujisawa, Roche, Novartis	Research Grants
Richard Kowalski	Cylex	Employee
Luke Lamers	Bristol Myers, Squibb Med Imag.	Grant Support
Katherine Lietz	La Roche Laboratories	Research Grants
Charles C. Marboe	XDx	Consultant
Mandeep Mehra	XDx	Consultant
Bruno Meiser	Roche	Consultant
Santiago Miriuka	Wyeth Canada	Research Grant
Robert Montgomery	MedImmune, Fujisawa	Speaker, Research Funding
Randall E. Morris	Novartis	Employee
W. Robert Morrow	Roche	Grant Support
Johannes Mueller	Berlin Heart	Board of Directors
John C. Mullen	Hoffman La Roche Ltd	Research Support: Grant in Aid
Tofy Mussivand	World Heart	Founder and Consultant
Walter E. Pae, Jr.	Arrow International	Research Support
Heather Ross	Novartis, Fujisawa, Wyeth	Consultant, Research Funding
Mitchell Saltzberg	CHF Solutions	Consultant
Leslie M. Shaw	Roche, Novartis	Grant Support, Scientific Advisory Board
Randall Starling	XDx	Research Support
Hans U. Stempfle	Brallo-Byk Guiden GMBH	Research Grant
Gabor Szabo	Inotek Pharmaceuticals	Consultant

Hiroyuki Tsukui
Hannah Valantine
Jaime Villanueva
Clyde W. Yancy
James B. Young
Andreas Zuckerman

Thoratec
Novartis
FujiSawa
Scios
World Heart
Roche, Genzyme

Thomas Burnett VAD Fellow
Consultant, Clinical Research
Grant
Research/Consultant/Speaker
Consultant, Research Support
Lecturer, Grant Support

The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of toward this Twenty Fifth Anniversary Meeting and Scientific Sessions

GOLD PARTNER

Roche
Fujsawa
Novartis

SILVER PARTNER

Chiron
XDx

THIS PAGE IS FOR Marriott MAP(S)

HOLD 4 PAGES FOR MEETING TEMPLATE

SCIENTIFIC PROGRAM

All meetings and activities will take place at the Philadelphia Marriott unless otherwise specified. All papers will be presented in English.

WEDNESDAY, APRIL 6, 2005

7:00 AM-1:00 PM

ISHLT Board of Directors Meeting (Room 403)

8:00 AM-6:00 PM

Speaker Ready Room Open (Room 502)

8:00 AM-6:00 PM

Press Office Open (Room 404)

10:00 AM-6:00 PM

Registration Desk Open (Ballroom Foyer)

NOON-8:00 PM

Exhibitor Set Up (Franklin Hall)

NOON-8:00 PM

Poster Display Session 1 Set Up (Franklin Hall)

12:30 PM-2:00 PM

SATELLITE SYMPOSIUM 1

Cutting Edge Concepts in Heart Transplantation (Salons G-L)

Supported by an Educational Grant From Roche

Chairs: Randall C. Starling, MD and Thomas J. Dengler, MD

12:30 PM **Cardiac Allograft Vasculopathy: Where Are We in 2005?** Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN

12:50 PM **When and Why Should we Use CNI and Steroid Sparing Strategies in Heart Transplantation?** Bruno Meiser, MD, University of Munich/Grosshadern, Munich, Germany

1:10 PM **Is There a Role for IL2R Induction or T-Cell Depletion in Heart Transplantation?** Andreas O. Zuckermann, MD, University of Vienna, Vienna, Austria

1:30 PM **What is the Current Role of Therapeutic Drug Monitoring in Heart Transplantation?** Leslie M. Shaw, PhD, University of Pennsylvania, Philadelphia, PA

1:45 PM **Panel Discussion**

12:30 PM-3:00 PM

SATELLITE SYMPOSIUM 2

Molecular Diagnostics in Heart and Lung Transplantation (Salons ABF)

Supported by an Educational Grant From XDx, Inc.

Chairs: Mandeep R. Mehra, MD and Thomas K. Waddell, MD

12:30 PM **Fulfilling Unmet Needs in Thoracic Transplantation**, Mandeep R. Mehra, MD, Oschner Medical Institutions, New Orleans, LA

12:50 PM **Update on the CARGO Trial**, Howard J. Eisen, MD, Hahnemann Hospital, Philadelphia, PA

1:10 PM **Practical Applications of Molecular Testing in Cardiac Transplantation**, Hannah Valentine, MD, Stanford University Medical Center, Stanford, CA

1:30 PM **Gene Expression Analysis in the Prediction of Primary Graft Dysfunction and LARGO Trial Update**, Shaf Keshavjee, FRCSC, MD, Toronto General Hospital, Toronto, Canada

1:50 PM **Gene Expression Monitoring of Acute and Chronic Lung Rejection**, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN
2:10 PM **New Protein Biomarkers of Lung Rejection**, Christine Wendt, MD, University of Minnesota, Minneapolis, MN
2:30 PM **Panel Discussion**

12:30 PM-3:00 PM

SATELLITE SYMPOSIUM 3

Transplant Immunobiology (Salon E)

Sponsored by an Educational Grant From Fujisawa

Chairs: Ronald H. Kerman, PhD, and Adriana Zeevi, PhD

12:30 PM **Antibody and Cell-Mediated Immunity in Heart and Lung Transplant Recipients**, Ronald H. Kerman, PhD, University of Texas Medical School, Houston, TX

12:50 PM **The Virtual Crossmatch: Defining Unacceptable Donor Antigens**, Nancy Reinsmoen, PhD, Duke University Medical Center, Durham, NC

1:10 PM **Humorally-Mediated Lung Injury after Transplantation**, Cynthia M. Magro, MD, Ohio State University, Columbus, Ohio

1:30 PM **Significance of Non-HLA Antibodies in Heart and Lung Transplantation**, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

1:50 PM **Transplantation of the Highly Sensitized Recipient**, Robert A. Montgomery, MD, DPhil, The Johns Hopkins University, Baltimore, MD

2:10 PM **Immunosuppressive Management of the Highly Sensitized Patient**, Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN

2:30 PM **Panel Discussion**

12:30 PM-3:00 PM

SATELLITE SYMPOSIUM 4

Managing the Transition from Child to Adult (Salon CD)

Chairs: Mark Boucek, MD and Linda Addonizio, MD

12:30 PM **Managing the Transition from Pediatrics to Adult Medicine for Grown-Up Patients**, Gary Webb, MD, University of Pennsylvania, Philadelphia, PA

1:00 PM **Psychosocial Challenges of Transitioning Patients**, Fabienne Dobbels, MSc, Katholieke University, Leuven, Belgium

1:30 PM **Pregnancy Post-Transplant**, Vincent T. Armenti, MD, Temple University School of Medicine, Philadelphia, PA

2:00 PM **Re-Transplantation for Grown-Up Pediatric Thoracic Organ Recipients: The Pediatric and Adult Perspectives**, Linda J. Addonizio, MD, Columbia Presbyterian Medical Center, New York, NY and Asif Hasan, MD, Freeman Hospital, Newcastle, United Kingdom

2:30 PM **Panel Discussion**

2:00 PM-2:15 PM

Coffee Break (Ballroom Pre-Function)

2:15 PM-6:00 PM

SATELLITE SYMPOSIUM 5A

Cardiopulmonary Assist Devices: Looking Beyond the Horizon (Salon G-L)

Chairs: Daniel Loisance and Stephen Large, FRCS

2:15 PM **Minimally Invasive Cardiac Assist Technology**, Steven F. Bolling, MD, University of Michigan Hospital, Ann Arbor, MI

2:35 PM **Downsizing Cardiac Assist Devices: Pediatric Applications**, Roland Hetzer, German Heart Institute, Berlin, Germany

2:55 PM **The Artificial Lung: Assist to Replacement**, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD

3:15 PM Revolutionary Designs in Blood Pumps

3:15 PM **Ventracor**, Donald S. Esmore, MBBS, FRACS, Alfred Hospital, Melbourne, Australia

3:25 PM **Heartmate III**, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

3:35 PM **DeBaKey VAD**, George M. Weiselthaler, MD, University of Vienna, Vienna, Austria

3:45 PM **Jarvik Heart**, O. Howard Frazier, MD, Texas Heart Institute, Houston, TX

3:55 PM Discussion

4:15 PM Break

SATELLITE SYMPOSIUM 5B

The Final Technology Solutions for End Stage Congestive Heart Failure (Salon G-L)

Chairs: Jack G. Copeland, MD and Leslie W. Miller, MD

4:30 PM **The Total Artificial Heart: Do We Have a Product?** O. Howard Frazier, MD, Texas Heart Institute, Houston, TX

4:50 PM **Destination LVAD Therapy: Contemporary Challenges and Results**, James W. Long, MD, PhD, LDS Hospital/Salt Lake Cardiovascular & Thoracic Surgery Associates, Salt Lake City, UT

5:10 PM **Alternative List Heart Transplantation Versus Destination LVADs: Is It Time for a Randomized Trial?** James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL

5:30 PM **Will All of Our Problems be Solved by Cells?** Dick Wiesel, MD,

5:50 PM Discussion

3:00 PM-3:30 PM

Coffee Break (Ballroom Pre-Function)

3:30 PM-6:00 PM

SATELLITE SYMPOSIUM 6

Interactions Between Innate and Acquired Immunity in Transplantation (Salons ABF)

Chairs: Mingyao Liu, MD and Fadi Lakkis, MD

3:30 PM **Danger Signals**, Polly Matzinger, PhD, National Institutes of Health, Bethesda, MD

4:00 PM **TLR Signalling in Minor and Major MHC Mismatch**, Daniel R. Goldstein, MD, Yale University School of Medicine, New Haven, CT

4:30 PM **TLR4 Polymorphisms in Lung Transplantation**, Scott M. Palmer, MD, Duke University, Durham, NC

5:00 PM **Adaptive Immune Responses Enhance Innate Immunity in Cardiac Transplantation**, David Perkins, MD, PhD, Brigham and Women's Hospital, Boston, MA

5:30 PM Panel Discussion

3:30 PM-6:00 PM

SATELLITE SYMPOSIUM 7

OB/BOS State of the Art (Salon E)

Chairs: Marc Estenne, MD and Paul Corris, MD

Pathogenesis

3:30 PM **Airway Remodeling: Lessons Learned from Asthma and COPD**, James C. Hogg, FRCP, St. Paul's Hospital, Vancouver, Canada

3:45 PM **Alloimmune Mechanisms: Innate Immunity, Humoral Immunity, De Novo Anti HLA Antibodies**, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, IN

4:00 PM **Non-alloimmune Mechanisms: Infectious**, Glen Westall, MBBS, FRACP, Alfred Hospital, Prahan, Australia

4:15 PM **Non-alloimmune Mechanisms: Non-infectious**, Annette Boehler, MD, University Hospital Zurich, Zurich, Switzerland

Treatment/Prevention

4:30 PM **Fundoplication**, R. Duane Davis, MD, Duke University Medical School, Durham, NC

4:45 PM **Azithromycin**, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD

5:00 PM **MMF – the European Trial: Comparison with Other Solid Organs**, Paul A. Corris, MB, FRCP, Freeman Hospital, Newcastle, United Kingdom

5:15 PM **Sirolimus – Everolimus**, Gregory I. Snell, FRACP, MBBS, Alfred Hospital, Prahran, Australia

5:30 PM **Therapeutic Drug Monitoring**, Allan R. Glanville, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

5:45 PM **Discussion**

3:30 PM-6:00 PM

SATELLITE SYMPOSIUM 8

Growing Older With A Transplant (Salon CD)

Chairs: Fabienne Dobbels, MSc, and Susan M. Chernenko, MN

3:30 PM **The New Generation of Older Transplant Recipients: Facts and Features**, Lorraine Evangelista, RN, PhD, University of California at Los Angeles, Los Angeles, CA

3:55 PM **New Approaches to the Older Patient in Transplantation: Shifting From Acute Care Models Towards Chronic Disease Management**, Sabina M. De Geest, RN, PhD, NFESC, University of Basel, Basel, Switzerland

4:20 PM **Psychosocial Functioning in Older Transplant Recipients: The Quantity/Quality Paradox**, Debi H. Dumas-Hicks, RN, PhD, NFESC, Ochsner Medical Institutions, New Orleans, LA

4:45 PM **Adherence in the Older Recipient: Grey Hair for the Health Care Professional?** Carol S. Stille, PhD, University of Pittsburgh, Pittsburgh, PA

5:10 PM **Ethical Dilemmas in Older Recipients – Are We Doing Them Justice?** Linda Wright, Toronto General Hospital, Toronto, Canada

5:35 PM **Discussion**

6:00 PM-7:00 PM

ISHLT Registry Executive Committee Meeting (Room 412)

6:30 PM-7:30 PM

Pediatric Transplantation Scientific Council Meeting (Salon ABF)
Mechanical Circulatory Support Council (Salon E)

6:30 PM-8:30 PM

Nursing and Social Sciences Council Research Seminar: A Clinician's Guide to Conducting and Publishing Research (Salon CD)

Overview of research questions and designs that dovetail with busy clinical practice

Strategies to minimize costs and maximize quality of data collection

Obtaining IRB approval and informed consent

Strategies for writing high quality, publishable abstracts

Strategies for preparing and submitting publishable manuscripts

8:30 PM-9:30 PM

Nursing and Social Sciences Council Meeting (Salon CD)

THURSDAY, APRIL 7, 2005

6:00 AM-6:00 PM

Speaker Ready Room (Room 502)

7:00 AM-8:00 AM

Morning Coffee/Visit Exhibits (Franklin Hall)

7:00 AM-10:00 AM
Poster Display Set-Up continued (Franklin Hall)

7:00 AM-5:30 PM
Registration Desk Open (Ballroom Foyer)

7:00 AM-6:00 PM
Press Office Open (Room 404)

7:00 AM-6:30 PM
Exhibits Open (Franklin Hall)

7:45 AM-10:00 AM
OPENING PLENARY SESSION (Salons G-L)
Moderators: Alec Patterson, MD and Shaf Keshavjee, MD

7:45 AM **Welcome**, Alec Patterson, MD, ISHLT President, Washington University, St. Louis, MO

7:50 AM **Scientific Program Report**, Shaf Keshavjee, FRCSC, MD, ISHLT Program Chair, Toronto General Hospital, Toronto, Canada

8:00 AM **Registry Report**, Marshall I. Hertz, MD, Registry Medical Director, University of Minnesota, Minneapolis, MN

8:30 AM **Invited Lecture: Molecular Diagnostics: State of the Art and Promise of the Future**, Manikkam Suthanthiran, MD, New York Hospital/Cornell Medical Center, New York, NY

9:00 AM **Invited Lecture: Bolivia 6000 Meters: Achieving New Heights After Heart Transplant**, Heather Ross, MD, University of Toronto, Toronto, Canada and Sylvain Bedard, Montreal, Canada

9:15 AM **Invited Lecture: Bridges Between Innate and Acquired Immunity in Transplantation**, Fadi Lakkis, MD, Yale University, New Haven, CT

10:00 AM-10:30 AM
Coffee Break/Visit Exhibits/Visit Posters (Franklin Hall)

10:30 AM-NOON
CONCURRENT SESSION 1
Prognosis After Heart Transplantation: Survival is not Enough (Salon G-L)
Moderators: Richard Rodeheffer, MD and James B. Young, MD

10:30 AM (1) Left Ventricular Systolic Dysfunction Is an Independent Predictor for Cardiac Death in Heart Transplant Recipients; K. Lietz, J.M. Herre,^{1,2} Cardiovascular Division, Eastern Virginia Medical School, Norfolk, VA; ²Sentara Cardiovascular Research Institute, Norfolk, VA

10:45 AM (2) Early Drop of Creatinine Clearance Is a Strong Predictor of Long-Term Renal Dysfunction, Chronic Dialysis and Mortality After Heart Transplantation; M. Cantarovich, N. Giannetti, M.D. Edwardes, G. Fontaine, R. Cecere, Transplantation, McGill University Health Center, Montreal, Quebec, Canada

11:00 AM (3) Relevance of Soluble HLA Levels for Patients Survival After Heart Transplantation; V. Rebmann, M. Zeth,¹ A. Dolar,¹ H.G. Jakob,² H. Grosse-Wilde,¹ Institute of Immunology, University Hospital of Essen, Essen, Germany; ²Department of Thoracic and Cardiovascular Surgery, University Hospital of Essen, Essen, Germany

11:15 AM (4) Relationship Between Objective and Subjective Variables of Functional Capacity After Heart Transplantation; C. Bara,¹ C. Kugler,¹ E. Guetzlaff,² K. Schallhorn,² M. Strueber,¹ A. Haverich,¹ U. Tegtbur,² Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; ²Sportsmedicine, Hannover Medical School, Hannover, Germany

11:30 AM (5) A Strategy of Aggressive Steroid Weaning and Routine Alendronate Therapy on Reducing Bone Loss Post Cardiac Transplant; G. Yong, H. Hayes,¹ G. O'Driscoll,¹ Cardiac Transplant Unit, Royal Perth Hospital, Perth, WA, Australia

11:45 AM (6) Cardiovascular Deaths in Heart Transplant Recipients: Does the Rejection Pattern Matter? A.G. Kfoury, J. Stehlik, D.G. Renlund, G.L. Snow, B. Dabbas, J.C. Stringham, E.M. Gilbert, M.E.H. Hammond, U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

10:30 AM-NOON
CONCURRENT SESSION 2

Beyond Quality of Life: When Nursing and Psychosocial Sciences Meet Behavior Medicine (Salon ABF)

Moderators: Michael G. Petty, MS, RN, CCNS and Bronwyn J. Levvey, RN

10:30 AM (7) Effect of Exercise Training on Weight Control in Patients With Chronic Heart Failure; L.S. Evangelista,¹ K. Dracup,² L.V. Doering,¹ M.A. Hamilton,³ ¹School of Nursing, University of California Los Angeles, Los Angeles, CA; ²School of Nursing, University of California San Francisco, San Francisco, CA; ³Ahmanson Cardiomyopathy Center, University of California Los Angeles Medical Center, Los Angeles, CA

10:45 AM (8) Hoping for the Best While Preparing for the Worst: Communication About End-of-Life Planning in Heart Transplant Programs; J. Yager,¹ A. Hernandez,¹ J. Tulsy,² S. Russell,³ ¹Cardiology, Duke University Medical Center, Durham, NC; ²General Medicine, Duke University Medical Center and VAMC, Durham, NC; ³Cardiology, Johns Hopkins Hospital, Baltimore, MD

11:00 AM (9) Longitudinal Assessment of Psychological Functioning After Paediatric Heart or Heart-Lung Transplantation; J.O. Wray,¹ R. Radley-Smith,¹ ¹Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

11:15 AM (10) Health-Related Quality of Life in 280 Transplant Recipients; C. Kugler,¹ S. Fischer,¹ J. Gottlieb,² A. Simon,¹ T. Welte,² A. Haverich,¹ M. Strueber,¹ ¹Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; ²Division of Respiratory Medicine, Hannover Medical School, Hannover, Germany

11:30 AM (11) Predictors of Negative Affect at 5-6 Years After Heart Transplantation; K.L. Grady,¹ B. Rybarczyk,² D.C. Naftel,³ J.K. Kirklin,³ C. White-Williams,³ J. Kobashigawa,⁴ J. Chait,⁴ J.B. Young,⁵ D. Pelegrin,⁵ J. Czerr,⁵ R. Higgins,¹ M. McLeod,¹ J. Rissinger,¹ A. Heroux,¹ ¹Cardiology, Rush University Medical Center, Chicago, IL; ²Cardiothoracic Surgery, University of Alabama, Birmingham, AL; ³Cardiology, University of California, Los Angeles, CA; ⁴Cardiology, Cleveland Clinic Foundation, Cleveland, OH

11:45 AM (12) Profiles and Predictors of Psychiatric Distress Across 4 Years After Heart Transplantation; M.A. Dew,¹ L. Myaskovsky,¹ A.F. DiMartini,¹ G.E. Switzer,² R.L. Kormos,³ ¹Psychiatry, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; ²Medicine, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; ³Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA

10:30 AM-NOON

CONCURRENT SESSION 3

Post Transplant Complications: Heart (Salon E)

Moderators: Stephen W. Hirt, MD and Niloo M. Edwards, MD

10:30 AM (13) Preventing Cardiac Allograft Vasculopathy - Long-Term Beneficial Effects of MMF; I. Kaczmarek,¹ P. Landwehr,¹ B. Meiser,¹ J. Groetzner,¹ P. Uberfuhr,¹ B. Reichart,¹ ¹Cardiac Surgery, LMU Munich, Grosshadern University Hospital, Munich, Germany

10:45 AM (14) Cutaneous Malignancies After Cardiac Transplantation - Risk Factors and Effect on Late Survival; M. Alam,¹ D. Silber,² M. Mullen,³ R. Brown,⁴ C. Yancy,⁵ D. Feldman,⁶ R. Oren,⁷ J. Kirklın,⁴ ¹Dermatology, Northwestern University, Chicago, IL; ²Hershey Medical Center, Hershey, PA; ³Loyola University Medical Center, Maywood, IL; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵University of Texas Southwestern Medical Center, Dallas, TX; ⁶Ohio State University, Columbus, OH; ⁷University of Iowa, Iowa City, IA

11:00 AM (15) Coronary Plaque Characterization With Intravascular Ultrasound Radiofrequency Data Analysis in Transplant Vasculopathy: Early Experience; M. Vanderheyden,¹ M. Goethals,¹ N. Kerre,¹ M. Walravens,² M. De Proft,¹ W. Wijns,¹ J. Bartunek,¹ F. Wellens,² ¹Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium; ²Department of Cardiac Surgery, OLV Ziekenhuis, Aalst, Belgium

11:15 AM (16) Quantitative Assessment of Cardiac Allograft Vasculopathy by Real-Time Myocardial Contrast Echocardiography; C. Uebles,¹ X. Hoyer,¹ P. Ueberfuhr,² H.-U. Stempfle,¹ ¹Department of Cardiology, Med. Poliklinik - Innenstadt, University of Munich, Munich, Germany; ²Department of Heart Surgery, Grosshadern, Munich, Germany

11:30 AM (17) Normalization of Right Ventricular Performance Evaluated by Magnetic Resonance Imaging (MRI) on the Late Follow-Up of Heart Transplantation (HT). Relationship Between Function, Exercise Capacity and Pulmonary Vascular Resistance; F. Bacal,¹ P.V. Pires,¹ J.R. Parga,¹ M.A. Rosario-Neto,¹ U.M. Costa,¹ F.D. Cruz,¹ V.S. Issa,¹ S.M.A. Ferreira,¹ V.M. Avila,¹ N.A.G. Stolf,¹ G.V. Guimaraes,¹ E.A. Bocchi,¹ ¹Heart Transplant Unit, Heart Institute (InCor)-University of Sao Paulo, Sao Paulo, Brazil

11:45 AM (18) Routine Chest CT Screening in High Risk Cardiac Transplant Patients May Improve Survival; D.H. Rosenbaum,¹ R.A. Bhojani,¹ P. Kaiser,¹ E. Dikmen,³ M. Paul,¹ C. Yancy,² W.S. Rjing,¹ J.M. DiMaio,¹ ¹Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX; ²Internal Medicine, UT Southwestern Medical Center, Dallas, TX; ³Thoracic Surgery, Kirikkale University, Kirikkale, Turkey

10:30 AM-NOON

CONCURRENT SESSION 4

Immunobiology in Lung Transplantation (Salon CD)

Moderators: Si M. Pham, MD and David S. Wilkes, MD

10:30 AM (19) Donor-Specific Transfusion and Anti-CD154 Induces Tracheal Allograft Tolerance Via Peripheral Deletion and Regulatory T Cells; R.M. Aris,¹ I.P. Neuringer,¹ K.P. McKinnon,² W.J. Brickey,² D.G. Sterka,¹ P. McNellie,¹ J.P.Y. Ting,² W. Chalermkulrat,¹ ¹Pulmonary Medicine and Cystic Fibrosis Center, University of North Carolina, Chapel Hill, NC; ²Department of Microbiology/Immunology, University of North Carolina, Chapel Hill, NC

10:45 AM (20) Simultaneous LFA-1 and CD40L Antagonism Prevents Airway Remodeling in Orthotopic Airway Transplantation: Implications for the Role of Respiratory Epithelium as an Antigenic Target and a Modulator of Fibrosis; T. Murakawa,¹ M.M. Kerklo,¹ M.R. Zamora,¹ F.L. Grover,¹ M.R. Nicolls,² ¹Surgery and Medicine, University of Colorado Health Sciences Center, Denver, CO

11:00 AM (21) Epithelial to Mesenchymal Transition in Clinically Stable Lung Transplant Recipients; I.A. Forrest,¹ D.M. Murphy,¹ J.L. Lordan,¹ G. Pritchard,¹ D. Jones,² H. Robertson,¹ T.E. Cawston,² J.H. Dark,¹ J.A. Kirby,¹ C. Ward,¹ P.A. Corris,¹ ¹Applied Immunobiology and Transplantation Group, University of Newcastle upon Tyne, Newcastle Upon Tyne, United Kingdom; ²Musculoskeletal Research Group (SCMS), University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom

11:15 AM (22) Long-Term Acceptance of Porcine Pulmonary Allografts Without Chronic Rejection; T. Shoji,¹ A. Muniappan,¹ D.A. Guenther,¹ H. Sahara,¹ J.C. Wain,¹ S.L. Houser,¹ R. Hasse,¹ M. Bravard,¹ J.C. Madsen,¹ J.S. Allan,¹ ¹Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA

11:30 AM (23) Association of Vascular Endothelial Growth Factor Gene Polymorphism With Acute Rejection After Lung and Heart-Lung Transplantation; S. Datta,¹ C. Leonard,² N. Yonan,² I.V. Hutchinson,³ ¹Cardiothoracic Unit, Manchester Royal Infirmary, Manchester, United Kingdom; ²Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom; ³Department of Immunology, School of Biological Sciences, University of Manchester, Manchester, United Kingdom

11:45 AM (24) The Role of NKR-P1A Following Lung Transplantation; J.E. Fildes,¹ A.H. Walker,² J. Thekkudan,³ K. Polster,¹ N. Yonan,¹ I.V. Hutchinson,⁴ C.T. Leonard,¹ ¹The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom; ²Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, United Kingdom; ³Department of Cardiothoracic Surgery, University Hospital of Wales, Cardiff, United Kingdom; ⁴Department of Immunology, School of Biological Sciences, University of Manchester, Manchester, United Kingdom

NOON-1:00 PM

Transplant Registry Meeting (Room 401)

12:15 PM-1:45 PM

LUNCHEON SYMPOSIUM

Proliferation Signal Inhibitors: Transition from Clinical Trial to Clinical Care (Salon ABF)

Supported by an Educational Grant From Novartis

Moderators: Howard J. Eisen, MD and Maria Frigerio, MD

12:15 PM **Molecular Biology of Proliferation Signal Inhibitors: New Insights**, Randall E. Morris, MD, Novartis Pharma AG, Basel, Switzerland

12:35 PM **Prevention of Cardiac Allograft Vasculopathy in Clinical Practice**, Hannah A. Valantine, MD, Stanford University School of Medicine, Stanford, CA

12:55 PM **Optimizing Proliferation Signal Inhibitors and CNIs: The German Experience**, Hans B. Lehmkuhl, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

1:15 PM **The Role of Proliferation Signal Inhibitors: Future Possibilities**, Heather J. Ross, MD, FRCPC, MHSC, Toronto General Hospital, Toronto, Canada

1:35 PM **Panel Discussion**

12:30 PM-1:30 PM

MINI-ORAL POSTER PRESENTATION SESSION 1 (Salon E)

Moderators: Marlene Rose, PhD and Richard N. Pierson, III, MD

12:30 PM (25) Aging Leads to Impaired Upregulation of ICOS in Response to Allostimulation; B.M. Tesar,¹ A. Asea,² D.R. Goldstein,¹ ¹Internal Medicine, Section of Cardiovascular Medicine, Yale University, New Haven, CT; ²Center for Molecular Stress Responses, Boston Medical Center, Boston, MA

- 12:35 PM (26) Breaking Tolerance to Solid Organ Allografts Via Allorecognition of Donor Class I Major Histocompatibility Complex Peptides; D.A. Guenther,¹ J.D. Mezrich,¹ A. Muniappan,¹ T. Shoji,¹ H. Sahara,¹ M. Bravard,¹ A. Pujara,¹ S.L. Houser,¹ D.H. Sachs,¹ J.C. Madsen,¹ Massachusetts General Hospital, Boston, MA
- 12:40 PM (27) Characterization of the Intragraft Macrophage-Fibroblast Axis; G.D. Wu,¹ N. Mishuhita,¹ Y.-S. Jin,¹ H. Zhu,¹ V. Starnes,¹ M.L. Barr,¹ Cardiothoracic Surgery Research, The Saban Research Institute, Children's Hospital, Los Angeles, CA
- 12:45 PM (28) Pretransplant Donor-Specific Transfusion Accelerates Complement-Dependent Cardiac Allograft Dysfunction; Z. Qian,¹ J. Liu,¹ K. Fox-Talbot,¹ B.A. Wasowska,¹ W.M. Baldwin, III,¹ Transplantation Laboratory, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
- 12:50 PM (29) Local Delivery of AIF-1 to Rat Carotid Arteries Increases Restenosis, Local G-CSF Expression, and Contributes to Recruitment of Bone Marrow-Derived Cells; S.E. Kelemen, C. Xing, A. Agelan, M.V. Autieri, Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA
- 12:55 PM (30) Anti-MHC Antibodies Stimulate Pro-Inflammatory Functions of Endothelial and Lymphoid Cells; B.A. Wasowska,¹ Z. Qian,¹ J.G. Bieler,¹ W.M. Baldwin,¹ Pathology, Johns Hopkins School of Medicine, Baltimore, MD
- 1:00 PM (31) Marked Inhibition of Cardiac Allograft Vasculopathy With Immunodominant Allopeptide-Pulsed Host Dendritic Cells; D.A. Guenther,¹ D.R. Johnston,¹ A. Muniappan,¹ T. Shoji,¹ R. Hasse,¹ M. Bravard,¹ S.L. Houser,¹ J.S. Allan,¹ D.H. Sachs,¹ J.C. Madsen,¹ Massachusetts General Hospital, Boston, MA
- 1:05 PM (32) Association of Donor Tumor Necrosis Factor-alpha Gene-308 Polymorphism With Acute Rejection After Heart Transplantation; S. Datta,¹ C. Densum,² N. Yonan,³ I.V. Hutchinson,⁴ Cardiothoracic Unit, Manchester Royal Infirmary, Manchester, United Kingdom; ²Cardiology Unit, Wythenshawe Hospital, Manchester, United Kingdom; ³Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom; ⁴Department of Immunology, School of Biological Sciences, University of Manchester, Manchester, United Kingdom
- 1:10 PM (33) The Synthetic Peptide D4F Attenuates Cardiac Allograft Vasculopathy; G.R. Hsieh,¹ G.T. Schnickel,¹ C. Garcia,¹ A. Shefizadeh,¹ W. Yao,¹ A. Ardehali,¹ Department of Surgery, Division of Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA
- 1:15 PM (34) Sirolimus Induces Endothelial Progenitor Cell Apoptosis; S.G. Miriuka,¹ V. Rao,² M. Peterson,¹ L. Tumiaty,¹ D. Delgado,¹ R. Mohan,¹ D. Ramzy,¹ H.J. Ross,¹ T.K. Waddell,² Internal Medicine, Toronto General Hospital; ²Surgery, Toronto General Hospital, Toronto, Ontario, Canada
- 1:20 PM (35) Sensitization by Blood Transfusion Results in Antibody Production That Correlates With C4d Deposition and Rejection; K. Minami,¹ K. Fox-Talbot,¹ B.A. Wasowska,¹ W.M. Baldwin, III,¹ Pathology, Johns Hopkins Medical Institute, Baltimore, MD
- 1:25 PM (36) Humoral Immunity During Acute Cellular Rejection in Lung Transplant Patients; O.A. Shlobin,¹ N. Lechtzin,¹ J.B. Orens,¹ B.B. Detrick,² W.M. Baldwin,² Pulmonary/Critical Care, Johns Hopkins Hospital, Baltimore, MD; ²Pathology, Johns Hopkins Hospital, Baltimore, MD

12:30 PM-1:30 PM

MINI-ORAL POSTER PRESENTATION SESSION 2 (Salon CD)

Moderators: Walter Klepetko, MD and Martin R. Zamora, MD

- 12:30 PM (37) pH Is Reduced in Exhaled Breath Condensate of Patients With Chronic Rejection After (Heart)Lung Transplantation; L.J. Dupont,¹ Y. Dewandeleer,¹ B. Vanaudenaerde,¹ D.E. Van Raemdonck,¹ G.M. Verleden,¹ Leuven Lung Transplant Team, University Hospital Gasthuisberg, K.U.Leuven, Leuven, Belgium
- 12:35 PM (38) The Role of Airway Neutrophilia in Patients With Acute Rejection (AR) After Lung Transplantation (LTx)? B. Vanaudenaerde,¹ L. Dupont,^{1,2} N. Geudens,¹ D. Van Raemdonck,² G. Verleden,^{1,2} Laboratory of Pneumology, KU Leuven; ²Lung Transplant Unit, UZ Gasthuisberg, Leuven, Belgium
- 12:40 PM (39) Reduction of Fas Ligand Levels in Bronchoalveolar Lavage Fluid in Lung Transplant Recipients Receiving Sirolimus; K.R. Janata, B. Lu, S. Bhorade, E. Garrity, W.T. Vigneswaran, Lung Transplantation, Pulmonary Critical Care, Loyola University Medical Center, Maywood, IL
- 12:45 PM (40) 10 Years Later: Lung Transplantation Enhances Survival; A.R. Glanville,¹ C.L. Aboyoum,¹ M.L. Pliit,¹ M.A. Malouf,¹ The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia
- 12:50 PM (41) Long-Term Outcomes of Single and Bilateral Lung Transplantation for Adults With Pulmonary Arterial Hypertension; M.M. Chakinala,¹ R.R. Hachem,¹ L.E. Morrow,² R.D. Yusen,¹ G.A. Patterson,³ E.P. Trulock,¹ Internal Medicine, Washington University, St. Louis, MO; ²Internal Medicine, Creighton University, Omaha, NE; ³Surgery, Washington University, St. Louis, MO
- 12:55 PM (42) Reduced Size Lung Transplantation for Fibrosis and Cystic Fibrosis - One Year Follow Up; M. Strueber,¹ A.R. Simon,¹ S. Fischer,¹ J. Gottlieb,² C. Hagl,¹ K. Kallenbach,¹ B. Gohrbandt,¹ H. Goerler,¹ A. Haverich,¹ T. Welte,² Hannover Thoracic Transplant Program; Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; ²Respiratory Medicine, Hannover Medical School, Hannover, Germany

1:00 PM (43) Human Metapneumovirus Infection in Lung Transplant Recipients; Clinical Presentation and Epidemiology; C. Geltner,¹ C. Larcher,² H. Fischer,³ D. Nachbaur,⁴ H. Huemer,² ¹Pulmonary Medicine, LKH Natters, Natters, Austria; ²Hygiene and Social Medicine, Medical University Innsbruck, Innsbruck, Austria; ³Pediatrics, Medical University Innsbruck, Innsbruck, Austria; ⁴Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria

1:05 PM (44) Pulmonary Retransplantation for Patients With the Bronchiolitis-Obliterans-Syndrom - A Single Center Experience; J. Gottlieb,¹ B. Gohrbandt,² J. Niedermeyer,¹ T. Welte,¹ M. Strueber,² ¹Respiratory Medicine, Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; ²Cardiothoracic and Vascular Surgery, Hannover Thoracic Transplant Program, Hannover, Germany

1:10 PM (45) Does Photopheresis Have a Role in the Battle Against BOS? D.C. McGiffin,¹ R.N. Brown,¹ J.K. Kirklin,¹ K.H. Hart,¹ K.R. Young,² G.L. Zorn,¹ K.J. Leon,² K.M. Wille,² ¹Surgery, University of Alabama at Birmingham, Birmingham, AL; ²Pulmonary, University of Alabama at Birmingham, Birmingham, AL

1:15 PM (46) Single Centre Experience With Bronchial Healing after Lung Transplantation: A Review of 555 Anastomoses; M. Jeyakanthan,¹ Q. Abid,¹ T. Pillay,¹ S.C. Clark,¹ J.H. Dark,¹ S. Schueler,¹ ¹Cardiopulmonary Transplantation Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom

1:20 PM (47) Daily Routine Patient-Controlled Lung Function Testing Using Electronic Spirometry Is Essential for Long-Term Outcome Following Lung Transplantation; C. Kugler,¹ S. Fischer,¹ J. Gottlieb,² B. Gohrbandt,¹ T. Welte,² A. Haverich,¹ M. Strueber,¹ ¹Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; ²Division of Respiratory Medicine, Hannover Medical School, Hannover, Germany

1:00 PM-2:00 PM

MCS D Database Meeting (Room 402)

2:00 PM-3:30 PM

CONCURRENT SESSION 5

The Impact of New Technology on LVAD Implementation (Salon G-L)

Moderators: Yoshifumi Naka, MD and George Wieselthaler, MD

2:00 PM (48) Clinical Results of the First 99 Patients With the Axial Flow Pump INCOR; P. Göttel,¹ R. Hetzer,² C. Schmid,¹⁸ J. Gummert,³ M. Schneider,⁴ G. Gerosa,⁵ R. Tandler,⁶ D. Birnbaum,⁷ A. Tschirkov,⁸ R. Körfer,⁹ V. Syrvidis,¹⁰ F. Beyersdorf,¹¹ M. Hendriks,¹² B. Meyns,¹³ M. Antoine,¹⁴ A. Wasler,¹⁵ L. Liu,¹⁶ H.K. Najm,¹⁷ M. Müller,^{1,2} ¹Clinical Surgery, Berlin Heart, Berlin, Germany; ²Deutsches Herzzentrum, Berlin, Germany; ³Herzzentrum Leipzig, Leipzig, Germany; ⁴Klinikum Links der Weser, Bremen, Germany; ⁵University of Padova, Padova, Italy; ⁶University of Erlangen, Erlangen, Germany; ⁷University of Regensburg, Regensburg, Germany; ⁸University Hospital St. Ekatarina, Sofia, Bulgaria; ⁹Herzzentrum NRW, Bad Oeynhausen, Germany; ¹⁰University of Vilnius, Vilnius, Lithuania; ¹¹University of Freiburg, Freiburg, Germany; ¹²Virga Jesse Ziekenhuis, Hasselt, Belgium; ¹³University Gasthuisberg, Leuven, Belgium; ¹⁴Hopital Erasme, Brussels, Belgium; ¹⁵University of Graz, Graz, Austria; ¹⁶East Sino Hosp, Shanghai, China; ¹⁷National Guard Hospital, Riyadh, Saudi Arabia; ¹⁸University of Münster, Münster, Germany

2:15 PM (49) Initial Human Experience With the Terumo DuraHeart - A Magnetically Levitated Centrifugal Left Ventricular Assist System; A. El-Banayosy,¹ L. Arusoglu,¹ M. Morshuis,¹ P. Sarnowski,¹ L. Kizner,¹ G. Tenderich,¹ C. Dagmar,¹ R. Koerfer,¹ ¹Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

2:30 PM (50) Effect of Pulsatile And Nonpulsatile Left Ventricular Assist Devices on Plasma Renin Activity;

H. Welp,¹ C. Etz,¹ T. Tjan,¹ H.H. Scheld,¹ C. Schmid,¹ ¹Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany

2:45 PM (51) Intermediate Experience With the Jarvik 2000 Axial Flow Left Ventricular Assist Device (LVAD);

S.M. Haj-Yahya,^{1,2} E.J. Birks,^{1,2} J. Hardy,¹ M. Hipkin,¹ C. Bowles,^{1,2} G. Dreyfus,¹ N. Banner,^{1,2} A. Khaghani,^{1,2} ¹Cardiothoracic Transplantation, Harefield, London, United Kingdom; ²NHLI, Imperial College, London, United Kingdom

3:00 PM (52) Does Total Implantability Reduce Infection With the Use of a Left Ventricular Assist Device (LVAD): The LionHeart™ European Experience; W.E. Pae,¹ J.P. Boehmer,¹ R. Korfer,² A. El Banayosy,² R. Hetzer,³ M. Viganò,⁴ A. Pavié,⁵ ¹Cardiothoracic Surgery and Cardiology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA; ²Cardiac Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany; ³Cardiac Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ⁴Cardiac Surgery, Università Pavia-Clinico San Matteo, Pavia, Italy; ⁵Cardiovascular Surgery, Institute de Cardiologie, Paris, France

3:15 PM (53) End-Stage Cardiac Failure Managed With Levitronix® Centrimag® Short-Term Ventricular Assist Device (VAD); F. De Robertis,¹ E.J. Birks,² P. Barlow,² N.R. Banner,² D.F. Shore,¹ G.D. Dreyfus,¹ J.R. Pepper,¹ A. Khaghani,¹ ¹Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; ²Transplant Medicine, Royal Brompton and Harefield NHS Trust,

Harefield, Middlesex, United Kingdom; ³Perfusion, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

2:00 PM-3:30 PM

CONCURRENT SESSION 6

Bronchiolitis Obliterans Syndrome (Salon ABF)

Moderators: Geert M. Verleden, MD, PhD and Selim M. Arcasoy, MD

2:00 PM (54) Azithromycin Reduces Airway Neutrophilia in Patients with Bronchiolitis Obliterans Syndrome; G.M. Verleden,^{1,3} L.J. Dupont,^{1,3} B.M. Vanaudenaerde,³ D.E. Van Raemdonck,^{2,3} ¹Respiratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium; ²Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium; ³Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

2:15 PM (55) Autoimmunity to Collagen-V May Lead to Chronic Rejection After Human Lung Transplantation; A. Bharat,¹ E. Trulock,² G.A. Patterson,³ A. Aloush,² T. Mohanakumar,^{1,4} ¹Surgery; ²Pulmonology/Internal Medicine; ³Cardiothoracic Surgery; ⁴Pathology; Washington University, St. Louis, MO

2:30 PM (56) HLA-Specific Antibodies Are Associated With Lymphocytic Bronchiolitis and Decreased Pulmonary Function After Lung Transplantation; A.L. Girona, R. Duquesnoy, S.A. Yousem, A.T. Iacono, K.J. Spichty, K.R. McCurry, A. Zeevi, Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA

2:45 PM (57) Survival After Bilateral Lung Transplantation Depends on the Maximum Lung Function Achieved Post-Transplant and the Development of Bronchiolitis Obliterans Syndrome (BOS); D. Hadjiliadis,¹ C.S. Berbrayer,¹ O. Hadjiliadis,² C. Chaparro,¹ S. Keshavjee,¹ ¹Toronto Lung Transplant Program, University of Toronto, Toronto, Ontario, Canada; ²Department of Statistics, Columbia University, New York, NY

3:00 PM (58) Assessment of Graft Function after Single-Lung Transplantation (SLT) by Single-Breath Washout in Lateral Decubitus; A. Van Muylem,¹ C. Knoop,¹ M. Estenne,¹ ¹Department of Chest Medicine, Erasme University Hospital, Brussels, Belgium

3:15 PM (59) Role of Surfactant Proteins and Phospholipids as Markers of BOS; F. D'Ovidio,¹ R. Ridsdale,¹ M. Mura,¹ H. Takahashi,² C. Gutierrez,¹ M. Hutcherson,¹ L. Singer,¹ A. Pierre,¹ D. Hadjiliadis,¹ C. Chaparro,¹ T. Waddell,¹ M. Liu,¹ M. Post,¹ S. Keshavjee,¹ ¹University of Toronto, Toronto, Canada; ²University of Sapporo, Sapporo, Japan

2:00 PM-3:30 PM

CONCURRENT SESSION 7

Novel Immunosuppressive Strategies in Cardiac Transplantation (Salon E)

Moderators: Manfred Hummel, MD and Robert C. Bourge, MD

2:00 PM (60) Everolimus in De Novo Cardiac Transplant Recipients: 48-Month (M) Follow-Up; J.M. Hare,¹ S. Perrone,² H. Eisen,³ K. McCurry,⁴ P. Hauptman,⁵ S. Simonsen,⁶ M. Crespo,⁷ J. Arizon,⁸ J. Kobashigawa,⁹ J. Jarcho,¹⁰ ¹Cardiology, Johns Hopkins Hospital, Baltimore, MD; ²Cardiaco, Fundacion Favalaro, Buenos Aires, Argentina; ³Cardiology, Temple University, Philadelphia, PA; ⁴Cardio/Thoracic Surgery, University of Pittsburgh, Pittsburgh, PA; ⁵Cardiology, St. Louis University Medical Center, St. Louis, MO; ⁶Surgery, Rikshospitalet, Oslo, Norway; ⁷Cardiaca, Hospital Juan Canalejo, Madrid, Spain; ⁸Cardiaco, Hospital Reina Sofia, Cordoba, Spain; ⁹Heart Transplant Program, University of California, Los Angeles, CA; ¹⁰Cardiology, Brigham and Women's Hospital, Boston, MA

2:15 PM (61) 12 Month Report of a 3 Arm Multicenter Comparison of Tacrolimus (TAC), MMF or TAC/Sirolimus(SRL) and Steroids vs Cyclosporine Microemulsion(CYA), MMF and Steroids in De Novo Cardiac Transplant Recipients; JW Kobashigawa, MD¹, LW Miller, MD², GM Felker, MD³, SD Russel, MD³, GA Ewald, MD⁴, M Zucker, MD⁵, L Goldberg, MD⁶, HJ Eisen, MD⁷, BK Rayburn, MD⁸, LE Wagoner, MD⁹, E Philbin, MD¹⁰, N Pereira, MD¹¹, B Czerska, MD¹², RL Kormos, MD¹³, M Weston, MD¹⁴, J Conte, MD¹⁵, J Hosenpud, MD¹⁶, K Aaronson, MD¹⁷, J Hill, MD¹⁸, JG Copeland, MD¹⁹, J Czer, MD²⁰, A Anderson, MD²¹, GW Dec, MD²², G Torre-Amione, MD²³, CW Yancy, MD²⁴, JD Vega, MD²⁵, JA Jarcho, MD²⁶, D Mancini, MD²⁷, G Bhat, MD²⁸, R First, MD²⁹, W Fitzsimmons, MSc, PharmD²⁹, D Tolzman, BSN²⁹, K Salm, BSN²⁹, J Gao, MD³⁰, ¹University of California, Los Angeles, CA; ²University of Minnesota, Minneapolis, MN; ³Duke University, Durham, NC; ⁴Barnes Hospital, St. Louis, MO; ⁵Beth Israel, Newark, NJ; ⁶University of Pennsylvania, Philadelphia, PA; ⁷Temple University, Philadelphia, PA; ⁸University of Alabama, Birmingham, AL; ⁹University of Cincinnati, Cincinnati, OH; ¹⁰Albany Medical College, Albany, NY; ¹¹Medical University of South Carolina, Charleston, SC; ¹²Henry Ford Hospital, Detroit, MI; ¹³University of Pittsburgh, Pittsburgh, PA; ¹⁴Tampa General Hospital, Tampa, FL; ¹⁵Johns Hopkins, Baltimore, MD; ¹⁶St. Luke's, Milwaukee, WI; ¹⁷University of Michigan, Ann Arbor, MI; ¹⁸University of Florida, Gainesville, FL; ¹⁹University of Arizona, Tucson, AZ; ²⁰Cedars Sinai, Los Angeles, CA; ²¹University of Chicago, Chicago, IL; ²²Massachusetts General, Boston, MA; ²³Methodist Houston, Houston, TX; ²⁴Baylor University, Dallas, TX; ²⁵Emory University, Atlanta, GA; ²⁶Brigham and Women's Hospital, Boston, MA; ²⁷Columbia University, New York, NY; ²⁸Jewish Hospital, Louisville, KY; ²⁹Fujisawa

Health Care, Inc., Deerfield, IL; ³⁰The EMMES Corp, Rockville, MD
2:30 PM (62) A 12-Month, Multicenter, Randomized, Adaptive Design, Open-Label Study To Evaluate the Benefit of C2-hr Monitoring of Neoral on Safety and Efficacy Outcomes in De Novo Cardiac Transplant Recipients Receiving Basiliximab Induction: 6-Month Outcomes; H. Ross,¹ M. Cantarovich, J. Arizon, J. Orus, L. Straatman, J. Howlett, E. Lage, M. Crespo, S. Wang, H. Haddad, L. Pulpon, N. Manito, B. Díaz Molina, M.A. Gómez, the Motown study group, Canada and Spain, ¹Toronto General Hospital, University of Toronto
2:45 PM (63) Improved Safety of Basiliximab (Simulect®) Over Antithymocyte Globulin (Thymoglobulin®) Induction Therapy in Heart Transplantation; M.F. Mattei,¹ P. Boissonnat,² M. Redonnet,³ I. Gandjbakhch,⁴ A. Mouly Bandini,⁵ R. Dorent,⁶ C. Yau,⁶ A.S. Blanc,⁶ ¹Cardiac Surgery, Hopital Brabois, Nancy; ²Cardiac Transplantation, Hopital Cardiologique, Lyon; ³Cardiac Surgery, Hopital Ch Nicolle, Rouen; ⁴Cardiac Surgery, Hopital Pitie-Salpetriere, Paris; ⁵Thoracic Surgery, Hopital La Timone, Marseille; ⁶Transplantation, Novartis, Rueil, France
3:00 PM (64) The Combination of Sirolimus and Tacrolimus for Primary Immunosuppression After Heart Transplantation – Is It Worth the Effort; M. Mueller,¹ B. Meiser,¹ J. Groetzner,¹ I. Kaczmarek,¹ B. Reichart,¹ ¹Department of Cardiac Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany
3:15 PM (65) Late-Onset T-Cell Activation and Cardiac Allograft Rejection Following Cessation of Daclizumab Induction Therapy; K. Lietz,¹ E. Burke,¹ M. Mercado,¹ Y. Naka,¹ D. Mancini,¹ S. Itescu,¹ ¹Department of Surgery and Cardiovascular Division, Columbia University, New York, NY

2:00 PM-3:30 PM

CONCURRENT SESSION 8

Listing and Outcomes in Pediatric Thoracic Transplantation (Salon CD)

Moderators: Maryanne R. Chrisant, MD and Thomas L. Spray, MD

2:00 PM (66) Sudden Cardiac Death Prior to Pediatric Heart Transplantation: Would Implantable Defibrillators Improve Outcome? E.K. Rhee,¹ C.E. Canter,¹ S. Basile,¹ D.C. Naftel,³ ¹Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO; ²Cardiac Surgery, University of Alabama at Birmingham, Birmingham, AL
2:15 PM (67) Abo-Incompatible Infant Heart Transplantation: The World Experience; L.J. West,¹ S.M. Pollock-BarZiv,¹ A. Ang,¹ A.I. Dipchand,¹ R. Boucek,² E. Blume,² M. Burch,³ C. Canter,² J. Coe,² J.H. Dark,³ B. Duncan,² R. Gajarski,² K. Kanter,² P. Kantor,¹ M. Kichuk-Chrisant,² S. Mital,² E. Pahl,¹ ¹Cardiology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada; ²USA Centre; ³UK Centre, United Kingdom; ⁴Canadian Centre, Canada
2:30 PM (68) Should Status II Patients Be Removed From the Pediatric Heart Transplant Waiting List: A Multi-Institutional Study; J.K. Kirklín,¹ D.C. Naftel,¹ F.B. Pearce,¹ C. White-Williams,¹ R.L. Caldwell,² H. Bartlett,³ P. Rusconi,⁴ B.V. Robinson,⁵ ¹University of Alabama at Birmingham, Birmingham, AL; ²Indiana University Medical Center, Indianapolis, IN; ³University of Iowa Hospitals and Clinics, Iowa City, IA; ⁴University of Miami, Miami, FL; ⁵University of North Carolina, Chapel Hill, NC
2:45 PM (69) Have Changes in UNOS Status System Improved Allocation in Pediatric Heart Recipients? L.J. Addonizio,¹ S.D. Zangwill,² D.N. Rosenthal,¹ D.C. Naftel,⁴ R. Korsin,¹ D.T. Hsu,¹ J.K. Kirklín,¹ ¹Pediatric Heart Transplant Study Group, ¹Columbia University, New York, NY; ²University of Wisconsin, Milwaukee, WI; ³Stanford University, Palo Alto, CA; ⁴University of Alabama, Birmingham, AL
3:00 PM (70) Outcome and Obstacles in Pediatric Lung and Heart-Lung Transplantation; A.R. Simon,¹ M. Strüber,¹ A. Görler,¹ M. Ballman,² S. Fischer,¹ B. Gohrbandt,¹ K. Kallenbach,¹ C. Hagl,¹ J. Freihorst,¹ A. Haverich,¹ ¹Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; ²Department of Pediatric Pneumology and Neonatology, Hannover Medical School, Hannover, Germany
3:15 PM (71) Living Donor Lobar Lung Transplantation Improves Survival Following Lung Re-Transplantation in Children; B.D. Kozower,¹ S.C. Sweet,¹ M. de la Morena,¹ P. Schuler,¹ T.J. Guthrie,¹ G.A. Patterson,¹ S.K. Gandhi,¹ C.B. Huddleston,¹ ¹Surgery and Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO

3:30 PM-4:00 PM

Coffee Break/Visit Exhibits/Visit Posters (Franklin Hall)

4:00 PM-5:30 PM

CONCURRENT SESSION 9

Cardiac Transplant Rejection: New Looks at an Old Hat (Salon G-L)

Moderators: Carla Baan, MD and Hannah Valantine, MD

4:00 PM (72) Gene Expression Profiling of Cardiac Allograft Recipients With Mild Acute Cellular Rejection; D. Bernstein,¹ S. Mital,² L. Addonizio,² S. Hunt,¹ M.C. Deng,² H. Baron,² S. Murali,³ D.Y. Jayama,⁴ T.M. Klingler,⁴ J.G. Wohlgenuth,⁴ S. Webber,³ ¹School of Medicine, Stanford University; ²College of Physicians and Surgeons, Columbia University; ³School of Medicine, University of Pittsburgh; ⁴XDx, Inc.

4:15 PM (73) The Influence of Corticosteroids on the Alloimmune Molecular Signature for Cardiac Allograft Rejection; R.C. Starling,¹ M.C. Deng,² J.A. Kobashigawa,³ D. Walther,⁴ J. Wohlgenuth,⁴ S. Rosenberg,⁴ M.R. Mehra,⁵ Cleveland Clinic, Cleveland, OH; and, ²Columbia University, New York, NY; ³University of California, Los Angeles, CA; ⁴XDX Inc; ⁵Ochsner Clinic, New Orleans, LA

4:30 PM (74) Dexamethasone at the Time of Heart Transplantation Is Not Equivalent to Methylprednisolone; S.E. Fedson,¹ A.B. Cochrane,² A.Y. Kim,¹ A.N. Husain,³ A.S. Anderson,¹ ¹Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL; ²Department of Pharmacology, University of Chicago, Chicago, IL; ³Department of Pathology, University of Chicago, Chicago, IL

4:45 PM (75) Justification of the Newly Proposed ISHLT Biopsy Grading Scale by Combining Grades 1A, 1B, and 2 into One Mild Rejection Grade; J.K. Patel,¹ T. Ro,¹ M.C. Fishbein,¹ B.T. Oeser,¹ A. Marquez,¹ H. Laks,¹ J.A. Kobashigawa,¹ Cardiology, University of California at Los Angeles, Los Angeles, CA

5:00 PM (76) Rejection With Hemodynamic Compromise: Objective Evidence for Efficacy of Photopheresis; J. Kirklin,¹ R. Brown,¹ D. Naftel,¹ S. Hubbard,¹ B. Rayburn,¹ D. McGiffin,¹ R. Bourge,¹ R. Benza,¹ J. Tallaj,¹ L. Pinderski,¹ S. Pamboukian,¹ J. George,¹ University of Alabama at Birmingham, Birmingham, AL

5:15 PM (77) Is Routine Surveillance Biopsy Obsolete? A Multi-Institutional Analysis; J. Stehlik,¹ R. Starling,² R. Brown,³ J. Fang,⁴ N. Lewis,⁵ M. Hess,⁶ M. Jessup,⁷ VA Medical Center, Salt Lake City, UT; ²Cleveland Clinic Foundation, Cleveland, OH; ³University of Alabama at Birmingham, Birmingham, AL; ⁴Brigham & Women's Hosp, Boston, MA; ⁵VA Medical Center, Richmond, VA; ⁶Medical College of Virginia, Richmond, VA; ⁷University of Pennsylvania, Philadelphia, PA

4:00 PM-5:30 PM

CONCURRENT SESSION 10

New Insights in Heart Failure Therapy (Salon ABF)

Moderators: Joseph G. Rogers, MD and Patricia A. Uber, PharmD

4:00 PM (78) Clinical Results With the Orqis® Medical Cancion® CRS™ Therapy; B. Czerska,¹ R.M. Oren,² M. Bohm,³ J. Sadowsky,⁴ A.B. Van Bakel,⁵ W.T. Abraham,⁶ A. Wasler,⁷ B. Cabuay,² S. Khanal,¹ K. Bartus,⁴ M.R. Zile,⁵ M.A. Konstam,⁸ Cardiology, Henry Ford Heart & Vascular Institute, Detroit, MI; ²Medicine, University of Iowa, Iowa City, IA; ³Internal Medicine, University Hospital Saarland, Homburg, Germany; ⁴Cardiology, John Paul II Hospital, Krakow, Poland; ⁵Cardiology, Medical University of South Carolina, Charleston, SC; ⁶Cardiovascular Medicine, The Ohio State University, Columbus, OH; ⁷Surgery, University of Graz, Graz, Austria; ⁸Medicine, Tufts-New England Medical Center, Boston, MA

4:15 PM (79) Successful Implementation of Heart Failure Self Management Tools Improves Survival; J.A. Hall,^{1,2} K.D. Rasmussen,^{1,2} T.K. French,¹ A.G. Kfoury,^{1,2} L.C. Hofmann,² D.G. Renlund,^{1,2,3} Heart Failure Prevention and Treatment Program, LDS Hospital, Salt Lake City, UT; ²UTAH Cardiac Transplant Program, LDS Hospital, Salt Lake City, UT; ³Division of Cardiology, University of Utah Health Science Center, Salt Lake City, UT

4:30 PM (80) Fish Oils Improve Body Composition in Cardiac Cachexia by Their Anti-Inflammatory Effects; R.V. Milani,¹ M.R. Mehra,¹ H.O. Ventura,¹ C.J. Lavie,¹ P.A. Uber,¹ R.L. Scott,¹ M.H. Park,¹ Cardiomyopathy and Heart Transplantation, Ochsner Clinic Foundation, New Orleans, LA

4:45 PM (81) Statins Shorten QTc Interval Without Affecting Plasma BNP Levels in Patients With Advanced Heart Failure; B. Vrtovec,¹ R. Okrajsek,¹ A. Golicnik,¹ M. Ferjan,¹ P.V. Juarez,² B. Radovancevic,² Division of Cardiology, Ljubljana University Medical Center, Ljubljana, Slovenia; ²Transplant Research, Texas Heart Institute, Houston, TX

5:00 PM (82) In the Long Term Heart Transplantation Provides Additional Benefit in Transplant Candidates With Uptitrated ACE-Inhibitor- and β -Blocker-Therapy; B. Meyer,¹ D. Moertl,¹ M. Huelsmann,¹ R. Pacher,¹ R. Berger,¹ Department of Cardiology, Medical University of Vienna, Vienna, Austria

5:15 PM (83) Should UNOS Status 2 Patients Be Transplanted? N.R. Shah,¹ G.A. Ewald,² D.A. Horstmannshof,² E.M. Geltman,² S.L. Moorhead,² N. Moazami,¹ Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; ²Cardiology, Washington University School of Medicine, St. Louis, MO

4:00 PM-5:30 PM

CONCURRENT SESSION 11

Extending the Donor Heart (Salon E)

Moderators: Stephen R. Large, MS, MRFP, FRCS and Arun K. Singhal, MD, PhD

4:00 PM (84) HLA-DR Matching Improves Survival After Heart Transplantation - Is It Time To Change Allocation Policies?; I. Kaczmarek,¹ P. Landwehr,¹ J. Groetzner,¹ B. Meiser,¹ U. Peter,¹ B. Reichart,¹ Cardiac Surgery, LMU Munich, Grosshadern University Hospital, Munich, Germany

4:15 PM (85) Long-Term Outcome of Alternate List Heart Transplant Patients; H. Laks,¹ F. Mitropoulos,¹ J. Odim,¹ J.K. Patel,¹ A. Marquez,¹ M. Plesa,¹ B.T. Oeser,¹ J.A. Kobashigawa,¹ Cardiology, University of California at Los Angeles, Los Angeles, CA

4:30 PM (86) Elevated Donor Sodium Levels Are a Risk Factor for Increased 1-Year Mortality After Heart Transplantation; D. Hofer,¹ J.M.A. Smits,² E. de Vries,² H. Antretter,¹ G. Laufer,¹ Department of Cardiac Surgery, University Hospital Innsbruck, Innsbruck, Austria; ²Eurotransplant International Foundation, Leiden, Netherlands

4:45 PM (87) Potential Suitability for Transplantation of Hearts From Human Non-Heart Beating Donors; Data Review From the Gift of Life Donor Program; A.K. Singhal,¹ J.D. Abrams,² J. Mohara,¹ R.D. Hasz,² H.M. Nathan,² C.A. Fisher,¹ S. Furukawa,¹ B.I. Goldman,¹ Cardiac and Thoracic Surgery, Pathology and Laboratory Medicine, Temple University School of Medicine, Philadelphia, PA; ²Gift of Life Donor Program, Philadelphia, PA

5:00 PM (88) CABG-Patched Donor Hearts: The Long Term Outcome; J. Odim,¹ H. Laks,¹ N.P. Almeda,¹ J.K. Patel,¹ J.A. Kobashigawa,¹ Cardiothoracic Surgery, University of California at Los Angeles, Los Angeles, CA

5:15 PM (89) Free Radical Scavenger MCI-186 Ameliorates Reperfusion Injury in Hearts Harvested From Non-Heart-Beating-Donors; Y. Kotani,¹ K. Ishino,¹ S. Osaki,¹ O. Honjo,¹ T. Suezawa,¹ K. Kanki,¹ T. Kohmoto,¹ M. Kawada,¹ C. Yutani,² S. Sano,¹ Cardiovascular Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

4:00 PM-5:30 PM

CONCURRENT SESSION 12

Primary Graft Dysfunction: Lung (Salon CD)

Moderators: Hiroshi Date, MD and Dirk Van Raemdonck, MD, PhD

4:00 PM (90) ISHLT PGD Grade Predicts Differential Mortality Following Lung Transplantation; J.D. Christie,^{1,2} V.N. Aha,¹ J.S. Sager,¹ A. Pocchettino,³ E. DeMissie,¹ L. Zhou,² R.M. Kotloff,¹ Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA; ²Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA; ³Thoracic Surgery, University of Pennsylvania, Philadelphia, PA

4:15 PM (91) Validation of the Proposed ISHLT Grading System for Primary Graft Dysfunction Following Lung Transplantation; M.E. Prekker,¹ D.S. Nath,¹ A.C. Johnson,¹ A.R. Walker,¹ M.I. Hertz,² P.S. Dahlberg,¹ Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN; ²Medicine, University of Minnesota, Minneapolis, MN

4:30 PM (92) Pulmonary Microcirculation After Clinical Lung Transplantation: In Vivo Intravitalmicroscopy; M. Kamler,¹ V. Milekhin,¹ I. Aleksic,¹ U. Herold,¹ R. Ragette,² H. Jakob,¹ Thoracic- and Cardiovascular Surgery, West German Heart Center Essen, University Hospital Essen, Essen, Germany; ²Pneumology, Ruhrlandklinik, University Hospital Essen, Essen, Germany

4:45 PM (93) Dilatation of Alveolar Capillaries After Lung Transplantation: Effects of Denervation; V. Milekhin,¹ M. Kamler,¹ N. Pizanis,¹ T. Ley,¹ H. Jakob,¹ Department of Thoracic- and Cardiovascular Surgery, West German Heart Center Essen, University Hospital Essen, Essen, Germany

5:00 PM (94) Effect of Donor Alcohol Consumption on Survival After Lung Transplantation; D. Hall,¹ T.K. Waddell,¹ A.F. Pierre,¹ S. Keshavjee,¹ D. Hadjiladis,¹ Toronto Lung Transplant Program, University of Toronto, Toronto, Ontario, Canada

5:15 PM (95) Evaluation of the Oxygenation Ratio in the Definition of Early Graft Dysfunction Post Lung Transplantation; T. Oto,¹ B.B. Levvey,¹ D.V. Pilcher,¹ M.J. Bailey,¹ G.I. Snell,¹ Heart & Lung Transplant Unit, The Alfred Hospital, Melbourne, Victoria, Australia

5:30 PM-6:30 PM

GENERAL POSTER SESSION/Wine and Cheese Reception (Franklin Hall)

(268) Early Goal Directed Therapy for Acutely Decompensated Heart Failure: Improving Clinical and Financial Outcomes for DRG127; M.T. Saltzberg,¹ M.R. Costanzo,¹ V. Gupta,² Midwest Heart Foundation, Downers Grove, IL; ²Data and Clinical Information, Cardinal Health, Naperville, IL

(269) Importance of Left Atrial Volume in Predicting Reduced Peak Aerobic Capacity in Advanced Systolic Dysfunction; R.V. Milani,¹ C.T. Davis,¹ C.J. Lavie,¹ M.R. Mehra,¹ Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA

(270) Acute Short Term Ultrafiltration Produces Sustained Hemodynamic Benefits in Acutely Decompensated Heart Failure Patients; M.T. Saltzberg,^{1,2} A. Neumann,¹ M.R. Costanzo,² Echocardiographic Core Laboratory, Midwest Heart Foundation, Downers Grove, IL; ²Midwest Heart Specialists, Naperville, IL

(271) Cardiac Resynchronization Therapy in End Stage Heart Failure Patients Listed for Cardiac Transplant; M.S. Bedi,¹ V. Gujral,¹ R. Kormos,¹ S. Murali,¹ Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA

(272) Characteristics of Patients With Stage D Heart Failure: Initial Report From the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE@-LM); C.W. Yancy,¹ G.C. Fonarow,² The ADHERE Scientific Advisory Committee,³ Cardiology, UT Southwestern Medical Center, Dallas, TX; ²Cardiology, University of California, Los Angeles, CA; ³Medical Affairs, Scios Inc., Fremont, CA

- (273) Change in Plasma Brain Natriuretic Peptide Is a Strong Predictor of Prognosis in Patients With Advanced Heart Failure Awaiting for Cardiac Transplantation; C. Campana, M. Pasotti, R. Albertini, S. Ghio, C. Klersy, L. Tavazzi, ¹Cardiology, Policlinico San Matteo, Pavia, Italy; ²Laboratory of Clinical Chemistry, Policlinico San Matteo, Pavia, Italy; ³Biometry and Clinical Epidemiology, Policlinico San Matteo, Pavia, Italy
- (274) Body Temperature Less Than 97.0 Degrees Fahrenheit Is Associated With Increased B-Type Natriuretic Peptide and Worse Response to Therapy in Heart Failure Patients; R.M. Delgado, G. Poulin, B. Radovancevic, B. Vrtovec, K. Albright, B. Kar, ¹Transplant Research, Texas Heart Institute, Houston, TX; ²Heart Failure Department, St. Luke's Episcopal Hospital, Houston, TX
- (275) Maturity and Adherence in Adolescent Heart Recipients; C.S. Stille, K. Lawrence, A. Bender, E. Olshansky, S. Webber, M.A. Dew, ^{1,3,4,5}School of Nursing, University of Pittsburgh, Pittsburgh, PA; ²Pediatric Heart & Lung Transplantation, Children's Hospital of Pittsburgh, Pittsburgh, PA; ³Psychiatry, University of Pittsburgh, Pittsburgh, PA; ⁴Psychology, University of Pittsburgh, Pittsburgh, PA; ⁵Epidemiology, University of Pittsburgh, Pittsburgh, PA
- (276) Depressive Symptoms in Heart Transplant Recipients in an Alternate List Program; J. Yager, K. Barbour, R. LaCaille, M. Felker, A. Hernandez, S. Russell, C. Milano, E. Stone, A. Brosse, J. Blumenthal, ¹Cardiology, Duke University Medical Center, Durham, NC; ²Psychology, Duke University Medical Center, Durham, NC; ³Cardiology, Johns Hopkins Hospital, Baltimore, MD; ⁴Surgery, Duke University Medical Center, Durham, NC; ⁵Psychology, University of Colorado, Boulder, CO
- (277) The Nature of a Healthy Transition After Lung Transplantation; A. De Vito Dabbs, K.R. Mc Curry, ¹School of Nursing, University of Pittsburgh; ²School of Medicine, University of Pittsburgh, Pittsburgh, PA
- (278) College Students Perceptions About Organ Donation; K.P. Boland, K.Q. Baker, A.B. Nicholson, Social Sciences, Cedar Crest College, Allentown, PA; Psychology, Cedar Crest College, Allentown, PA; Social Sciences, Cedar Crest College, Allentown, PA
- (279) Evaluation of a Psychological Intervention (Structured Activity Camp) To Reduce Anxiety and Enhance Self-Esteem in Adolescents Post-Transplant; T. Lunnon-Wood, J. Wray, P. Whitmore, R. Radley-Smith, P. Aurora, M. Elliott, ¹Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom; ²Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom
- (280) Impact of Chronic Renal Dysfunction on Long Term Survival and Quality of Life in Pediatric Thoracic Transplants; R. Radley-Smith, N.R. Banner, M. Carby, J.O. Wray, ¹Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom
- (281) Efficacy of Implantable Cardioverter Defibrillator in Children With Dilated Cardiomyopathy; P. Rusconi, D. Lage, E.R. Rosenkranz, G.S. Wolff, M.-L. Young, ¹Pediatrics, University of Miami Medical School, Miami, FL; ²Surgery, University of Miami School of Medicine, Miami, FL
- (282) High Prevalence of Gastroesophageal Reflux in Children Post Lung Transplantation - A Single Center Experience; C. Benden, P. Aurora, J.I. Curry, P. Whitmore, M.J. Elliott, ¹Cardiothoracic Transplant Unit, Great Ormond Street Hospital for Children, London, United Kingdom; ²Neonatal and Paediatric Surgery Directorate, Great Ormond Street Hospital for Children, London, United Kingdom
- (283) Recurrence of Coronary Artery Disease in Children After Retransplantation; M.A. Kuhn, D.D. Deming, R.E. Chinnock, A.J. Razzouk, R.L. Larsen, ¹Pediatrics, Loma Linda University Children's Hospital and Medical Center, Loma Linda, CA; ²Cardiothoracic Surgery, Loma Linda University Children's Hospital and Medical Center, Loma Linda, CA
- (284) Conversion From Trough (C0) to 2 Hour (C2) Monitoring of Cyclosporine Level in Pediatric Heart Transplant Patients- An Intent-To-Treat Study; C.E. Canter, S.P. Hmiel, R.W. Shepherd, S.A. Lassa-Claxton, M. Landt, ¹Pediatrics, Washington University, St. Louis, MO
- (285) Pre-Transplant Parental Psychosocial Assessment Predicts Medical Outcome in Children After Orthotopic Heart Transplantation; D.M. Stone, J. Dupuis, J. Leleszi, D. Allasio, T.P. Singh, ¹Pediatrics, Children's Hospital of Michigan, Detroit, MI
- (286) Monitoring of Epstein-Barr Viral Load in Pediatric Heart and Lung Transplant Recipients by Real Time PCR; C. Benden, P. Aurora, M. Burch, D. Cubitt, M.J. Elliott, ¹Cardiothoracic Transplant Unit, Great Ormond Street Hospital for Children, London, United Kingdom; ²Department of Virology, Great Ormond Street Hospital for Children, London, United Kingdom
- (287) Renal Benefit of Rapamycin in Pediatric Heart Transplant Patients; I.C. Balfour, S.W. Srun, E.G. Wood, C.W. Belsha, D.L. Marshall, B.R. Ferdman, Department of Pediatrics, St. Louis University School of Medicine, St. Louis, MO
- (288) Intravenous Steroids Do Not Increase Perioperative Airway Complication Risk in Pediatric Lung Transplant Patients; J. Nigro, M.V. Horn, V.A. Starnes, M.L. Barr, M.S. Woo, ¹Cardiothoracic Surgery, Childrens Hospital Los Angeles, Los Angeles, CA
- (289) Autologous Tissue Engineered With Mesenchymal Stem Cells for Cardiac Repair After Myocardial Infarction in Rats: Feasibility and Histological Data; P. Maureira, J. Nloga, Y. Grignon, Y. Li, T. Lacroux, F. Groubatch, J.-F. Stoltz, J.-P. Villemot, N. Tran, ¹Laboratory of School Surgery, Faculty of Medicine-Nancy, Nancy, France; ²Laboratory of Pathology, University Hospital Center of Nancy, Nancy, France; ³Department of Cell Therapy and Tissue Engineering, UMR-CNRS 7563, Faculty of Medicine-Nancy, Nancy, France

- (290) In Vivo Location of Intramyocardial Implanted ^{111}Tc -Sestamibi SPECT in a Rat Model of Myocardial Infarction; Assessment with Dual Energy Pinhole $^{99\text{m}}\text{Tc}$ -Sestamibi SPECT in a Rat Model of Myocardial Infarction; N. Tran,^{1,2} F. Maskali,³ P. Franken,⁴ J. Nloga,¹ T. Lahoutte,⁴ P. Maureira,¹ Y. Li,¹ P.-Y. Marie,³ G. Karcher,³ J.-F. Stoltz,² J.-P. Villemot,¹ ¹Laboratory of Surgery School, Faculty of Medicine-Nancy, Nancy, France; ²Department of Cell Therapy and Tissue Engineering, UMR7563 CNRS, Faculty of Medicine-Nancy, Nancy, France; ³Department of Nuclear Medicine- EA3447, CHU-Nancy, University Hospital Center of Nancy, Nancy, France; ⁴Department of Nuclear Medicine, AZ-VUB, Brussels, Belgium
- (291) WITHDRAWN
- (292) Interactions Between Complement and Coagulation in Mouse Lung Hyperacute Rejection: Characterization Using Soluble Thrombin Inhibition and APT070, a Novel Membrane-Bound Complement Inhibitor; B.-N. Nguyen,¹ T. Zhang,¹ A. Laaris,¹ N. Coppard,² B. Bradford,² R.N. Pierson III,¹ A.M. Azimzadeh,¹ ¹University of Maryland, Baltimore, MD; ²Adprotech, Essex, United Kingdom
- (293) Successful Control of Early Bacterial and Fungal Infections in a Preclinical Cardiac Xenotransplantation Model That Achieves Prolonged Survival; S.S. Teotia,¹ R.C. Walker,¹ J.M. Schirmer,¹ H.D. Tazelaar,¹ G.W. Byrne,¹ J.S. Logan,¹ C.G.A. McGregor,¹ ¹William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN
- (294) Apoptosis as a Prognostic Indicator of Long-Term Mortality and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy Undergoing Palliative Surgical Treatment; L.F.P. Moreira,¹ M.L. Higuchi,¹ F. Bacal,¹ N.G. Stolf,¹ S.A. Oliveira,¹ ¹Surgery Division, Heart Institute (Incor), University of São Paulo Medical School, São Paulo, SP, Brazil
- (295) NT-proBNP as a Marker of Recovery after High-Risk Coronary Artery Bypass Grafting in Patients With Severe Impaired LV-Function; M. Rothenburger,¹ M. Hoppe,¹ J. Stypmann,² T. Wichter,² E. Berendes,³ C. Etz,¹ A. Loeher,¹ H.H. Scheld,¹ C. Schmid,¹ ¹Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany; ²Cardiology and Angiology, University Hospital Muenster, Muenster, Germany; ³Anesthesiology and Operative Intensive Care Medicine, University Hospital Muenster, Muenster, Germany
- (296) Modulation of Myofibroblast Differentiation by Peroxisome Proliferator-Activated Receptor-(gamma) (PPARgamma): A Role for Transforming Growth Factor-beta (TGFbeta) Signaling; A.M. Ramirez,^{1,2} H. Rivera,³ J.D. Ritzenthaler,² S. Roser,³ J. Roman,^{2,3} ¹McKelvey Lung Transplantation Center, Emory University; ²Division of Pulmonary, Allergy, and Critical Care; ³Atlanta Veterans Affairs Medical Center, Atlanta, GA
- (297) Expression and Anti-Proliferative Effects of Interleukin-19 (IL-19) in Allografted Hearts and Cultured Smooth Muscle Cells; S.E. Kelemen, H.J. Eisen, B.I. Goldman, M.V. Autieri, ¹Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA
- (298) Genetic Polymorphisms and Bronchiolitis Obliterans Syndrome Post Lung Transplantation; I.A. Forrest,¹ L. Nicholson,² R. Platt,² C. Ward,¹ J.H. Dark,¹ P.G. Middleton,² P.A. Corris,¹ ¹Applied Immunobiology and Transplantation, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; ²School of Clinical Laboratory Sciences (Haematology), University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
- (299) Diverse Pathways of Cardiac Allograft Rejection Correlate With Distinct Pathogenic Mechanisms of Cardiac-Specific Autoimmunity; M. Zwierzchoniowska,¹ R.C. Robbins,¹ E.V. Fedoseyeva,¹ ¹CT Surgery, Stanford University, Stanford, CA
- (300) The Anti-Inflammatory Properties of Mycophenolate Mofetil in Experimental Lung Ischemia Reperfusion Injury; A.S. Farivar,¹ B.C. Mackinnon-Patterson,¹ A.S. McCourtie,¹ M.S. Mulligan,¹ ¹Thoracic Surgery, University of Washington Medical Center, Seattle, WA
- (301) Inhalative Immunosuppression Via Tobacco Smoke Significantly Increases Graft Survival After Orthotopic Lung Transplantation in the Rat; A.R. Simon,¹ T. Köster,¹ C. Mörike,¹ Y. Li,¹ S. v. Hörsten,² T. Tschernig,² A. Haverich,¹ ¹Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; ²Department of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany
- (302) Gene Expression Changes Associated With Ischemia-Reperfusion Injury Following Rat Lung Transplantation; G. Koukoulis,¹ Y. Yuan,² T. Egan,² ¹Cardiac Surgery, Hopital San Matteo, University of Pavia, Pavia, Italy; ²Surgery, University of North Carolina, Chapel Hill, NC
- (303) Effects of Immunosuppressants (Calcineurin-Antagonists and m-TOR-Inhibitors) on Endothelial Cell Signals and Replication; D.E. Birnbaum,¹ K. Lehle,¹ F.X. Schmid,¹ J.G. Preuner,¹ ¹Clinic for Cardio-Thoracic Surgery, University Hospital Regensburg, Regensburg, Germany
- (304) Migration of Mesenchymal Stem Cells to Allograft Is Related to CD44-Hyaluronan Interaction and Regulated by Platelet-Derived Growth Factor; H. Zhu,¹ M.L. Barr,¹ Y.-S. Jin,¹ N. Mishuhita,¹ V. Starnes,¹ G.D. Wu,¹ ¹Cardiothoracic Surgery Research, Childrens Hospital Los Angeles, Los Angeles, CA
- (305) Peripheral Blood Natural Killer Cells and CMV Activation Following Lung Transplantation; J.E. Fildes,¹ A.H. Walker,² J. Thekkudan,³ K. Polster,⁴ M. Guiver,⁴ N. Yonan,¹ I.V. Hutchinson,⁵ C. Leonard,¹ ¹The Transplant Centre, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom; ²Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, United Kingdom; ³Department of Cardiothoracic Surgery, University Hospital of Wales, Cardiff, United Kingdom; ⁴Department of Virology, Manchester Royal Infirmary, Manchester, United Kingdom; ⁵The Department of Immunology, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom

- (306) Poly (ADP-ribose) Polymerase Inhibition Improves Cardiac Function During Cardiac Rejection; G. Szabó, S. Hagl, C. Szabó, ¹ Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; ²Inotek Pharmaceuticals Corporation, Beverly, MA
- (307) Glucocorticoids Prior to Brain Death Shift the Balance between Pro- and Anti-Inflammatory Mediators in the Myocardium; K.M. McLean, ^{1,2} J.M. Lyons, ^{1,2} J.Y. Duffy, ^{1,2} S. Akhter, ¹ C.J. Wagner, ² J.M. Pearl, ^{1,2} ¹Department of Surgery, University of Cincinnati, Cincinnati, OH; ²Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
- (308) Right Ventricular Pressure Load in Pigs: Progressive Loss of Contractility w/o Ischemia and Downregulation of Ca²⁺ Handling Proteins; M. Coulibaly, ¹ H. Doerge, ¹ C. Muehlfeld, ³ F.A. Schoendube, ¹ Cardiothoracic and Vascular Surgery, University Hospital, Göttingen, Germany; ²Department of Anatomy, University Hospital, Göttingen, Germany
- (309) VEGF and PDGF Have Distinct Roles in Development of Experimental Obliterative Bronchiolitis - A Therapeutic Approach; M. Hollmén, ¹ J.M. Tikkanen, ¹ P.K. Koskinen, ¹ K.B. Lemström, ¹ Transplantation Laboratory, Helsinki University, Helsinki, Finland
- (310) Deletion of Alloreactive Cells in Neonatal Induction of Cardiac Allograft Acceptance by Splenocytes vs Fetal Liver Cells; L. Mai, ¹ K.S. Tao, ¹ H. Lang, ¹ J.W. Chamberlain, ¹ L.J. West, ¹ Cardiology and Immunology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada
- (311) The Role of Alloantibody in Neonatally-Induced Cardiac Allograft Acceptance; K. Parameswaran, ¹ K. Tao, ¹ L. Mai, ¹ K. Tyerman, ¹ X. Fan, ¹ L.J. West, ¹ Cardiology and Immunology, Hospital for Sick Children/University of Toronto, Toronto, Ontario, Canada
- (312) Clarithromycin Has a Preventive Effect on Chronic Rejection by Downregulation of Innate Immunity and Mesenchymal Growth; K.F. Remund, ¹ Z. Guo, ¹ T. Rechsteiner, ¹ M. Hofer, ¹ P. Vogt, ² E.W. Russi, ¹ A. Boehler, ¹ Division of Pulmonary Medicine and Lung Transplant Program, University Hospital, Zurich, Switzerland; ²Department of Pathology, University Hospital, Zurich, Switzerland
- (313) Additional VLA 4 Blockade Increases Immunosuppressive Properties of Cyclosporine A After Cardiac Transplantation; M.H.C. Richter, ¹ H. Bittner, ¹ M. Barten, ¹ J. Gummert, ¹ F. Mohr, ¹ University of Leipzig, Heart Center of Leipzig, Leipzig, Germany
- (314) Should Humoral Rejection Be Included in the New ISHLT Biopsy Grading Scale? J.A. Kobashigawa, ¹ M.C. Fishbein, ¹ J.K. Patel, ¹ B.T. Oeser, ¹ N.P. Almeda, ¹ S. Alison-Mayne, ¹ A. Seid, ¹ H. Laks, ¹ Cardiology, University of California at Los Angeles, Los Angeles, CA
- (315) Can Histologic Parameters Be Used to Screen Biopsies for Antibody Mediated Rejection? A Retrospective Study of 3179 Biopsies; M.E.H. Hammond, ¹ J. Stehlik, ¹ G. Snow, ¹ D.G. Renlund, ¹ J.T. Seaman, ¹ B. Dabbas, ¹ A.G. Kfoury, ¹ U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT
- (316) C4d in Antibody-Mediated Rejection – How Sensitive Is It? J. Stehlik, ¹ A.G. Kfoury, ¹ D.G. Renlund, ¹ E.M. Gilbert, ¹ J.C. Stringham, ¹ B. Dabbas, ¹ E.H. Hammond, ¹ U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT
- (317) The Cellular Infiltrate in the Human Artery Wall with Transplant Coronary Artery Disease: A T-Helper 1 Memory Response; J. van Kuik, ¹ J. van Loosdregt, ¹ D.F. van Wichen, ¹ M.F.M. van Oosterhout, ¹ A.H. Bruggink, ¹ C.C. Baan, ² N. de Jonge, ¹ F.H.J. Gmelig-Meyling, ¹ R.A. de Weger, ¹ Pathology, University Medical Centre Utrecht, Utrecht, Netherlands; ²Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
- (318) Abdominal Only Approach for HeartMate LVAD Pump Replacement; A.H. Healy, ¹ C.R. Wecker, ¹ K.E. Nelson, ¹ R. Khodaverdian, ¹ J.W. Long, ¹ Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT
- (319) Successful Outpatient Management of Patients With Ventricular Assist Devices: A 14 Year Experience; A.N. Patel, ¹ H. Tsukui, ¹ E. Stanford, ¹ J.R. Buchanan, ¹ L. Carozza, ¹ S. Winowich, ¹ S. Murali, ¹ M. Dennis, ¹ R.L. Kormos, ¹ Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
- (320) Increased Incidence of Bridge-to-Recovery with Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy Supported by LVAS; M. Nishimura, ¹ S. Kyo, ¹ M. Ogiwara, ¹ M. Ishikawa, ¹ Cardiovascular Surgery, Saitama Medical School, Iruma County, Saitama, Japan
- (321) Stroke Complications Following Implantation of the Cardiowest Total Artificial Heart: University of Arizona Experience; P.E. Nolan, ¹ F.A. Arabia, ² R.G. Smith, ³ G.K. Sethi, ² P.H. Tsau, ² D.M. McClellan, ³ M.S. McCarthy, ⁴ M.J. Slepian, ² J.G. Copeland, ² Pharmacy Practice and Science, University of Arizona, Tucson, AZ; ²Cardiovascular and Thoracic Surgery, University of Arizona, Tucson, AZ; ³Marshall Foundation Artificial Heart Program, University Medical Center, Tucson, AZ; ⁴Transplantation Service, University Medical Center, Tucson, AZ; ⁵Internal Medicine, University of Arizona, Tucson, AZ
- (322) Stroke Following Left Ventricular Assist Device Implantation Increases Length of Stay but Does Not Decrease Survival; N.C. Dang, ¹ J. Kay, ¹ V.K. Topkara, ¹ M.L. Mercado, ¹ K.H. Kruger, ¹ M.C. Oz, ¹ Y. Naka, ¹ Surgery, Columbia-Presbyterian Medical Center, New York, NY
- (323) Right Heart Failure Following Left Ventricular Assist Device Implantation; N.C. Dang, ¹ M.L. Mercado, ¹ J. Kay, ¹ V.K. Topkara, ¹ K.H. Kruger, ¹ M.S. Aboodi, ¹ T.P. Martens, ¹ I. George, ¹ F.H. Cheema, ¹ M.C. Oz, ¹ Y. Naka, ¹ Surgery, Columbia-Presbyterian Medical Center, New York, NY
- (324) Left Ventricular Assist Device Implantation Is Associated With Improvement in Renal Function Among Patients With Pre-Implant Renal Insufficiency; J. Butler, ¹ R.L. Howser, ² C. Geisburg, ¹ R.N. Pierson III, ³ Cardiology Division, Vanderbilt University Medical Center, Nashville, TN; ²World Heart Inc., Oakland, CA; ³Division of Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD

(325) Improved Results Treating Primary Lung Allograft Failure Using Venovenous Extracorporeal Membrane Oxygenation (ECMO); M.G. Hartwig, J.Z. Appel, S.S. Lin, S. Simsir, R. Messier, R. Davis,¹ Department of Surgery, Duke University, Durham, NC

(326) Reversal of Pulmonary Hypertension With LVAD Therapy; M. Tierney,¹ R.E. Southard,¹ D.L. Joyce,¹ G.P. Noon,¹ M. Loebe,¹ M.M. Koerner,² G. Torre-Amione,² Surgery, Baylor College of Medicine, Houston, TX; ²Cardiology, Baylor College of Medicine, Houston, TX

(327) Continuous Aortic Flow Augmentation Using the Orqis® Cancion® CRS™ Therapy in Patients with Severe Heart Failure: Determinants of the Hemodynamic Response; M.R. Zile,¹ R.M. Oren,² M. Bohm,³ J. Sadowski,⁴ A.B. Van Bakel,¹ B. Czerska,⁵ W.T. Abraham,⁶ A. Wasler,¹ B. Cabuay,² K. Bartus,⁴ M.A. Konstam,⁸ ¹Medicine, MUSC, Charleston, SC; ²Medicine, University of Iowa, Iowa City, IA; ³Internal Medicine, University Hospital Saarland, Homburg, Germany; ⁴Cardiology, John Paul II Hospital, Krakow, Poland; ⁵Cardiology, Henry Ford, Detroit, MI; ⁶Medicine, Ohio State, Columbus, OH; ⁷Transplantation, University Hospital Graz, Graz, Austria; ⁸Medicine, Tufts-New England MC, Boston, MA

(328) Salvage Ventricular Assistance for Patients Undergoing Cardiopulmonary Resuscitation: Long Term Results; G. Bolotin,¹ J. Raman,¹ N. Thomas,¹ V. Jeevanandam,¹ Section of Cardiac and Thoracic Surgery, The University of Chicago, Chicago, IL

(329) Comparison of Infections in the Cardiowest TAH, the Novacor Left Ventricular Assist System and the Thoratec Ventricular Assist Device in 137 Patients; T.K. Burke,¹ H.R. Bradshaw,¹ R.G. Smith,¹ F.A. Arabia,² M. McCarthy,¹ J.G. Copeland,² Artificial Heart Program, University Medical Center, Tucson, AZ; ²Sarver Heart Center, University of Arizona, Tucson, AZ

(330) Brain Natriuretic Peptide Levels in Serum and Heart in Patients Supported With a Left Ventricular Assist Device; A.H. Bruggink,¹ D.F. van Wichen,¹ J. van Kuik,¹ F.H.J. Gmelig-Meyling,¹ R.A. de Weger,¹ N. de Jonge,² Pathology, University Medical Center Utrecht, Utrecht, Netherlands; ²Heart Lung Center, Utrecht, Netherlands

(331) Successful Aggressive Withdrawal of Prednisone for De Novo Heart Transplant Patients in the Era of Modern Immunosuppression; M.S. Levy,¹ C. Imai, A.-M. Kaan, L. Straatman, A. Ignaszewski,¹ Cardiology, St. Paul's Hospital, Vancouver, Canada

(332) Lower Incidence of Graft Vasculopathy (CAD) and Better Survival of Patients with Developed CAD: Potential Impact of Different Regimens; E. Szent-Ivanyi,¹ A. Aliabadi,¹ D. Dunkler,¹ S. Rödler,¹ A. Kocher,¹ M. Grimm,¹ E. Wolner,¹ A. Zuckermann,¹ Department of Cardio-Thoracic Surgery, Medical University of Vienna, Vienna, Austria

(333) Maintenance Immunosuppression with Mycophenolate Mofetil: Long-Term Efficacy After Heart Transplantation; M. Dandel,¹ H. Lehmkuhl,¹ C. Knosalla,¹ O. Grauhan,¹ R. Hetzer,¹ Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

6:00 PM - 7:00 PM

Heart Failure and Transplant Medicine Scientific Council Meeting (Room 412)

Pulmonary Transplantation Scientific Council Meeting (Room 401)

Infectious Disease Scientific Council Meeting (Room 402)

7:00 PM – 8:00 PM

Bus departure to National Constitution Center

7:30 PM – 8:30 PM

Poster Display Session 1 Tear-Down (Franklin Hall)

7:30 PM-10:00 PM

**PRESIDENT'S GALA RECEPTION
(National Constitution Center)**

FRIDAY, APRIL 8, 2005

6:00 AM-6:00 PM

Speaker Ready Room (Room 502)

7:00 AM-8:00 AM

Morning Coffee/Visit Exhibits (Franklin Hall)

7:00 AM-5:30 PM

Registration Desk Open (Ballroom Foyer)

7:00 AM-6:00 PM

Press Office Open (Room 404)

7:00 AM-6:30 PM

Exhibits Open (Franklin Hall)

8:00 AM-10:00 AM

PLENARY SESSION (Salon G-L)

Moderators: Robert L. Kormos, MD and ?????????????

8:00 AM **Presidential Address**, Alec Patterson, MD, ISHLT President, Washington University, St. Louis, MO

8:30 AM (96) **Featured Abstract Presentation: Results of a Multicenter Randomized Clinical Trial for the Assessment of a Cardiac Support Device in Patients with Heart Failure**; D.L. Mann,¹ M.A. Acker,² M. Jessup,² H.N. Sabbah,³ R.C. Starling,⁴ S.H. Kubo,⁵ ¹Baylor College of Medicine, Houston, TX; ²University of Pennsylvania, Philadelphia, PA; ³Henry Ford Health Care System, Detroit, MI; ⁴The Cleveland Clinic Foundation, Cleveland, OH; ⁵Acorn Cardiovascular, Inc., St. Paul, MN

8:45 AM (97) **Featured Abstract Presentation: Successful Bridge to Clinical Lung Transplantation Using the Pumpless Extracorporeal Lung Assist Device Novalung® in Patients With Severe Ventilation-Refractory Hypercapnia**; S. Fischer,¹ A. Meyer,¹ B. Gohrbandt,¹ A. Simon,¹ J. Gottlieb,¹ T. Welte,¹ A. Haverich,¹ M. Struber,¹ ¹Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, Germany

9:00 AM (98) **Featured Abstract Presentation: Initial Multicenter Clinical Results With the Heartmate® II Axial Flow Left Ventricular Assist Device**; F.D. Pagani,¹ M. Strueber,² Y. Naka,³ R.L. Kormos,⁴ J.W. Long,⁵ R.D. Dowling,⁶ H.T. Massey,⁷ D.J. Farrar,⁸ O.H. Frazier,⁹ ¹University of Michigan, Ann Arbor, MI; ²Medizinisch Hochschule, Hannover, Germany; ³Columbia University, New York, NY; ⁴University of Pittsburgh, Pittsburgh, PA; ⁵LDS Hospital, Salt Lake City, UT; ⁶University of Louisville, Louisville, KY; ⁷University of Rochester, Rochester, NY; ⁸Thoratec Corporation, Pleasanton, CA; ⁹Texas Heart Insitutet, Houston, TX

9:15 AM (99) **Featured Abstract Presentation: Outcome of Children Bridged to Transplant With Ventricular Assist Devices: A Multi-Institutional Study**; E.D. Blume,¹ D.C. Naftel,² H.J. Bastardi,¹ B.W. Duncan,³ J.K. Kirklin,² S.A. Webber,⁴ ¹Department of Cardiology, Children's Hospital Boston, Boston, MA; ²Department of Surgery, University of Alabama, Birmingham, AL; ³Pediatric and Congenital Heart Surgery, Cleveland Clinic Foundation, Cleveland, OH; ⁴Pediatric Cardiology, University of Pittsburgh Children's Hospital, Pittsburgh, PA

9:30 AM **Invited Lecture: Future of Mechanical Support: A Global Perspective**, Timothy Baldwin, PhD, National Institutes of Health, Bethesda, MD

10:00 AM-10:30 AM

Coffee Break/View Exhibits/View Posters (Franklin Hall)

10:30 AM-NOON

CONCURRENT SESSION 13

Selection of LVAD Recipients and Effect on Outcome (Salon G-L)

Moderators: Martin Struber, MD and Roberta C. Bogaev, MD

10:30 AM (100) **Favourable Results of Mechanical Circulatory Support Extended Beyond One Year**; M.J. Jurmann,¹ Y. Weng,¹ T. Drews,¹ M. Pasic,¹ E. Hennig,¹ J. Mueller,¹ R. Hetzer,¹ ¹Herz-, Thorax- und Gefaesschirurgie, Deutsches Herzzentrum Berlin, Berlin, Germany

10:45 AM (101) **Bridge to Eligibility: LVAS Support in Patients With Relative Contraindications to Transplantation**; J.B. Young,¹ J.G. Rogers,² P.M. Portner,³ P.E. Oyer,³ B.S. Edwards,⁴ S.F. Davis,⁵ T.B. Icenogle,⁶ F.L. Johnson,⁷ R.L. Kormos,⁸ S.L. Lansman,⁹ S.W. Restaino,¹⁰ ¹Cleveland Clinic, Cleveland, OH; ²Washington University, St. Louis, MO; ³Stanford University, Stanford, CA; ⁴Mayo Clinic, Rochester, MN; ⁵Vanderbilt University, Nashville, TN; ⁶Sacred Heart Medical Center, Spokane, WA; ⁷University Maryland, Baltimore, MD; ⁸University Pittsburgh, Pittsburgh, PA; ⁹Mt Sinai, New York, NY; ¹⁰Presbyterian Hospital, New York, NY

11:00 AM (102) **Post-Transplant Survival in Older Patients Bridged to Heart Transplant With Left Ventricular Assist Device Support**; D.B. Dyke,¹ P. Malani,¹ F.D. Pagani,² S. Wright,² M. Daly-Myers,² K. Aaronson,¹ T. Koelling,¹ R. Baliga,¹ J. Matthews,¹ A. Wu,¹ ¹Division of Cardiovascular Medicine,

University of Michigan Health System, Ann Arbor, MI; ²Section of Adult Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI

11:15 AM (103) Clinical Outcomes With Mechanical Circulatory Support Devices: A Retrospective Analysis of the Impact of Age in 1,365 LVAD Recipients; T. Mussivand,¹ D.A. Hasle,¹ K.S. Holmes,¹

¹Cardiovascular Devices Division, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

11:30 AM (104) Waitlist Mortality Risk Among Heart Transplant Candidates by Urgency Status and Ventricular Assist Device (VAD) Use; R.M. Merion,¹ T.E. Hulbert-Shearon,¹ R.T. Bustami,² R.A. Wolfe,¹

W.S. Ring,³ S. Murray,¹ ¹Research, SRTR/University of Michigan, Ann Arbor, MI; ²Research, SRTR/URREA, Ann Arbor, MI; ³Surgery, University of Texas Southwestern Medical School, Dallas, TX

11:45 AM (105) Advances in Patient and Economic Outcomes Associated With Left Ventricular Assist Devices for Destination Therapy; K. Nelson,¹ K. Tong,² A. Ellman,² J. Long,¹ ¹Department of Cardiovascular Surgery and Utah Artificial Heart Program, Latter Day Saints Hospital, Salt Lake City, UT; ²Division of Outcomes Research, Quorum Consulting, Inc., San Francisco, CA

10:30 AM-NOON

CONCURRENT SESSION 14

Post Transplant Infectious Disease: Old and New Viruses (Salon ABF)

Moderators: Kate Gould, MB, BS and **TBD**

10:30 AM (106) Use of the Multi Combination Bactericidal Test To Detect Optimal Antimicrobial Combinations for the Treatment of Pseudomonas Aeruginosa and Burkholderia Cepacia in Patients Undergoing Lung Transplantation;

L. Archer,¹ K. Morris,¹ J.D. Perry,¹ J.H. Dark,² P.A. Corris,² F.K. Gould,¹ ¹Microbiology Department, Freeman Hospital; ²Applied Immunology and Transplantation Group, Freeman Hospital, Newcastle upon Tyne, United Kingdom

10:45 AM (107) Outcomes With Hepatitis C Following Cardiac Transplantation: 10 Year Follow-Up; K. Lake,¹ K. Aaronson,¹ D. Naftel,² C. Smith,³ D. Renland,⁴ B. Czerska,⁵ R. Higgins,⁶ B. Radovancevic,⁷ S. Russell,⁸ M. Pritzker,³ ¹University of Michigan Medical Center, Ann Arbor, MI; ²University of Alabama at Birmingham, Birmingham, AL; ³Abbott Northwestern Hospital, Minneapolis, MN; ⁴LDS Hospital, Salt Lake City, UT; ⁵Henry Ford Hospital, Detroit, MI; ⁶Rush Presbyterian Medical Center, Chicago, IL; ⁷St. Luke's Episcopal Hospital, Houston, TX; ⁸Johns Hopkins University, Baltimore, MD; ⁹Minnesota Gastroenterology, Minneapolis, MN

11:00 AM (108) Intravenous Ribavirin Is a Safe and Cost-Effective Treatment for Respiratory Syncytial Virus Infection After Lung Transplant; A.R. Glanville,¹ C.L. Aboyoum,¹ M.L. Plit,¹ M.A. Malouf,¹ ¹The Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia

11:15 AM (109) Hepatitis B Vaccination in Heart Transplant Candidates; W.Q. Foster,¹ A. Murphy,¹ D.J. Vega,² W.M. Book,¹ ¹Internal Medicine, Emory University School of Medicine, Atlanta, GA; ²Surgery, Emory University School of Medicine, Atlanta, GA

11:30 AM (110) Mortality Associated With Use of Hepatitis C Positive Donors in Alternate List Heart Transplantation; S.D. Russell,¹ G.M. Felker,¹ L. Blue,¹ M.B. Higginbotham,¹ C.A. Milano,² ¹Medicine, Duke University Medical Center, Durham, NC; ²Surgery, Duke University Medical Center, Durham, NC

11:45 AM (111) Human Metapneumovirus - The First Series of a New Virulent Infection in Lung Transplant Recipients; P.M. Hopkins,¹ S.M. Williamson,¹ F.D. Kermeen,¹ E.T. McQueen,² T.P. Sloots,² K.D. McNeil,¹ M.D. Nissen,² ¹Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia; ²Clinical Virology Research Unit, Royal Children's Hospital, Brisbane, Queensland, Australia

10:30 AM-NOON

CONCURRENT SESSION 15

Genes and Cytokines in Lung Reperfusion Injury (Salon E)

Moderators: Marc De Perrot, MD and Bryan F. Meyers, MD

10:30 AM (112) Repertaxin, a Novel IL-8 Receptor Inhibitor, Ameliorates Ischemia-Reperfusion Injury After Experimental Lung Transplantation; S. Dharmarajan,¹ M. Hayama,¹ T. Ishiyama,¹ M. Okazaki,¹ J. Kim,¹ A.S. Krupnick,¹ D. Kreisel,¹ G.A. Patterson,¹ ¹Department of Surgery, Washington University School of Medicine, St. Louis, MO

10:45 AM (113) Dynamic Changes in Cytokine Gene Expression During Cold Ischemia Predicts Outcome After Lung Transplantation in Humans; H. Kaneda,¹ T.K. Waddell,¹ M. Liu,¹ S. Keshavjee,¹ ¹Thoracic Surgery Research Laboratory, Toronto General Hospital Research Institute, Toronto, Ontario, Canada

11:00 AM (114) Gene Expression Profiling of Donor Lungs Identifies a Gene Signature Associated With Ischemia-Reperfusion Injury; S. Dharmarajan,¹ M. Hayama,¹ A. Polpitya,¹ T. Ishiyama,¹ M. Okazaki,¹ J. Kim,¹ A.S. Krupnick,¹ D. Kreisel,¹ J.P. Cobb,¹ M.A. Watson,¹ G.A. Patterson,¹ ¹Department of Surgery, Washington University School of Medicine, St. Louis, MO

11:15 AM (115) Early Hemodynamic Lung Injury During Donor Brain Death Enhances Reperfusion Injury After Lung Transplantation; V.S. Avlonitis,¹ J.A. Kirby, J.H. Dark,¹ School of Surgical and Reproductive Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom

11:30 AM (116) Donor Glutathione S-Transferase Genotype Is Associated with Primary Graft Dysfunction Following Lung Transplantation; J.D. Christie,¹ R. Aplenc, J. DeAndrade,² S. Kawut,³ A. Milstone,⁴ A. Weinacker,⁵ L. Zhou,¹ J. Mazzotta,¹ E. DeMissie,¹ E.W. Ely,⁴ for the Lung Transplant Outcome Group, ¹Pulmonary Medicine, University of Pennsylvania, Philadelphia, PA; ²Pulmonary Medicine, University of Alabama Birmingham, Birmingham, AL; ³Pulmonary Medicine, Columbia University, NY, NY; ⁴Pulmonary Medicine, Vanderbilt University, Nashville, TN; ⁵Pulmonary Medicine, Stanford University, Palo Alto, CA

11:45 AM (117) Rapid Donor Lung Analysis in Humans Lung Transplantation With Quantitative Multiplex Rapid RT-PCR Assay; H. Kaneda,¹ X. Bai,¹ T.K. Waddell,¹ M. Liu,¹ S. Keshavjee,¹ Thoracic Surgery Research Laboratory, Toronto General Hospital, Toronto, Ontario, Canada

10:30 AM-NOON

CONCURRENT SESSION 16

Novel Immunosuppressive Strategies in Lung Transplantation (Salon CD)

Moderators: Andres Varela, MD and Gregory I. Snell, FRACP, MBBS

10:30 AM (118) Randomised Trial of Cyclosporin C0 vs. C2 Monitoring in De Novo Lung Transplant Recipients: Interim Results; J. Cornelissen,¹ A. Wood,² S. Pasupathy-Rajah,³ A. Trull,¹ J. Wallwork,¹ Clinical Pharmacology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; ²MRC Biostatistics Unit, Cambridge, United Kingdom; ³Transplant Unit, Papworth Hospital NHS Trust, Cambridge, United Kingdom

10:45 AM (119) A Randomized Control Trial of Daclizumab vs. Anti-Thymocyte Globulin Induction for Lung Transplantation; J.C. Mullen,¹ A. Dueck, M.J. Bentley,¹ D.L. Modry,¹ K. Stewart,¹ D.C. Lien,¹ P.F. Halloran,¹ University of Alberta, Edmonton, Alberta, Canada

11:00 AM (120) Rabbit Antithymocyte Globulin Induction Therapy for Lung Transplantation Does Not Affect Long-Term Allograft Function or Survival; M.G. Hartwig,¹ L.D. Snyder,² J.Z. Appel,¹ S. Simsir,¹ S.S. Lin,¹ S.M. Palmer,² R.D. Davis,¹ Department of Surgery, Duke University, Durham, NC; ²Department of Medicine, Duke University, Durham, NC

11:15 AM (121) One Year Complete Follow-Up of a Prospective Randomized International Investigator Driven Study Comparing Tac and CsA (+ MMF / Steroids) After Lung Transplantation in 274 Patients; H. Reichenspurner,¹ A. Glanville,² W. Klepetko,³ R. Lama,⁴ G.M. Verleden,⁵ C. Bravo,⁶ M. Estenne,⁷ S. Hirt,⁸ F.Z. Goni,⁹ J. Aubert,¹⁰ J.M. Borro,¹¹ P. Usetti,¹² T. Wahlers,¹³ C. Aboyoun,² H. Treede,^{1,11} Department of Cardiovascular Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ²Alfred Hospital, University of Sydney, Sydney, Australia; ³University of Vienna, Vienna, Austria; ⁴University of Cordoba, Cordoba, Spain; ⁵University of Leuven, Leuven, Belgium; ⁶University of Barcelona, Barcelona, Spain; ⁷University of Bruxelles, Bruxelles, Belgium; ⁸University of Kiel, Kiel, Germany; ⁹University of Santander, Santander, Spain; ¹⁰University of Lausanne, Lausanne, Switzerland; ¹¹University of La Coruna, La Coruna, Spain; ¹²University of Madrid, Madrid, Spain; ¹³University of Jena, Jena, Germany

11:30 AM (122) Safety of EBV DNA Guided Reduction of Immunosuppression After Lung Transplantation;

E. Verschuuren,¹ A. de Haan,² B. Hepkema,² M. Erasmus,³ J. Prop,² W. Timens,² G. Koeter,¹ W. van der Bij,¹ Pulmonology, University Hospital, Groningen, Netherlands; ²Pathology and Medical Biology, University Hospital, Groningen, Netherlands; ³Cardiothoracic Surgery, University Hospital, Groningen, Netherlands

11:45 AM (123) Long-Term Follow Up of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine Inhalation Solution (CyIS) in Lung Transplant Recipients; A. Iacono, W. Capra, S. Shrewsbury, B. Johnson, W. Grgurich, T. Corcoran, J. Youssef, D. Smith-Seiler, G. Smaldone, A. Zeevi, S. Yousem, J. Fung, J. Dauber, G. Burchart, K. McCurry, B. Griffith, Pulmonary Transplantation/Pulmonary Critical Care, University of Pittsburgh, Pittsburgh, PA; Cardiothoracic Surgery, University of Maryland, Baltimore, MD; Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

NOON-12:15 PM

Annual Business Meeting (Members only) (Salon G-L)

12:15 PM-2:00 PM

ISHLT Editorial Board Meeting (Rooms 401-402)

12:15 PM-1:45 PM

LUNCHEON SYMPOSIUM: Viral Infections in Thoracic Transplantation: What's New, What's Hot (Salon ABF)

Supported by an Educational Grant from Roche

Moderators: Jay A. Fishman, MD and Martin Zamora, MD

12:15 PM **What is the Current Role of CMV Prophylaxis?** Jim J. Egan, MD, Mater Misericordiae Hospital, Dublin, Ireland

12:35 PM **Community Acquired Respiratory Viruses**, Atul Humar, MD, Toronto General Hospital, Toronto, Canada

12:50 PM **Donor Issues: How Do You Handle Hepatitis B and C Positive Donors?** Robin Avery, MD, Cleveland Clinic, Cleveland, OH

1:10 PM **Challenge of PTLD: Answers from EBV and Xenotransplantation**, Jay A. Fishman, MD, Massachusetts General Hospital, Boston, MA

1:30 PM **Discussion**

12:30 PM – 1:30 PM

MINI-ORAL POSTER PRESENTATION SESSION 3 (Salon E)

Moderators: Bruce R. Rosengard, MD and Joren C. Madsen, MD

12:30 PM (124) Cyclic Strain of Adult Stem Cells Modulates Matrix Metalloproteinase Activity: Mechanism for Promoting Cell-Based Cardiac Remodeling; P.B. Bolno,¹ A.S. Wechsler,¹ S. Ranggappa,¹ J.Y. Kresh,¹ Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA

12:35 PM (125) Does Stem Cell Therapy for Ischemic Cardiomyopathy Result in the Improvement of Congestive Heart Failure: A Prospective Randomized Study; A.N. Patel,¹ L. Geffner,² R.F. Vina,² H.C. Urschel,³ M. Mathier,¹ R.L. Kormos,¹ F. Benetti,² Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; ²Benetti Foundation, Rosario, Argentina; ³Baylor University Medical Center, Dallas, TX

12:40 PM (126) Bioartificial Tissue Grafts Improve Left Ventricular Function in Ischemic Rat Hearts; I. Kutschka,¹ T. Kofidis,¹ I.Y. Chen,² A.Y. Sheikh,¹ J. Pearl,¹ S.L. Hendry,¹ G. Hoyt,¹ D.R. Lebl,¹ R.C. Robbins,¹ ¹Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; ²Department of Radiology, Stanford University School of Medicine, Stanford, CA

12:45 PM (127) (alpha)-gal Induces Monocyte (beta)-2 Integrin Activation and Firm Adhesion on ICAM-1 and ICAM-2;

M.D. Peterson,¹ S. Hyduk,² M.I. Cybulsky,² T.K. Waddell,¹ ¹Department of Surgery, University of Toronto, Toronto, Ontario, Canada; ²Department of Lab Medicine, University of Toronto, Toronto, Ontario, Canada

12:50 PM (128) CD154 and CD28/B7 Costimulation Pathways Regulate Both Natural and Induced Anti-Pig Antibodies in Baboons; G. Wu, T. Zhang, B.-N. Nguyen, C. Schroder, S. Pfeiffer, A. Laaris, H. Zhou, Q. Feng, A. Azimzadeh, R.N. Pierson III, Division of Cardiac Surgery, University of Maryland and Baltimore VA Medical Center, Baltimore, MD

12:55 PM (129) Benefits of Cardiac Resynchronization Therapy (CRT) in Patients With Advanced Congestive Heart Failure Listed for Heart Transplant; F. Oliva, M. Frigerio, M. Lunati, F. Turazza, A. Garascia, G. Foti, G. Masciocco, G. Distefano, I. Vicini, V. Burrone, Cardiology and Cardiac Surgery Department "A. De Gasperis", Ospedale Niguarda Cà Granda, Milan, Italy

1:00 PM (130) Static Cardiomyoplasty with Synthetic Elastic Net Suppresses Ventricular Dilatation and Dysfunction After Myocardial Infarction in the Rat; A.T. Kawaguchi,¹ A. Kishida,² T. Yamaoka,³ Cardiovascular Surgery, Tokai University, Isehara, Kanagawa, Japan; ²Tokyo Medical and Dental University, Tokyo, Japan; ³Kyoto Institute of Technology, Kyoto, Japan

1:05 PM (131) Computer Aided Free Wall Plication; A New Approach for Ventricular Reduction Surgery; G. Szabó,¹ P. Soós,² C.J. Beller,¹ A. Juhász-Nagy,² Cardiothoracic Surgery, University of Heidelberg, Heidelberg, Germany; ¹Cardiovascular Surgery, Semmelweis University, Budapest, Hungary

1:10 PM (132) Influence of Viral Infection in the Murine Orthotopic Tracheal Transplantation Model in the Development of Obliterative Airway Disease (OAD); E.Y. Kuo,¹ M.J. Walter,² W. Chapman,¹ T. Mohanakumar,¹ Department of Surgery, Washington University, St. Louis, MO; ²Department of Medicine, Washington University, St. Louis, MO

1:15 PM (133) Age Dependent Rejection After Heterotopic Experimental Heart Transplantation; S. Holinski,¹ D. Modersohn,¹ C. Proch,² R. Meyer,² W. Konertz,¹ Department of Cardiovascular Surgery, Charite-University-Hospital, Berlin, Germany; ²Department of Pathology, German-Heart-Center, Berlin, Germany

1:20 PM (134) Immunosuppression With FK778 and Tacrolimus Prevents the Development of Posttransplant Obliterative Airway Disease; T. Deuse,¹ S. Schrepfer,¹ F. Koch-Nolte,² M. Haddad,³ E. Schwedhelm,⁴ R. Boeger,⁴ H. Schaefer,⁵ H. Reichenspurner,¹ Cardiovascular Surgery, University Hospital, Hamburg, Germany; ²Immunology, University Hospital, Hamburg, Germany; ³Clinical Chemistry, University Hospital, Hamburg, Germany; ⁴Pharmacology, University Hospital, Hamburg, Germany; ⁵Pathology, University Hospital, Hamburg, Germany

1:25 PM (135) Influence of Cyclosporin A on Mucociliary System After Lung Transplantation in Rats; A.M. Xavier, P.P. Fernandes, A.T. Correia, R. Pazetti, M.M. Said, M. Canzian, L.F.P. Moreira, F.B. Jatene, Cirurgia Cardiopneumologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

12:30 PM-1:30 PM

MINI-ORAL POSTER PRESENTATION SESSION 4 (Salon CD)

Moderators: Stephan Schueler, MD and Donald S. Esmore, MD

12:30 PM (136) Neutrophilia Is an Inflammatory Signature of Chronic Heart Failure Modulated by Left Ventricular Assist Devices (VAD); H. Tsukui,¹ A.N. Vallejo,² A.N. Patel,¹ R.L. Kormos,¹ Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Pediatrics and Immunology, University of Pittsburgh, Pittsburgh, PA

12:35 PM (137) Incidence of Reoperation To Repair / Replace the Novacor LVAS; G. Faggian,¹ J.A. Elefteriades,² R. Hetzer,³ D.S. Esmore,⁴ H. Matsuda,⁵ R.N. Pierson III,⁶ Cardiac Surgery, University Hospital, Verona, Italy; ²Cardiothoracic Surgery, Yale University School of Medicine, New Haven, CT; ³Cardiothoracic Surgery, German Heart Center, Berlin, Germany; ⁴Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia; ⁵First Department Surgery, Osaka University Medical School, Osaka, Japan; ⁶Cardiothoracic Surgery, University of Maryland Medical Center, Baltimore, MD

12:40 PM (138) Clinical Durability of the LionHeart™ Left Ventricular Assist Device (LVAD): Comparison to Bench Testing and Implications for Future Designs; J.P. Boehmer,¹ W.E. Pae,¹ J.P. Lewis,² A.J. Snyder,¹ W.J. Weiss,¹ G. Rosenberg,¹ Surgery, Penn State College of Medicine, Hershey, PA; ²Arrow, Intl., Reading, PA

12:45 PM (139) Risk Factor Analysis for Bridge to Transplantation with the Cardiwest TAH; J.G. Copeland,¹ R.G. Smith,¹ F.A. Arabia,¹ P.E. Nolan,¹ M.J. Slepian,¹ Sarver Heart Center, University of Arizona, Tucson, AZ

12:50 PM (140) Effects of Sensitization in LVAD Recipients Following Heart Transplantation; M. Macha,¹ S.M. Khan,¹ S. Green,¹ J.P. Gaughan,² D. Beltramo,¹ J. Monacchio,¹ A.K. Singhal,¹ J.M. McClurken,¹ S. Furukawa,¹ Cardiothoracic Surgery, Temple University, Philadelphia, PA; ²Physiology, Temple University, Philadelphia, PA

12:55 PM (141) Pediatric Bridge to Heart Transplantation: Application of the Berlin Heart, Medos, and Thoratec Ventricular Assist Devices; F.A. Arabia,¹ P.H. Tsau,¹ R.G. Smith,² P.E. Nolan,³ V. Paramesh,¹ R.K. Bose,¹ D.S. Woolley,¹ G.K. Sethi,¹ B.E. Rhenman,¹ J.G. Copeland,¹ Sarver Heart Center, University of Arizona, Tucson, AZ; ²Artificial Heart Program, University Medical Center, Tucson, AZ; ³Pharmacy Practice and Science, University of Arizona, Tucson, AZ

1:00 PM (142) Evaluation of Cyclosporin (CsA) Profiles Month 2 to 6 in an International Phase III Randomized, Multicenter, Double-Blind Study of Everolimus in De Novo Heart Transplant Recipients; H.J. Eisen,¹ D. Mancini,² M. Vigano,³ J. Kobashigawa,⁴ School of Medicine, Temple University, Philadelphia, PA; ²Department of Medicine, Columbia Presbyterian Medical Center, New York, NY; ³IRCCS, Policlinico San Matteo, Pavia, Italy; ⁴Division of Cardiology, University of California at Los Angeles Medical Center, Los Angeles, CA

1:05 PM (143) A Randomized Control Trial of Daclizumab Versus Anti-Thymocyte Globulin Induction for Heart Transplantation; J.C. Mullen,¹ A. Dueck,¹ M.J. Bentley,¹ D.L. Modry,¹ S.H. Wang,¹ J.R. Burton,¹ W.J. Tymchak,¹ A. Koshal,¹ D. Ross,¹ P.F. Halloran,¹ University of Alberta, Edmonton, AB, Canada

1:10 PM (144) Biologic Activity of Csa in Cardiac Allograft Recipients Can Be Monitored by Measuring Suppression of NFAT-Regulated Gene Expression; M.H. Konstandin,¹ M. Schoels,² R. Klingenberg,¹ T. Giese,² T.J. Dengler,¹ Department of Cardiology, University of Heidelberg, Heidelberg, Germany; ²Institut of Immunology, University of Heidelberg, Heidelberg, Germany

1:15 PM (145) Comparison of Sublingual to Oral Tacrolimus Administration in Lung Transplantation; R.J. Janata,¹ A. Boukhamseen,¹ H.J. Kramer,² L. Michalski,³ S. Bhorade,¹ W. Vigneswaran,⁴ E.R. Garrity,¹ J. Villanueva,¹ Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL; ²Preventive Medicine and Epidemiology, Nephrology, Loyola University Medical Center, Maywood, IL; ³Pharmacology, Loyola University Medical Center, Maywood, IL; ⁴Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL

1:20 PM (146) The Feasibility of Complete Withdrawal of Oral Corticosteroids Following Lung Transplantation; P.A. Corris,¹ A.J. Fisher,¹ R. Rutherford,¹ J. Lordan,¹ Applied Immunology and Transplantation Group, University of Newcastle, Newcastle upon Tyne, Tyne and Wear, United Kingdom

2:00 PM-3:30 PM

CONCURRENT SESSION 17

Facing the Nemesis: Cardiac Transplant Vasculopathy (Salon G-L)

Moderators: David Taylor, MD and James K. Kirklin, MD

2:00 PM (147) Influence of Donor Transmitted Atherosclerosis on the Development of Cardiac Allograft Vasculopathy; H. Li,¹ K. Tanaka,¹ H. Anzai,¹ B. Oeser,¹ J. Kobashigawa,¹ J.M. Tobis,¹ Cardiology, University of California at Los Angeles, Los Angeles, CA

2:15 PM (148) The Risk of Cardiac Death in Heart Transplant Recipients With and Without Angiographically Detected Coronary Vasculopathy; K. Lietz,¹ J.M. Herre,^{1,2} Cardiovascular Division, Eastern Virginia Medical School, Norfolk, VA; ²Sentara Cardiovascular Research Institute, Norfolk, VA

2:30 PM (149) Blood Glutathione as a Marker of Cardiac Allograft Vasculopathy in Heart Transplant Recipients;

B. De Chiara,¹ M. Frigerio,² J. Campolo,¹ M. Parolini,¹ F.G. Oliva,³ G. Masciocco,² A. Garascia,² C. Fiorentini,³ E. Vitali,² O. Parodi,¹ CNR Clinical Physiology Institute, Section of Milan, Niguarda Ca' Granda Hospital, Milan, Italy; ²Cardiothoracovascular Department, Niguarda Ca' Granda Hospital, Milan, Italy; ³Division of Cardiology, S. Paolo Academic Hospital, Milan, Italy

2:45 PM (150) High Rejection Score Is Associated with Lower Coronary Flow Reserve in Heart Transplantation Recipients With Normal Coronary Angiography; F. Tona,¹ A.L.P. Caforio,¹ R. Montisci,² C. Sarais,¹ A. Angelini,³ A. Gambino,⁴ G. Toscano,⁴ G. Feltrin,⁴ D. Calzolari,¹ A. Ramondo,¹ A. Vinci,¹ M.G. Leone,¹ G. Thiene,³ G. Gerosa,⁴ S. Iliceto,¹ Cardiology, University of Padova, Italy; ²Cardiology, University of Cagliari; ³Pathology; ⁴Cardiovascular Surgery, University of Padova, Padova, Italy

3:00 PM (151) Long-Term Follow-Up of the Stanford Diltiazem for Retardation and Prevention of Transplant Coronary Artery Disease Study; S.Z. Gao,¹ B. Cantin,¹ D. Weisshaar,² H. Parekh,² S. Hunt,¹ J. Schroeder,¹ CVMED, Stanford University, Stanford, CA; ²CVMED, Kaiser Permanente, San Francisco, CA

3:15 PM (152) Donor-Transmitted Coronary Atherosclerosis: Impact on Outcome After Heart Transplantation;

O. Grauhan,¹ H. Chang,¹ R. Meyer,² N. Hiemann,² W. Albert,³ H. Lehmkuhl,¹ M. Dandel,¹ M. Hummel,⁴ C. Knosalla,¹ M. Pasic,¹ Y. Weng,¹ R. Hetzer,¹ Cardiovascular and Thoracic Surgery, German Heart Institute, Berlin, Germany; ²Pathology, German Heart Institute, Berlin, Germany; ³Psychosomatic, German Heart Institute, Berlin, Germany; ⁴Internal Medicine, Paulinenkrankenhaus, Berlin, Germany

2:00 PM-3:30 PM

CONCURRENT SESSION 18

Immunosuppression and Rejection in Lung Transplantation (Salon ABF)

Moderators: Murali M. Chakinala, MD and Jonathan B. Orens, MD

2:00 PM (153) Six Month Results of Sirolimus Versus Azathioprine in a Tacrolimus Based Immunosuppressive Regimen in Lung Transplantation; S.M. Bhorade,¹ V. Ahya,² R. Kotloff,² M. Baz,³ V. Valentine,⁴ S. Arcasoy,⁵ R. Love,⁶ W.T. Vigneswaran,¹ E.R. Garrity,¹ Medicine, Loyola University Medical Center, Maywood, IL; ²Medicine, University of Pennsylvania, Philadelphia, PA; ³Medicine, University of Florida, Gainesville, FL; ⁴Medicine, Ochsner Transplant Center, New Orleans, LA; ⁵Medicine, Columbia University, New York, NY; ⁶Cardiovascular Surgery, University of Wisconsin, Madison, WI

2:15 PM (154) Campath Preconditioning Followed by Low Maintenance Immunosuppression in Lung Transplant Recipients; K.R. McCurry,¹ A.L. Girnita,¹ D.B. Zaldonis,¹ S. Husain,¹ K. Spichy,¹ J. Pilewski,¹ T.E. Starzl,¹ A. Zeevi,¹ University of Pittsburgh Medical Center, Pittsburgh, PA

2:30 PM (155) Differences in Survival and De Novo Anti-Donor Antibody Development Among Lung Transplant Recipients Presensitized to Third Party Class I and Class II HLA Antigens; J.Z. Appel,¹ M.G. Hartwig,¹ E. Cantu,¹ S.M. Palmer,¹ N.L. Reinsmoen,¹ R.D. Davis,¹ Lung Transplant Program, Duke University Medical Center, Durham, NC

2:45 PM (156) Subendothelial C4d Deposition and Intragraft B Cell Infiltrates Are Associated With High-Grade Acute Rejection in Lung Transplantation; A.L. Girnita,¹ D.N. Ionescu,¹ S.A. Yousem,¹ D. Zaldonis,¹ K.R. McCurry,¹ A. Zeevi,¹ Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA

3:00 PM (157) Tacrolimus in Lung Transplantation: New Strategies To Optimize Dose; R. Ragette,¹ M. Kamler,¹ G. Weinreich,¹ H. Teschler,¹ H. Jakob,² Pneumology, Ruhrlandklinik, University Hospital of Essen, Essen, Germany; ²Thoracic and Cardiovascular Surgery, German Heart Center Essen, University Hospital of Essen, Essen, Germany

3:15 PM (158) Measurement of Immune Function in Lung Transplant Recipients Using the Cylex Immuknow Assay; A. Zeevi,¹ K. McCurry,¹ A. Girnita,¹ K. Spichy,¹ H. Shahid,¹ D. Zaldonis,¹ J. Britz,² D. Post,² R. Kowalski,² University of Pittsburgh, Pittsburgh, PA; ²Cylex Inc, Columbia, MD

2:00 PM-3:30 PM

CONCURRENT SESSION 19

Alternatives to Transplantation (Salon E)

Moderators: Robert C. Robbins, MD and Thomas K. Waddell, MD

2:00 PM (159) Transplantation of Flk1-Positive Embryonic Stem Cells Improves Cardiac Function After Acute Myocardial Infarction in Mice; H. Nakajima,¹ S. Baba,² G.U. Premaratne,¹ X. Lin,¹ N. Kanemitsu,¹ K. Tambara,¹ T. Ikeda,¹ T. Nakahata,² M. Komeda,¹ Cardiovascular Surgery, Kyoto University, Kyoto, Japan; ²Pediatrics, Kyoto University, Kyoto, Japan

2:15 PM (160) No Evidence for Cardiac Differentiation of Human Endothelial Progenitor Cells After Coculture with Neonatal Rat Cardiomyocytes; I. Gruh,¹ J. Beilner,¹ U. Bloemer,¹ A. Haverich,¹ U. Martin,¹ Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Hannover Medical School, Hannover, Germany

2:30 PM (161) Xenogenic Ex Vivo Perfusion of Lungs From GalT KO Pigs; B.-N. Nguyen,¹ C. Schroder,¹ J.S. Allan,² T. Zhang,¹ G. Wu,¹ A.M. Azimzadeh,¹ H.J. Shuurman,³ D.H. Sachs,² R.N. Pierson III,¹

¹University of Maryland & Baltimore VAMC, Baltimore, MD; ²TBRC & Massachusetts General Hospital, Boston, MA; ³Immerge Biotherapeutics Inc, Cambridge, MA
2:45 PM (162) Cardiac Xenotransplantation: Early Success in the Orthotopic Position; C.G.A. McGregor,¹ G.W. Byrne,¹ W.R. Davies,¹ K. Oi,¹ V.P. Rao,¹ H.D. Tazelaar,¹ R.C. Walker,¹ C.J. Gostout,¹ J.S. Logan,¹ Mayo Clinic William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN
3:00 PM (163) Long-Term Result of Left Ventricular Restoration Surgery for Idiopathic Dilated Cardiomyopathy To Treat End-Stage Heart Failure; T. Horii,¹ T. Isomura,¹ F. Nomura,¹ H. Suma,¹ Cardiovascular Surgery, Hayama Heart Center, Hayama, Japan
3:15 PM (164) Surgical Ventricular Remodeling for Severe Left Ventricular Dysfunction (EF(1e)20%); N.D. Patel,¹ C.J. Barreiro,¹ J.A. Williams,¹ M. Waldron,¹ T.P. Fitton,¹ P. Bonde,¹ J.V. Conte,¹ Department of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD

2:00 PM-3:30 PM

CONCURRENT SESSION 20

Markers of Cardiac Allograft Rejection (Salon CD)

Moderators: **TBD** and Michael C. Fishbein, MD

2:00 PM (165) Production of Donor Specific Anti-MHC Class II Antibodies Is Associated With Cardiac Graft Vasculopathy; J.D. Smith,¹ D.J. Anna,¹ F.E. Rachel,¹ P. Ariala,¹ B.R. Nicholas,² M. Andrew,² M.L. Rose,¹ Transplant Immunology, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Cardiology Department, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom

2:15 PM (166) Phosphorylation of S6 Ribosomal Protein at Serine 235/236 Is a Marker of Human Heart Transplantation; E.J. Lepin,¹ L. Hong,¹ Q.J. Zhang,¹ D.W. Gjertson,¹ J.A. Kobashigawa,¹ M.C. Fishbein,¹ E.F. Reed,¹ Departments of Pathology and Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA

2:30 PM (167) Distinctive Peripheral Blood Gene Expression Profiles in Patients Forming Nodular Endocardial Infiltrates (Quilty Lesions) Following Heart Transplantation; C.C. Marboe,¹ P.G. Lal,² K. Chu,¹ J. Wohlgemuth,² G. Berry,³ M. Billingham,³ Pathology, Columbia University Medical Center, New York, NY; ²Expression Diagnostics, South San Francisco, CA; ³Pathology, Stanford University Medical Center, Stanford, CA

2:45 PM (168) Early Growth-Response Factor-1 Is Involved in Cellular Injury of Transplanted Hearts; D. Abraham,¹ S. Aharinejad,² A. Zuckermann,² P. Paulus,¹ R. Schaefer,¹ M. Grimm,² Cardiovascular Research, Anatomy and Cell Biology, Vienna Medical University, Vienna, Austria; ²Cardiothoracic Surgery, Vienna Medical University, Vienna, Austria

3:00 PM (169) Vascular Expression of hsp-27 Is Associated with Absence of Graft Vasculopathy After Cardiac Transplantation; M. Rose,¹ A. De Sousa,¹ E. Mc Gregor,² R. Wait,³ A. Mitchell,⁴ N. Banner,⁴ M. Dunn,⁵ National Heart and Lung Institute, Imperial College, Harefield, Middlesex, United Kingdom; ²Proteome Sciences plc, London, United Kingdom; ³Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom; ⁴Cardiology, Royal Brompton and Harefield Hospitals, Harefield, Middlesex, United Kingdom; ⁵Neuroscience, Institute of Psychiatry, London, United Kingdom

3:15 PM (170) Humoral Rejection in Human Cardiac Allografts: Evaluation of Immunoglobulins and Complement Activation Products C4d and C3d; E.R. Rodriguez,¹ D.V. Skojeck,³ A. Zachary,¹ E.K. Kasper,² W.M. Baldwin,¹ Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; ²Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ³Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

3:30 PM-4:00 PM

Coffee Break/View Exhibits/View Posters (Franklin Hall)

4:00 PM-5:30 PM

CONCURRENT SESSION 21

Philip K. Caves Award Candidate Presentations (Salon ABF)

Moderators: George Tellides, MD and Abbas Ardehali, MD

4:00 PM (171) Human Mesenchymal Progenitor Cells Induce Arteriogenesis and Cardiac Regeneration Following Acute Ischemia in Irradiated Nude Rats; T.P. Martens,¹ M.D. Schuster,¹ F.H. Cheema,¹ F. See,² V.K. Topkara,¹ D.L. Colman,¹ A.W. Tulloch,¹ A. Boyle,² A.C. Zannettino,³ S. Gronthos,³ M.C. Oz,³ S. Itescu,¹ Surgery, Columbia University, New York; ²Melbourne University, Melbourne, Australia; ³Institute of Medical and Veterinary Science, Adelaide, Australia

4:15 PM (172) Bone Marrow Stem Cells Prevent Post-Transplant Obliterative Airway Disease in Mice; F. D'Imperio,¹ M. Liu,¹ S. Keshavjee,¹ T.K. Waddell,¹ Thoracic Surgery, University of Toronto, Toronto, Ontario, Canada

4:30 PM (173) LVAD Support Severely Affects the Integrity of Myocardial Basement Membranes; A.H. Bruggink,¹ M.F.M. Oosterhout,¹ N. de Jonge,¹ J.P.M. Cleutjens,² J. van Kuik,¹ F.H.J. Gmelig-Meyling,¹

R.A. de Weger,¹ ¹Pathology, University Medical Center, Utrecht, Utrecht, Netherlands; ²Pathology, Academic Hospital Maastricht, Maastricht, Netherlands
4:45 PM (174) CCR5 Blockade Attenuates Cardiac Allograft Vasculopathy in Non-Human Primates Treated With Cyclosporine A; B.-N. Nguyen,¹ R.N. Pierson III,¹ C. Schroder,¹ T. Zhang,¹ G. Wu,¹ A. Hammed,¹ I. Singer,² L. Peterson,² A.M. Azimzadeh,¹ J.A. DeMartino,² ¹University of Maryland & Baltimore VAMC, Baltimore, MD; ²Merck Research Laboratories, Rahway, NJ
5:00 PM (175) Donor Lung Surfactant Protein Gene Expression Predicts Early and Long-Term Outcome; F. D'Ovidio,¹ H. Kaneda,¹ C. Andrade,¹ M. Mura,¹ H. Takahashi,² C. Gutierrez,¹ M. Hutcheon,¹ A. Pierre,¹ D. Hadjiliadis,¹ C. Chaparro,¹ L.G. Singer,¹ T.K. Waddell,¹ M. Liu,¹ S. Keshavjee,¹ ¹Toronto Lung Transplant Program, University of Toronto, Toronto, Ontario, Canada; ²Sapporo Medical School, University of Sapporo, Sapporo, Japan
5:15 PM (176) Cd4⁺ Cd25⁺ Regulatory T Cells Mediate Antigen-Specificity in a Novel TCR Transgenic Model of Alloimmunity; S.E. Sandner,¹ A. Sanchez-Fueyo,² L.A. Turka,³ T.B. Strom,² M.H. Sayegh,¹ ¹Transplantation Research Center, Harvard Medical School, Boston, MA; ²BIDMC, Harvard Medical School, Boston, MA; ³Medicine, University of Pennsylvania, Philadelphia, PA

4:00 PM-5:30 PM

CONCURRENT SESSION 22

Just the Bad and the Ugly of VAD Use (Salon G-L)

Moderators: Francis D. Pagani, MD, PhD and Vivek Rao, MD, PhD

4:00 PM **Invited Lecture: The Future of Congestive Heart Failure Therapy: Macrotechnology vs Microbiology**, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

4:15 PM (177) Improved Durability of the HeartMate XVE Provides Safe Mechanical Support up to One Year but Is Associated With High Risk of Device Failure in the Second Year; J. Martin,¹ O. Friesewinkel,¹ C. Benk,¹ S. Sorg,¹ S. Schultz,¹ F. Beyersdorf,¹ ¹Department of Cardiovascular Surgery, Freiburg University Medical Center, Freiburg, Germany

4:30 PM (178) The Impact of Device Type on Humoral Sensitization; D.L. Joyce,¹ R.E. Southard,¹ G.P. Noon,¹ G.A. Land,² G. Torre-Amione,³ M. Loebe,¹ Michael E. DeBakey ¹Department of Surgery, Baylor College of Medicine, Houston, TX; ²Histocompatibility and Transplant Immunology, The Methodist Hospital, Houston, TX; ³Cardiology, Baylor College of Medicine, Houston, TX

4:45 PM (179) Changes in Myocardial Pro- and Anti-Inflammatory Cytokines During and One Year After Successful LVAD Implantation; E.J. Birks,¹ L.E. Felkin,¹ J. Hardy,¹ P. Tansley,¹ J. Hall,¹ L.W. Miller,¹ N.R. Banner,¹ A. Khaghani,¹ P.J.R. Barton,¹ M.H. Yacoub,¹ ¹Transplant Unit, Harefield Hospital, Middlesex, United Kingdom

5:00 PM (180) Impact of Hypogammaglobulinemia on Infections in Patients With Ventricular Assist Devices; T. Shah,¹ M.H. Yamani,¹ A. McNeill,¹ R.K. Avery,² S. Mawhorter,² S. Saber,² D. Cook,³ T. Buda,⁴ M. Yeager,⁴ R.E. Hobbs,¹ D. Taylor,¹ M. Banbury,⁴ J. Navia,⁴ J.B. Young,¹ N. Smedira,⁴ R.C. Starling,¹ ¹Cardiovascular Medicine; ²Infectious Disease; ³Allogen Laboratory; ⁴Cardiothoracic Surgery, The Cleveland Clinic Foundation, Cleveland, OH

5:00 PM (181) WITHDRAWN

5:15 PM (182) Reduced Embolic Complications With Noyacor LVAS: A Multicenter Experience; J.A. Elefteriades,¹ A. El-Banayosy,² P. Noirhomme,³ E. Vitali,⁴ B. Reichart,⁵ S.L. Lansman,⁶ P. Hendry,⁷ V. Kasirajan,⁸ ¹Cardiothoracic Surgery, Yale University School of Medicine, New Haven, CT; ²Cardiothoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; ³Cardiothoracic Surgery, St. Luc Hospital, Brussels, Belgium; ⁴Cardiothoracic Surgery, Niguarda CaGranda, Milano, Italy; ⁵Cardiothoracic Surgery, Grosshadern Hospital, Munich, Germany; ⁶Cardiothoracic Surgery, Mount Sinai Medical Center, New York, NY; ⁷Cardiothoracic Surgery, Ottawa Heart Institute, Ottawa, Ontario, Canada; ⁸Cardiothoracic Surgery, McGuire VA Medical Center, Richmond, VA

4:00 PM-5:30 PM

CONCURRENT SESSION 23

Post Transplant Complications: Lung (Salon E)

Moderators: Annette Boehler, MD and Kenneth R. McCurry, MD

4:00 PM (183) Thrombotic Microangiopathy After Lung Transplantation; R.R. Hachem,¹ M.M. Chakinala,¹ R.D. Yusen,¹ G.A. Patterson,¹ E.P. Trulock,¹ ¹Lung Transplantation Program, Washington University School of Medicine, St. Louis, MO

4:15 PM (184) Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplantation; B. Yates,¹ C. Ward,¹ D. Murphy,¹ I. Forrest,¹ A.J. Fisher,¹ J. Lordan,¹ P.A. Corris,¹ Applied Immunobiology and Transplantation Group, University of Newcastle, Newcastle upon Tyne, Tyne and Wear, United Kingdom

4:30 PM (185) Does the Presence of Preoperative Mild or Moderate Coronary Artery Disease Affect the Short and Long Term Outcomes of Lung Transplant Recipients? C. Choong,¹ B. Meyers,¹ T. Guthrie,¹ E.

Trulock,¹ R. Hachem,¹ M. Chakinala,¹ G.A. Patterson,¹ N. Moazami,¹ ¹Surgery, Washington University, St Louis, MO

4:45 PM (186) Recurrence of Alpha 1-Antitrypsin Deficiency Emphysema on Computed Tomography (CT) after Lung Transplantation; S.A. Sathyapala, N.K. Gupta, J.-P. Westwood, J. Partridge, M.R. Carby, Transplant Medicine, Harefield Hospital, Royal Brompton & Harefield NHS Trust, Harefield, Middlesex, United Kingdom

5:00 PM (187) Presentation, Treatment and Outcome of 24 Patients with Posttransplant Lymphoproliferative Disorder (PTLD) after Lung Transplantation; J. Misleh, A. Loren, V. Ahya, R. Kotloff, L. Douglas, N. Aqai, D. Tsai, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

5:15 PM (188) Resolution of Severe Reperfusion Injury Post Lung Transplantation Following the Administration of Endobronchial Surfactant; F.D. Kermeen,¹ P.M. Hopkins,¹ J.J. McCarthy,² M.D. Ziegenfuss,² D.V. Mullany,² K.D. McNeil,¹ ¹Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia; ²Intensive Care Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

4:00 PM-5:30 PM

CONCURRENT SESSION 24

Biology of Vascular and Cardiac Allograft Injury (Salon CD)

Moderators: Gerald J. Berry, MD and Michael S. Mulligan, MD

4:00 PM (189) Common Anti-Inflammatory and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allografts; A.I. Nykänen,¹ K. Pajusola,² M. Keränen,¹ K. Alitalo,² P.K. Koskinen,¹ K.B. Lemström,¹ ¹Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; ²Molecular Cancer Biology Laboratory, Biomedicum, University of Helsinki, Helsinki, Finland

4:15 PM (190) Cyclosporine Decreases Vascular Progenitor Cells Following Cardiac Transplantation and Attenuates Progenitor Cell Growth In Vitro; W.R. Davies,¹ S. Wang,² K. Oi,¹ N.M. Caplice,² C.G.A. McGregor,¹ ¹William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN; ²Division of Cardiovascular Diseases and Molecular Medicine Program, Mayo Clinic, Rochester, MN

4:30 PM (191) Inflammatory and Pro-Thrombotic Protein Expression Is Induced in Human Vascular Endothelial Cells by Lymphocyte-Associated Light; S. Celik,¹ C.A. Gleissner,¹ A.O. Doesch,¹ M. Konstandin,¹ T.J. Dengler,¹ ¹Division of Cardiology, University of Heidelberg, Heidelberg, Germany

4:45 PM (192) Corticosteroids Enhance Cyclosporine-Induced Vascular Injury; Interactive Effect between Endothelin-1 and Nitric Oxide Bioavailability; D. Ramzy,¹ L.C. Tumiati,¹ N. Xu,¹ S. Miriuka,¹ D.H. Delgado,¹ H.J. Ross,¹ V. Rao,¹ ¹Cardiovascular Surgery, Toronto General Hospital, Toronto, Ontario, Canada

5:00 PM (193) Downregulation of CD8+ T Cell Cytotoxicity Via Perforin/ Granzyme B Pathway Protects Cardiac Allograft Myocytes in Interleukin-4 and -10 Combined Gene Therapy; H. Furukawa,¹ K. Oshima,¹ H. Russell,¹ T. Tung,¹ G. Cui,¹ H. Laks,¹ L. Sen,¹ ¹Surgery, University of California at Los Angeles Medical Center/School of Medicine, Los Angeles, CA

5:15 PM (194) Gene Transfer of the Tryptophan-Catabolizing Enzyme Indoleamine 2,3-Dioxygenase Prolongs Rat Cardiac Allograft Survival; J. Li-Zhong,^{1,4} E. Simeoni,^{1,3} S. Fleury,^{1,3} L.K. von Segesser,² G. Vassalli,¹ ¹Cardiology, University of Lausanne Medical Center, Lausanne, Switzerland; ²Cardiovascular Surgery, University of Lausanne Medical Center, Lausanne, Switzerland; ³Experimental Surgery, University of Lausanne Medical Center, Lausanne, Switzerland

5:30 PM-6:30 PM

GENERAL POSTER SESSION/Wine and Cheese Reception (Franklin Hall)

(334) A Comparison Between Antithymocyte Globulin and Dacluzimab Induction Therapy for Lung Transplantation. A Retrospective Analysis of the Frequency of Acute Cellular Rejection in 270 Patients; C.M. Burton,¹ A.S. Jensen,¹ S. Boesgaard,¹ N. Milman,¹ H. Arendrup,¹ K. Eliassen,¹ C.B. Andersen,¹ M. Iversen,¹ J. Carlsen,¹ ¹Division of Lung Transplantation, Hjertecentret, Rigshospitalet, Copenhagen, Denmark

(335) Does Induction Therapy Have a Significant Impact on Survival in Lung Transplantation? A Prospective, Randomized, Controlled Study Comparing Zenapax, Thymoglobulin and NO Induction; S.H. Allan,¹ M.C. Borja,¹ J.B. Orens,² S.C. Yang,¹ G.B. Diette,² J.V. Conte,¹ ¹Department of Cardiothoracic Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; ²Department of Pulmonary Medicine, Johns Hopkins Medical Institutions, Baltimore, MD

(336) The Long Term Effect of Daclizumab on Bronchiolitis Obliterans Syndrome; R.J. Janata,¹ S.M. Bhorade,¹ J. Villanueva,¹ ¹Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL

(337) Sirolimus (SRL) and Its Effects after 12 Month Therapy on Patients With Calzineurin (CNI) Induced Renal Dysfunction; K. Hariri, S. Roedler, D. Dunkler, E. Szent-Ivanyi, A. Aliabadi, M. Grimm, E. Wollner,

- A. Zuckermann, Department of Cardiothoracic Surgery, Department of Cardiothoracic Surgery, Vienna, Austria
- (338) Everolimus(EVL) vs Azathioprine(AZA): Results of a Double Blind Longitudinal Lung Transplant(LTx) Bronchoalveolar Lavage(BAL) and Endobronchial Biopsy(EBB) Study; B. Levvey,¹ L. Zheng, M. Bailey,² B. Orsida, T. Kotsimbos, H. Whitford, T.J. Williams, G.I. Snell,¹ Allergy, Immunology & Respiratory Medicine, Alfred Hospital & Monash University, Melbourne, Victoria, Australia; ²Epidemiology & Preventative Medicine, Monash University, Melbourne, Victoria, Australia
- (339) The Inhibition of Cyclooxygenase-2 Improves Donor Heart Function Following Long-Term Preservation; K. Oshima,¹ H. Tsutsumi,¹ I. Takeyoshi,¹ J. Mohara,¹ T. Nameki,¹ K. Matsumoto,² Y. Morishita,¹ Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan; ²Department of Pathology, Nippon Medical School Second Hospital, Kawasaki, Kanagawa, Japan
- (340) Resuscitation of the Brain Dead Donor Heart Using Hormones in a Porcine Model; A. Hing,¹ M. Hicks,¹ S.R. Garlick,² L. Gao,³ S.H. Kesteven,³ M.K. Wilson,⁴ M.P. Feneley,³ P.S. Macdonald,¹ Transplant Program, The Victor Chang Cardiac Research Institute, Sydney, Australia; ²Department of Anaesthetics, St. Vincent's Hospital, Sydney, Australia; ³Cardiovascular Mechanics Program, The Victor Chang Cardiac Research Institute, Sydney, Australia; ⁴Department of Cardiothoracic Surgery, St. Vincent's Hospital, Sydney, Australia
- (341) Complement Regulators Are Down Regulated by Ischemia Reperfusion in Heart Transplantation; E. Moseley,¹ M. Goddard,¹ S. Stoica,¹ S. Large,¹ J. Wallwork,¹ C. Atkinson,¹ Pathology Department, Papworth NHS Trust, Cambridge, United Kingdom
- (342) Cariporide Improves Long Term Cardiac Preservation in a Porcine Model of Heart Transplantation; A. Hing,¹ M. Hicks,¹ L. Gao,¹ S.C. Faddy,¹ A.C. McMahon,² S.H. Kesteven,² M.P. Feneley,² M.K. Wilson,³ P.S. Macdonald,¹ Transplant Program, The Victor Chang Cardiac Research Institute, Sydney, Australia; ²Cardiovascular Mechanics Program, The Victor Chang Cardiac Research Institute, Sydney, Australia; ³Department of Cardiothoracic Surgery, St. Vincent's Hospital, Sydney, Australia
- (343) Long-Term Outcome of Palpable Coronary Artery Disease in Donor Hearts Used for Transplantation; P. Botha,¹ G. Parry,¹ L. Mitchell,¹ J. Forty,¹ J.H. Dark,¹ Department of Cardio-Pulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom
- (344) Preservation of Non-Heart-Beating Cardiac Donor Using Isolated Myocardial Perfusion: The Importance of Initial Controlled Reperfusion; S. Osaki,¹ K. Ishino,¹ Y. Kotani,¹ O. Honjo,¹ T. Suezawa,¹ K. Kanki,¹ T. Kohmoto,¹ S. Sano,¹ Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
- (345) Prediction of Functional Recovery of 60-Min Warm Ischemic Hearts From Asphyxiated Canine Non-Heart-Beating Donors; M. Hirota,¹ K. Ishino,¹ S. Sano,¹ Cardiovascular Surgery, Okayama University Medical School, Okayama, Japan
- (346) Coronary Endothelium Contributes to the Altered Vasoreactivity for Relevant Levels of Serotonin After Brain Death; P. Herijgers,¹ Y. Nishimura,¹ W. Flameng,¹ C.E.H.A., K.U.Leuven, Leuven, Belgium
- (347) Is Donor Airway Microbiology a Predictor of Outcome in Lung Transplant Recipients? S. Gilbert,¹ K.R. McCurry,¹ A. El-Sherif,¹ S. Husain,² Division of Thoracic Surgery, University of Pittsburgh, Pittsburgh, PA; ²Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA
- (348) Pulmonary Vein Gas as a Tool for Assessing Donor Lungs; J. Thekkudan,¹ J.E. Fildes,¹ S. Datta,¹ A.A. Machaal,¹ C.T. Leonard,¹ N. Yonan,¹ The Wythenshawe Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom
- (349) Inhalative Pretreatment of Donor Lungs Using the Aerosolized Prostacyclin Analogon Iloprost Ameliorates Reperfusion Injury; T. Wittwer,¹ U.F.W. Franke,¹ M. Ochs,² T. Sandhaus,¹ J. Richter,² T. Wahlers,¹ Cardiothoracic and Vascular Surgery, Friedrich-Schiller University, Jena, Germany; ²Electron Microscopy, University of Goettingen, Goettingen, Germany
- (350) From Research to Reality: Development of a Clinical Non Heart Beating Donor(NHBD) Lung Transplant(LTx) Program; B. Levvey,¹ R. McEgan,¹ T. Oto,¹ L. Eriksson,² A. Griffiths,¹ T. Williams,¹ F. Rosenfeldt,¹ G. Snell,¹ Lung Transplant Service, Alfred Hospital, Melbourne, Victoria, Australia; ²Respiratory Medicine, University Hospital, Lund, Sweden
- (351) Non-Standard Donor Lungs: Are They More Prone to Acute Rejection? G.T. Schnickel,¹ D.J. Ross,² S. Lackey,¹ A. Shefizadeh,¹ A. Ardehali,¹ Division of Cardiothoracic Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA; ²Division of Pulmonary Medicine, Critical Care and Hospitalists, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA
- (352) The Impact of Lung Transplantation on Quality of Life in Patients With COPD; R.D. Yusen,¹ K.L. Brown,¹ T.E. Habrock,¹ W. Sumner,¹ R.F. Nease,¹ G.A. Patterson,¹ E.P. Trulock,¹ B. Littenberg,² Washington University School of Medicine, St. Louis, MO; ²University of Vermont, Burlington, VT
- (353) Effect of Pretransplantation Prednisone on Survival After Lung Transplantation; V.G. Valentine,¹ S.G. LaPlace,¹ L. Seoane,¹ P.M. McFadden,¹ D.M. Fuchs,¹ D.E. Taylor,¹ Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA
- (354) Outcome of Patients With Primary Pulmonary Hypertension after Listing for Transplantation: Benefits of Therapy with Iloprost and Bosentan; M. Dandel,¹ H.B. Lehmkühl,¹ Y. Weng,¹ S. Mulahasanovic,¹ H. Böttcher,¹ C. Knosalla,¹ O. Grauhan,¹ R. Hetzer,¹ Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

- (355) Pregnancy Outcomes in Female Lung Transplant Recipients; L.A. Coscia,¹ C.H. McGrory,¹ R. Chotiner,¹ M.J. Moritz,² V.T. Armenti,¹ Surgery, Temple University School of Medicine, Philadelphia, PA; ²Surgery, Drexel University College of Medicine, Philadelphia, PA
- (356) Clinical Outcome Following Concomitant Cardiac Operation at the Time of Lung Transplantation; G.T. Schnickel,¹ D.J. Ross,² F. Mitropolous,¹ S. Lackey,¹ A. Shefizadeh,¹ A. Ardehali,¹ Division of Cardiothoracic Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA; ²Division of Pulmonary Medicine, Critical Care and Hospitalists, David Geffen School of Medicine at University of California, Los Angeles, CA
- (357) Clinical and Functional Status of Cystic Fibrosis (CF) Heart-Lung Transplant (HLT) Recipients Surviving More Than Ten Years; K.M. Gyi,¹ M.R. Carby,² M.E. Hodson,¹ ¹Department of Cystic Fibrosis, Royal Brompton and Harefield NHS Trust, London, United Kingdom; ²Department of Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom
- (358) Does Perfadex Improve Clinical Outcomes in Lung Transplantation? R.F. Kelly, A.R. Walker, A.C. Johnson, D.S. Nath, M.E. Prekker, C.S. Herrington, P.S. Dahlberg, Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN
- (359) Metabolic Consequences of Lung Transplantation; V.G. Valentine,¹ D.M. Fuchs,¹ L. Seoane,¹ G.A. Lombard,¹ S.G. LaPlace,¹ D.E. Taylor,¹ Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA
- (360) Pharmacokinetics of Mycophenolate and Its Glucuronidated Metabolites in Stable Lung Transplant Recipients; N. Partovi,^{1,2} L. Ting,² M.H.H. Ensom,² W. Riggs,² R.D. Levy,³ ¹Pharmaceutical Sciences, Vancouver General Hospital; ²Pharmaceutical Sciences, University of British Columbia; ³Faculty of Medicine, University of British Columbia, Vancouver, Canada
- (361) Measuring the Impact of Infection on T Cell Immunity in Lung Transplant Recipients Treated With a T Cell Depletion Protocol; A. Zeevi,¹ A.L. Girmita,¹ K.J. Spichy,¹ H. Shahid,¹ D. Zaldonis,¹ J. Britz,² R. Kowalski,² J. Woodcock,² D. Post,² K.R. McCurry,¹ ¹Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Cylex Inc., Baltimore, MD
- (362) Caution Using a Calcineurin Inhibitor-Free Renal Sparing Protocol for Heart Transplant Patients With Renal Dysfunction; J.K. Patel,¹ J.A. Kobashigawa,¹ A. Marquez,¹ B.T. Oeser,¹ A. Velleca,¹ R. Camara,¹ H. Laks,¹ ¹Cardiology, University of California at Los Angeles, Los Angeles, CA
- (363) Doppler Evaluation of Cardiac Allograft Dysfunction in Long-Term Heart Transplantation Recipients With Normal Coronary Angiograms; F. Tona,¹ A.L.P. Caforio,¹ A. Gambino,² G. Feltrin,² G. Toscano,² D. Calzolari,¹ C. Sarais,¹ O. Paccagnella,¹ A. Vinci,¹ M.G. Leone,¹ A. Angelini,³ A. Ramondo,³ G. Thiene,³ G. Gerosa,² S. Illiceto,¹ ¹Cardiology, University of Padova; ²Cardiovascular Surgery; ³Pathology, University of Padova, Padova, Italy
- (364) Usefulness of Mitral Annulus Velocities for Detection of Rejection After Heart Transplantation; K.M. Kraszewski,¹ M. Sobieszczanska,² J. Korewicki,² P. Hoffman,¹ ¹Department of Adult Congenital Heart Disease, National Institute of Cardiology, Warszawa, Poland; ²Department of Heart Failure, National Institute of Cardiology, Warszawa, Poland
- (365) Pre Transplant but Not Post Transplant Anemia Is Associated With Reduced One Year Survival After Cardiac Transplantation; A.B. Taegtmeier,^{1,2} P. Rogers,¹ J.B. Breen,¹ N.R. Banner,¹ P.J. Barton,² M.H. Yacoub,² ¹Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom
- (366) Accelerated Naive CD8 T-Cell Homing During Acute Cellular Rejection After Clinical Heart Transplantation; P. Athanassopoulos,¹ L.M.B. Vaessen,² A.H.M.M. Balk,³ A.P.W.M. Maat,¹ A.J.J.C. Bogers,¹ W. Weimar,² ¹Cardiothoracic Surgery, Erasmus MC; ²Internal Medicine, Erasmus MC; ³Cardiology, Erasmus MC, Rotterdam, Netherlands
- (367) Percutaneous Coronary Interventions With Stents in Cardiac Transplant Recipients; F.M. Bader,¹ E.M. Gilbert,¹ A.G. Kfoury,² N. Humayun,¹ Y. Al-Saghir,¹ M.E. Hagan,³ H. Thomas,³ J.D. Scholnick,¹ D.G. Renlund,² ¹Cardiology, University of Utah, Salt Lake City, UT; ²Cardiology, LDS Hospital, Salt Lake City, UT; ³Cardiology, George E. Wahlen VA Medical Center, Salt Lake City, UT
- (368) Pretransplant QTc Interval Duration Predicts Outcome of Heart Failure Patients Undergoing Cardiac Transplantation; B. Vrtovec,¹ A.P. Yazdanbakhsh,¹ I.D. Gregoric,¹ R. Radovancevic,¹ P.V. Juarez,¹ B. Radovancevic,¹ ¹Transplant Research, Texas Heart Institute, Houston, TX
- (369) Longitudinal Monitoring of Cardiac Allograft Recipients Using Peripheral Blood Gene Expression Profiling: A Retrospective Observational Analysis of Molecular Testing in 19 Case Studies; H.J. Eisen,¹ M.C. Deng,² T.M. Klingler,³ G.E. Williams,³ J.G. Wohlgemuth,³ M.R. Mehra,⁴ ¹Cardiology, Temple University, Philadelphia, PA; ²Cardiology, Columbia University, New York, NY; ³XDx, Inc.; ⁴Cardiology, OchsnerInstitutes, New Orleans, LA
- (370) The uPA/PAI-1 Molecular Defect in Idiopathic Dilated Cardiomyopathy (DCM) Persists After Cardiac Transplantation; S. Aharinejad,¹ M. Grimm,¹ A. Zuckermann,¹ P. Paulus,² R. Schaefer,² D. Abraham,² ¹Cardiothoracic Surgery, Vienna Medical University, Vienna, Austria; ²Cardiovascular Research, Anatomy and Cell Biology, Vienna Medical University, Vienna, Austria
- (371) Outcomes of an Alternate List Strategy for Heart Transplantation; M. Felker,¹ C.A. Milano,² J.E. Yager,¹ A.F. Hernandez,¹ L. Blue,¹ M.B. Higginbotham,¹ A.J. Lodge,² S.D. Russell,¹ ¹Department of Medicine, Duke University Medical Center, Durham, NC; ²Department of Surgery, Duke University Medical Center, Durham, NC
- (372) Self-Administered Fingerprick Sampling To Determine Cyclosporine C₂ Blood Levels in Transplant Patients;

N. Yonan,¹ R. Martyszczuk,¹ A. Machaal,¹ A. Baynes,¹ J. Thekkudam,¹ B.G. Keevil,¹ ¹Transplant Programme, Wythenshawe Hospital, Manchester, United Kingdom

(373) Clinical Utility of Mycophenolic Acid (MPA) Area-Under-the-Curve (AUC) Measurements in Stable Patients After Heart Transplantation (HTX); A.O. Doesch,¹ P. Ehlermann,¹ A. Koch,² P. Staritz,¹ T.J. Dengler,¹ ¹Division of Cardiology, University of Heidelberg, Heidelberg, Germany; ²Division of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

(374) The Role of Pressure-Flow Derived Measurements in the Evaluation of Coronary Physiology of Heart Transplant Recipients; G. Davidavicius, S. Mansour, M. Vanderheyden, B. de Bruyne, F. Wellens, M. Goethals, Cardiology, Cardiovascular Center Aalst, Aalst, Belgium

(375) Impaired Coronary Flow Reserve: A New Noninvasive Predictor of Cardiac Allograft Vasculopathy Severity and Diffusion; F. Tona,¹ A.L.P. Caforio,¹ R. Montisci,² C. Sarais,¹ A. Angelini,³ A. Gambino,⁴ G. Toscano,⁴ G. Feltrin,⁴ D. Calzolari,¹ A. Ramondo,¹ A. Vinci,¹ M.G. Leone,¹ G. Thiene,³ G. Gerosa,⁴ S. Iliceto,¹ ¹Cardiology, University of Padova; ²Cardiology, University of Cagliari, Cagliari, Italy; ³Pathology; ⁴Cardiovascular Surgery, University of Padova, Padova, Italy

(376) Evaluation of Transplant Coronary Disease in Young Adults; Utility of Myocardial Contrast Echocardiography; L. Lamers, G. Ensing, E. Loccrichio, M. Zamberlan, D. Crowley, R. Gajarski, Pediatrics, University of Michigan, Ann Arbor, MI

(377) Factors Affecting Survival Post Heart Transplantation: Comparison of Pre and Post 1999 Listing Protocols; A.A. Bove, R.C. Cross, A.M. Kashem, S. Furukawa, J.B. McClurken, G.O. Berman, H.J. Eisen, Cardiology, Temple University, Philadelphia, PA

(378) Erythropoietin Treatment of Anemia Post Heart Transplantation Raises Hemoglobin Levels and Improves Quality of Life; C.A. Gleissner,¹ R.H. Klingenberg,¹ M. Konstandin,¹ S. Celik,¹ T.J. Dengler,¹ ¹Department of Cardiology, University of Heidelberg, Heidelberg, Germany

(379) Cyclosporine Profiling in Heart Transplant Patients: Correlation with Clinical Outcome; J. Barnard,¹ J. Thekkudam,¹ S. Richardson,¹ R. Martyszczuk,¹ M. Bittar,¹ N. Khasati,¹ B. Keevil,² N. Yonan,¹ ¹The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe, Manchester, United Kingdom; ²Department of Biochemistry, South Manchester University Hospitals NHS Trust, Wythenshawe, Manchester, United Kingdom

(380) Twelve Months Results of Enteric-Coated Mycophenolate Sodium (EC-MPS) in De Novo Heart Transplant Patients Showed Excellent Efficacy and Safety; J.A. Kobashigawa,¹ D.G. Renlund,² G. Gerosa,³ A. Caforio,³ H. Ross,⁴ H.B. Lehmkuhl,⁵ H. Eisen,⁶ J. Segovia,⁷ R. Brambilla,⁸ ¹University of California, Los Angeles, CA; ²Heart Failure Treatment and Prevention, Salt Lake City, UT; ³Policlinico University Hospital, Padova, Italy; ⁴Toronto General Hospital, Toronto, Ontario, Canada; ⁵Deutsches Herzzentrum, Berlin, Germany; ⁶Temple University Hospital, Philadelphia, PA; ⁷Hospital Universitario Puerta de Hierro, Madrid, Spain; ⁸Novartis Pharma AG, Basel, Switzerland, for the international CERL080A2401 study group

(381) Everolimus (Certican®) in Heart Transplantation – Early Experience; H. Lehmkuhl,¹ M. Hummel,¹ M. Dandel,¹ O. Grauhan,¹ C. Knosalla,¹ R. Hetzer,¹ ¹Department for Heart, Thoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

(382) Negative Association between CMV-Viraemia and Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients; I.A. Forrest,¹ A. Krause,² P.A. Corris,¹ J.H. Dark,¹ F.K. Gould,² ¹Applied Immunobiology and Transplantation Group, University of Newcastle upon Tyne and Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Department of Medical Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(383) Sirolimus-Associated Thrombotic Thrombocytopenic Purpura (TTP): Report of Three Cases and Review of the Literature; A.E. Eyzaguirre,¹ R.B. Love,² D.A. Hargate,¹ R. Schilz,¹ ¹Pulmonary and Critical Care Medicine, University Hospitals of Cleveland, Cleveland, OH; ²Cardiothoracic Surgery, University of Wisconsin, Madison, WI

(384) Tricuspid Valve Replacement After Cardiac Transplantation; R. Alharethi,² F.M. Bader,² A.G. Kfoury,¹ E.M. Gilbert,² D.G. Renlund,¹ ¹Cardiology, LDS Hospital, Salt Lake City, UT; ²Cardiology, University of Utah, Salt Lake City, UT

(385) Early Experience with Ezetimibe in the Management of Hyperlipidemia Post-Cardiac Transplant; S.A. Virani,¹ C. Imai,¹ K.H. Humphries,¹ J. Frolich,² A. Ignaszewski,¹ ¹Division of Cardiology, University of British Columbia; ²Department of Pathology, University of British Columbia, Vancouver, Canada

(386) Percutaneous Coronary Intervention With Stent Deployment for the Treatment of Graft Vasculopathy After Cardiac Transplantation - A Single Center Experience; B. Sheick-Yousif,¹ J. Lavee,¹ Y. Har Zahav,² ¹Heart Transplantation Unit, Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Israel; ²Heart Institute, Sheba Medical Center, Tel Hashomer, Israel

(387) Validation of Algorithm for Diagnosis and Treatment of Cytomegalovirus (CMV) Infection in Heart Transplant Recipients Based of pp65 Antigenaemia by Quantitative Polymerase Chain Reaction (PCR); M.W. Zakliczynski,¹ S. Dworniczak,¹ U. Mazurek,¹ M. Zembala,¹ ¹Department of Transplantation, Silesian Center for Heart Disease, Zabrze, Poland

(388) Successful Outcome Following Lung Transplantation for Recipients Colonised With Filamentous Fungi at Time of Transplant; D.A. Wearmouth,¹ L. Archer,¹ P.A. Corris,² J.H. Dark,² F.K. Gould,¹ ¹Department of Medical Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Applied Immunobiology and Transplantation Group, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(389) Review of Patient Outcomes of Aspergillus Prophylaxis With Voriconazole After Lung Transplantation; J.B. Lehman,¹ G.A. Smallwood,² L.A. Lesniak,³ E.C. Lawrence,⁴ ¹Center for Transplantation, Emory University Hospital, Atlanta, GA; ²Department of Pharmacy, Emory University Hospital, Atlanta, GA; ³McKelvey Lung Transplantation Center, Emory University Hospital, Atlanta, GA; ⁴McKelvey Lung Transplantation Center, Emory University Hospital, Atlanta, GA

(390) Clostridium Difficile Colitis after Lung Transplantation: The Role of Routine Prophylaxis; A. Bertani,¹ S. Husain,² K.R. McCurry,¹ A. Bqjoukos,¹ ¹Department of Thoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Department of Infectious Disease, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Department of Critical Care, University of Pittsburgh Medical Center, Pittsburgh, PA

(391) Risk Factors for Perioperative Mortality and Nosocomial Infections in Lung Transplantation; E. Mattner,¹ S. Fischer,² H. Weissbrodt,¹ A.R. Simon,² P. Struckmeier,² J. Gottlieb,³ T. Welte,³ P. Gastmeier,¹ M. Strueber,² ¹Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; ²Department of Thoracic Surgery, Hannover Medical School, Hannover, Germany; ³Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

(392) Mucociliary Clearance Following Lung Transplantation Is Impaired and Improves With Acute Albuterol Inhalation; B.L. Laube,¹ Y.J. Karmazyn,¹ J.B. Orens,¹ P.J. Mogayzel,¹ ¹Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD

(393) Potential Benefits of Treating Hypercholesterolemia and Hypertension in Lung Allograft Recipients; V.G. Valentine,¹ L. Seoane,¹ D.M. Fuchs,¹ S.G. LaPlace,¹ G.A. Lombard,¹ D.E. Taylor,¹ ¹Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

6:00 PM-7:00 PM

Pathology and Basic Science Scientific Council Meeting (Room 401)
Cell Transplantation/Tissue Engineering Scientific Council Meeting (Room 402)
Pulmonary Arterial Hypertension Scientific Council Meeting (Room 412)
History and Archives Council Meeting (Room 403)

6:30 PM-MIDNIGHT

Poster Teardown (Franklin Hall)

6:30 PM-MIDNIGHT

Exhibit Hall Teardown (Franklin Hall)

SATURDAY APRIL 9, 2005

6:00 AM-5:00 PM

Speaker Ready Room Open (Room 502)

7:00 AM-8:00 AM

Morning Coffee (Ballroom Foyer)

7:00 AM-NOON

Registration Desk Open (Ballroom Foyer)

7:00 AM-NOON

Poster Teardown (Franklin Hall)

7:00 AM-NOON

Exhibit Hall Teardown (Franklin Hall)

7:00 AM-4:00 PM

Press Office Open (Room 404)

7:30 AM-9:30 AM

PLENARY SESSION (Salons G-L)

Moderators: Jon Kobashigawa, MD and John Wallwork, MD

7:30 AM **Research Grant Awards Presentations**

7:45 AM **Invited Lecture: Toward Clinical Tolerance**, Christian Larsen, MD, Emory University, Atlanta, GA

8:15 AM (195) **Featured Abstract Presentation: Effect of Immunosuppression on Foxp3 Expression In Vitro and In Vivo after Clinical Heart Transplantation**; C.C. Baan,¹ B.J. van der Mast,¹ A.M.A. Peeters,¹ S.S. Korevaar,¹ A.H.M.M. Balk,² W. Weimar,¹ ¹Internal Medicine, Erasmus MC; ²Cardiology, Erasmus MC, Rotterdam, Netherlands

8:25 AM (196) **Featured Abstract Presentation: Generation of CD8⁺CD28⁻ T Suppressor Cells in Heart Transplant Recipients**; S. Galluzzo,¹ A.J. Naiyer,¹ J. Manavalan,¹ L. Scotto,¹ S. Kim-Shulze,¹ D. Mancini,¹ R. Cortesini,¹ N. Suci-Foca,¹ ¹Department of Pathology, Columbia University, New York, NY

8:35 AM **Invited Lecture: Clinical Neonatal Tolerance**, Lori J. West, MD, DPhil, Hospital for Sick Children, Toronto, Canada

8:55 AM **Invited Lecture: Regulatory T-Cells**, Professor Herman Waldmann, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom

9:30 AM-9:45 AM

Coffee Break (Ballroom Foyer)

9:45 AM-11:15 AM

CONCURRENT SESSION 25

Myocardial Recovery: Myth or Magic (Salons G-L)

Moderators: Srinivas Murali, MD and Roland Hetzer, MD, PhD

9:45 AM (197) Changes of the Collagen Composition in the Heart Induced by Microcurrent Application. A Future Approach to Heart Failure Treatment? J. Mueller,¹ B. Kapeller,² G. Wallukat,¹ K. Macfelda,² ¹Research, Berlin Heart, Berlin, Germany; ²Institute of Biomedical Research, Vienna, Austria

10:00 AM (198) Long-Term Outcome in Patients With Idiopathic Dilated Cardiomyopathy After Weaning From Left Ventricular Assist Devices; M. Dandel,¹ Y. Weng,¹ H. Siniawski,¹ E. Potapov,¹ R. Hetzer,¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

10:15 AM (199) Maximal Oxygen Uptake Improvements With Long-Term LVAD Support; J.C. Matthews,¹ F.D. Pagani,² S. Wright,² M. Daly-Myers,² D.B. Dyke,¹ ¹Division of Cardiovascular Medicine, The University of Michigan, Ann Arbor, MI; ²Section of Adult Cardiac Surgery, The University of Michigan, Ann Arbor, MI

10:30 AM (200) Improvement of Sympathetic Nerve Activity Rather Than Myocardial Fibrosis May Contribute to Functional Recovery of Idiopathic Cardiomyopathy During Prolonged Mechanical Ventricular Support; G. Matsumiya,¹ O. Monta,¹ Y. Sawa,¹ N. Fukushima,¹ H. Matsuda,¹ ¹Department of Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

10:45 AM (201) Evaluation of Serum Markers in Heart Failure: Study in Heart Transplant and Assist Device Candidates; S. Buz,¹ N. Qedra,¹ F. Wagner,¹ C. Knosalla,¹ M. Pasic,¹ Y. Weng,¹ R. Hetzer,¹ ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

11:00 AM (202) Five-Year Experience With Driving Privileges for LVAD Patients; W.H. Perry,¹ A.L. Eccles,¹ A.H. Healy,¹ C.R. Wecker,¹ K.E. Nelson,¹ K.A. McCloy,¹ R. Khodaverdian,¹ J.W. Long,¹ ¹Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT

9:45 AM-11:15 AM

CONCURRENT SESSION 26

Post Transplant Infectious Disease: Fungi, Mycobacteria and More (Salon ABF)

Moderators: Shahid Husain, MD and Robert D. Levy, MD

9:45 AM (203) Nebulized Liposomal Amphotericin B (n-LAB) Prophylaxis for Aspergillus Infection in Lung Transplantation (LT): Pharmacokinetics, Safety and Efficacy; V. Monforte,¹ A. Roman,¹ J. Gavalda,² P. Usseti,⁴ R. Lopez,³ C. Bravo,¹ L. Pou,³ ¹Pneumology, Hospital Vall d'Hebron, Barcelona, Spain; ²Infectious Diseases, Hospital Vall d'Hebron, Barcelona, Spain; ³Pneumology, Clinica Puerta de Hierro, Madrid, Spain; ⁴Biochemistry, Hospital Universitari Vall d'Hebron, Barcelona, Spain

10:00 AM (204) Intrapulmonary Penetration of Voriconazole in Lung Transplant Patients; B. Capitano,¹ B.A. Potoski,¹ S. Husain,² S. Zhang,¹ D.L. Paterson,² S.M. Studer,³ K.R. McCurry,⁴ R. Venkataraman,¹ ¹School of Pharm., University of Pittsburgh, Pittsburgh, PA; ²Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA; ³Division of Pulmonary and Critical Care Medicine., University of Pittsburgh, Pittsburgh, PA; ⁴Department of Surgery, University of Pittsburgh, Pittsburgh, PA

10:15 AM (205) A Retrospective Comparison of Aerosolized Amphotericin B Deoxycholate to Aerosolized Amphotericin B Lipid Complex in Preventing Invasive Aspergillosis in Lung Transplant Recipients; L. Drozhinin,¹ P. Chin-Hong,³ C. Hoopes,² J. Golden,¹ S. Hays,¹ ¹Pulmonary and Critical Care, University of

California, San Francisco, San Francisco, CA; ²Thoracic Surgery, University of California, San Francisco, San Francisco, CA; ³Infectious Disease, University of California, San Francisco, San Francisco, CA
10:30 AM (206) Infectious Complications at Six Months in Lung Transplant Recipients Undergoing Pretransplant T-Cell Depletion With Alemtuzumab; S. Husain,¹ S. Studer,² D.L. Paterson,¹ D.B. Zaldonis,³ E.J. Kwak,¹ K.R. McCurry,³ ¹Infectious Disease, University of Pittsburgh, Pittsburgh, PA; ²Pulmonary and Critical Care; ³Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
10:45 AM (207) Isolation of Atypical Mycobacteria in Lung and Heart-Lung Transplant Recipients; K. Thaning, N. Roy, A.V. Hall, M.E. Hodson, M.R. Carby, Transplant Medicine, Harefield Hospital, Middlesex, United Kingdom; Transplant Medicine, Harefield Hospital, Middlesex, United Kingdom; Microbiology, Harefield Hospital, Middlesex, United Kingdom; Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
11:00 AM (208) An International Survey of Mycobacterium Abscessus Infections in Lung Transplant Recipients; S.M. Chernenko,¹ A. Humar,¹ C. Chaparro,¹ M.A. Hutcheon,¹ S. Keshavjee,¹ L.G. Singer,¹ ¹Toronto Lung Transplant Program, Toronto General Hospital, Toronto, Ontario, Canada

9:45 AM-11:15 AM

CONCURRENT SESSION 27

New Insights in Heart Failure Prognosis (Salon E)

Moderators: Mariell Jessup, MD and Hans-Ulrich Stempfle, MD

9:45 AM (209) Prognostic Survival Scores in Patients Referred for Cardiac Transplantation; A.B. Taegtmeier,¹ I.A. Bolad,¹ S.J. Bond,² S. Bentzen,² A.M. Crook,¹ N.R. Banner,¹ ¹Transplant Unit, Harefield Hospital, London, United Kingdom; ²Biostatistics Department, Mount Vernon Hospital, London, United Kingdom

10:00 AM (210) Early Recovery Cardiopulmonary Parameters after Exercise Testing as Predictors of Mortality in CHF Patients; S. Dimopoulos,¹ M. Anastasiou-Nana,² D. Sakellariou,¹ S. Kapsimalakou,¹ P. Roditis,¹ K. Kritikos,¹ S. Gyftopoulos,¹ S. Nanas,¹ C. Roussos,¹ ¹Pulmonary and Critical Care Medicine, University of Athens, Greece; ²Clinical Therapeutics, University of Athens, Greece

10:15 AM (211) Elevated B-Type Natriuretic Peptide Is Associated With Ventricular Tachyarrhythmic Events Determined by ICD Interrogation in Congestive Heart Failure Patients; R. Klingenberg,¹ C. Zugck,¹ R. Becker,¹ D. Schellberg,¹ G. Heinze,² R. Kell,¹ A. Remppis,¹ W. Schoels,¹ H.A. Katus,¹ T.J. Dengler,¹ ¹Cardiology, University Hospital Heidelberg, Heidelberg, Germany; ²Section of Clinical Biometrics, University of Vienna, Vienna, Austria

10:30 AM (212) Effects of Gender on Peak Oxygen Consumption and the Timing of Cardiac Transplantation; S. Elmariah,¹ L.R. Goldberg,¹ M.T. Allen,¹ A. Kao,² ¹Department of Medicine, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Mid-America Heart Institute, Kansas City, MO

10:45 AM (213) Permanent Pacing Is a Risk Factor for the Development of Heart Failure: A Statewide Study; R.S. Freudenberger,¹ A.C. Wilson,¹ J.M. Hare,² J.B. Kostis,¹ ¹Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ; ²Medicine, Johns Hopkins School of Medicine, Baltimore, MD

11:00 AM (214) Racial Differences in Peak VO₂ and Survival in Heart Failure Patients; S. Elmariah,¹ L.R. Goldberg,¹ M.T. Allen,¹ A. Kao,² ¹Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA; ²Mid America Heart Institute, Kansas City, MO

9:45 AM-11:15 AM

CONCURRENT SESSION 28

Long Term Concerns and Complications after Pediatric Thoracic Transplantation (Salon CD)

Moderators: Anne I. Dipchand, MD and Stuart C. Sweet, MD, PhD

9:45 AM (215) Myocardial Perfusion SPECT With ^{99m}Tc-MIBI in Coronary Vasculopathy Following Pediatric Heart Transplantation; K.J. Guleserian,¹ L.B. Armsby,² R.R. Thiagarajan,² J.E. Mayer Jr.,¹ L.B. Smoot,² S.T. Treves,³ E.D. Blume,² ¹Cardiovascular Surgery, Childrens Hospital Boston, Boston, MA; ²Cardiology, Childrens Hospital Boston, Boston, MA; ³Nuclear Medicine, Childrens Hospital Boston, Boston, MA

10:00 AM (216) Development and Significance of Late Diastolic Dysfunction in Pediatric Heart Transplant Patients; V.B. Sivarajan,¹ J. Acampora,¹ B.J. Clark III,¹ J.W. Gaynor,¹ B.D. Hanna,¹ S.M. Paridon,¹ T.L. Spray,¹ G. Wernovsky,¹ H. Zhao,¹ M.R.K. Chrisant,¹ ¹Division of Cardiology, Childrens Hospital of Philadelphia, Philadelphia, PA

10:15 AM (217) Adjunctive Mycophenolate vs. Azathioprine for Prevention of Rejection in Pediatric Heart Transplant Recipients; W.R. Morrow,¹ J.G. Parker,¹ D.C. Naftel,² S. Mital,³ C.C. Canter,⁴ J.J. Drummond-Webb,¹ I.H. Kajevska,¹ J.C. Bryant,¹ J.K. Kirklin,² ¹Pediatrics and Surgery, University of Arkansas for Medical Sciences, Little Rock, AR; ²Surgery, University of Alabama at Birmingham, Birmingham, AL; ³Pediatrics, Columbia University, New York, NY; ⁴Pediatrics, Washington University, St. Louis, MO

10:30 AM (218) Rejection in Presensitized Pediatric Heart Transplant Recipients With a Positive Donor Crossmatch Utilizing Perioperative Plasmapheresis and Cytolytic Therapy; D.B. Holt,¹ D.M. Lublin,² D.L.

Phelan,² C.B. Huddleston,³ J.E. Saffitz,² C.E. Canter,¹ ¹Pediatrics, Washington University, St. Louis, MO; ²Pathology, Washington University, St. Louis, MO; ³Surgery, Washington University, St. Louis, MO
10:45 AM (219) Chronic High Epstein-Barr Virus Load Carrier State and Risk for Late Onset PTLD / Malignant Lymphoma; M.A. Bingler,¹ S.A. Miller,¹ G.J. Boyle,¹ M.G. Michaels,¹ M. Green,¹ R.M. Wadowsky,¹ D.T. Rowe,¹ V.O. Morell,¹ E.S. Quivers,¹ S.A. Webber,¹ Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA
11:00 AM (220) Chronic Renal Failure in a 10-Year National Cohort of Pediatric Heart Transplant Recipients; C.K. Lee,^{1,2} L.L. Christensen,³ J.C. Magee,⁴ A.O. Ojo,⁴ A.B. Leichtman,⁴ N.D. Bridges,² ¹Pediatric Cardiology, Children's National Medical Center, Washington, DC; ²National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; ³SRTR/URREA, Ann Arbor, MI; ⁴SRTR/University of Michigan, Ann Arbor, MI

11:15 AM – 1:15 PM

ISHLT Board of Directors Meeting (Room 412)

11:30 AM-1:00 PM

LUNCH SYMPOSIUM: Current Trends in Lung Transplantation (Salon ABF)

Supported by Educational Grant from Chiron

Moderators: Lianne Singer, MD and Edward Garrity, MD

11:30 AM **Recent Trials of Immunosuppression in Lung Transplantation**, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom

11:50 AM **Induction Therapy: The Evidence in Lung Transplantation**, Kenneth R. McCurry, MD, University of Pittsburgh, Pittsburgh, PA

12:10 PM **Inhaled Therapies in Lung Transplantation: Antimicrobial Strategies**, Jeffrey Golden, University of California San Francisco, San Francisco, CA

12:30 PM **Inhaled Cyclosporine in Lung Transplantation**, Aldo Iacono, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

12:50 PM **Discussion**

11:45 AM – 12:45 PM

MINI-ORAL POSTER PRESENTATION SESSION 5 (Salon E)

Moderators: Heather J. Ross, MD, FRCPC, MHSC and Donna M. Mancini, MD

11:45 AM (221) Coronary Stenosis Detection by 16-Slice Computed Tomography in Heart Transplant Patients: Comparison With Conventional Coronary Angiography and Impact on Clinical Management; G. Romeo, L. Houyel, J.-F. Paul, P. Brenot, J.-Y. Riou, C.-Y. Angel, Radiology, Marie-Lannelongue Hospital, Le Plessis-Robinson, France

11:50 AM (222) Mechanism and Prevention of Tricuspid Valve Regurgitation After Orthotopic Heart Transplantation; C. Knosalla,¹ M. Dandel,¹ S. Buz,¹ F. Knollmann,² Y.-G. Weng,¹ M. Pasic,¹ O. Grauhan,¹ H.B. Lehmkuhl,¹ R. Hetzer,¹ Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Department of Radiology, Charite-University Medicine Berlin, Berlin, Germany

11:55 AM (223) Effects of a Phosphodiesterase Type 5 Inhibitor (Sildenafil) Evaluated by 24-Hour Blood Pressure Monitoring and Exercise Capacity in Heart Transplanted Patients. A Double-Blind, Placebo-Controlled, Cross-Over, Randomized Study. Preliminary Results; G.V. Guimaraes, V.M. d'Avila, P.V. Pires, F.D. Cruz, N.A. Stolf, P.R. Chizzola, E.A. Bocchi, Heart Institute (InCor), University Sao Paulo Medical School, Sao Paulo, Brazil

NOON (224) The Cumulative Effect of Acute Rejection on the Development of Cardiac Allograft Vasculopathy; S.C. Stoica, F. Cafferty, M. Pauriah, C.J. Taylor, L.D. Sharples, J. Wallwork, S.R. Large, J. Parameshwar, Transplantation, Papworth Hospital, Cambridge, United Kingdom

12:05 PM (225) Improving Clinical Practice: Should We Give Influenza Vaccinations to Heart Transplant Patients? C. White-Williams,¹ R. Brown,¹ J. Kirklin,¹ K. St. Clair,³ S. Keck,² J. O'Donnell,⁴ D. Pitts,⁴ A. Van Bakel,⁵ ¹University of Alabama at Birmingham, Birmingham, AL; ²Massachusetts General Hospital, Boston, MA; ³Mid America Heart Institute of St. Luke's Hospital, Knasas City, MO; ⁴Clarian Health Partners, Indianapolis, IN; ⁵Medical University of South Carolina, Charleston, SC

12:10 PM (226) Comparison of Non-Invasive Versus Invasive Monitoring for Detection of Heart Transplant Rejection and Cardiac Vasculopathy in Cardiac-Transplant Recipients; E. Usta,¹ C. Burgstahler,² S. Schroeder,² A. Kuettner,³ A.F. Kopp,³ G. Ziemer,¹ H. Aebert,¹ Department of Thoracic, Cardiac and Vascular Surgery, University of Tuebingen; ²Department of Internal Medicine, Division of Cardiology; ³Department of Diagnostic Radiology, University of Tuebingen, Tuebingen, Germany

12:15 PM (227) Interleukin-6, C-Reactive Protein and Cardiac Allograft Vasculopathy; C.A. Labarrere,¹ M.A. Ortiz,¹ H.L. DiCarlo,¹ G.L. Campana,¹ M.J. Sosa,¹ C.L. Terry,¹ D.E. Pitts,² D.A. Hormuth,² M.C. Deng,³ ¹ImmunoPathology, Methodist Research Institute, Clarian Health Partners, Inc., Indianapolis, IN; ²Clarian Health Transplant Center, Clarian Health Partners, Inc., Indianapolis, IN; ³Heart Failure Center Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY

12:20 PM (228) Value of pro-BNP Determinations in the Follow-Up of Heart Transplantation; A. Cuppoletti,¹ E. Roig,¹ P.-V. Felix,¹ V. M Isabel,¹ A. Rivera,¹ C. Botta,¹ J. Orus,¹ E. Marin,¹ ¹Cardiovascular Institute, Hospital Clinic, Barcelona, Spain

12:25 PM (229) Sirolimus in Heart Transplantation: A Single Center Experience; M. Walravens,¹ M. Vanderheyden,² M. Goethals,² B. Vanvlem,³ J. De Meester,³ N. Kerre,² F. Wellens,¹ ¹Cardiovascular Surgery, Onze Lieve Vrouw Clinic, Aalst, Belgium; ²Cardiology, Onze Lieve Vrouw Clinic, Aalst, Belgium; ³Nephrology, Onze Lieve Vrouw Clinic, Aalst, Belgium

12:30 PM (230) Low Mannose-Binding Lectin and Increased Complement Activation Correlate to Allograft Vasculopathy and Rejection After Human Heart Transplantation; A.E. Fiane,¹ T. Ueland,¹ S. Simonsen,¹ H. Scott,¹ P. Aukrust,¹ T.E. Mollnes,¹ Department of Thoracic and Cardiovascular Surgery, Rikshospitalet University Hospital; Research Institute for Internal Medicine; Department of Cardiology; Department of Pathology; Section of Clinical Immunology and Infection Diseases, Medical Department; Institute of Immunology, Rikshospitalet University Hospital, Oslo, Norway

12:35 PM (231) Aggressive Anti-Cytomegalovirus Prophylaxis and Acute Rejection in High Risk Patients: Beat the Virus and Prevent the Rejection; L. Potena,¹ C. Holweg,¹ H. Luikart,¹ E. Mocarski,¹ D. Lewis,¹ J. Cooke,¹ C. Chin,¹ S. Hunt,¹ H. Valentine,¹ ¹Stanford University, Stanford, CA

12:40 PM (232) Coronary Perfusion Pressure Is a Critical Determinant of Expression of B-Type Natriuretic Peptide in Pulmonary Arterial Hypertension; P.A. Uber,¹ M.H. Park,¹ R.L. Scott,¹ M.H. Richie,¹ M.R. Mehra,¹ ¹Cardiomyopathy and Heart Transplantation, Ochsner Clinic Foundation, New Orleans, LA

11:45 AM-12:45 PM

MINI-ORAL POSTER PRESENTATION SESSION 6 (Salon CD)

Moderators: James B. Young, MD and Tom Egan, MD

11:45 AM (233) Anemia Is Common in Patients Referred for Heart Transplant and Hemoglobin Is Related to Prognostic Factors but Is Not an Independent Survival Predictor; A.B. Taegtmeier,¹ A.M. Crook,² N.R. Banner,¹ ¹Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Westminster Primary Care Trust, London, United Kingdom

11:50 AM (234) Cardiac Power Output Is a Primary Determinant of B-Type Natriuretic Peptide Expression in Severe Heart Failure; M.R. Mehra,¹ P.A. Uber,¹ R.L. Scott,¹ M.H. Park,¹ M. Richie,¹ H.O. Ventura,¹ ¹Cardiomyopathy and Heart Transplantation, Ochsner Clinic Foundation, New Orleans, LA

11:55 AM (235) Simplified Prognostic Models for the Assessment of Ambulatory Heart Failure; I. Bolad,¹ A. Taegtmeier,¹ S. Bond,² S. Bentzen,² N. Banner,¹ ¹Transplant Unit, Harefield Hospital, Middlesex, United Kingdom; ²Medical Statistics, Mount Vernon Hospital, Middlesex, United Kingdom

NOON (236) Association of G3-Subclass Auto-Abs and NYHA Functional Status in Clinical Peripartum Cardiomyopathy; R. Warraich,¹ J. Fett,³ M. Frenneaux,⁴ K. Sliwa,² M. Yacoub,¹ ¹Cardiothoracic Surgery, Harefield Hospital, London, United Kingdom; ²Cardiology, Baragwanath Hospital, Johannesburg, South Africa; ³Adult Medicine, Hospital Albert Schweitzer, Deschappellers, Haiti; ⁴Cardiology, Quebec Hospital, Birmingham, United Kingdom

12:05 PM (237) Digoxin Therapy Increases Mortality Only in Female Heart Patients With a Prolonged QTc Interval; B. Vrtovec,¹ R.M. Delgado,¹ I.D. Gregoric,¹ R. Radovancevic,¹ B. Radovancevic,¹ ¹Transplant Research, Texas Heart Institute, Houston, TX

12:10 PM (238) Glycine Supplementation to LPD Flush Preservation or as i.v.-Donor Preconditioning Improves Early Graft Function in a Porcine Single Left Lung Transplantation Model after 24 Hours of Cold Ischemia; B. Gohrbandt,¹ S.P. Sommer,¹ G. Warnecke,¹ S. Fischer,¹ A. Haverich,¹ M. Strueber,¹ ¹Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany

12:15 PM (239) The Role of the (Beta)-Adrenergic Receptor Kinase in Myocardial Dysfunction Following Brain Death; P.K. Pandalai,¹ J.M. Lyons,² J.Y. Duffy,² K.M. McLean,² C.J. Wagner,² J.M. Pearl,² W.H. Merrill,¹ S.A. Akhter,¹ ¹Division of Cardiac Surgery, University of Cincinnati College of Medicine, Cincinnati, OH; ²Pediatric Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH

12:20 PM (240) Recovery of Alveolar Microcirculation After Lung Transplantation in a Pig Model: Direct Visualization by OPS Imaging; N. Pizanis,¹ V. Milekhin,¹ M. Kamler,¹ K. Kaiser,¹ I. Aleksic,¹ T. Ley,¹ H. Jakob,¹ ¹Dept of Thoracic and Cardiovascular Surgery, West German Heart Center Essen, University Hospital of Essen, Essen, Germany

12:25 PM (241) The Effect of Time From Donor Brain Death to Retrieval on Reperfusion Injury After Lung Transplantation; V.S. Avlonitis,¹ J.A. Kirby,¹ J.H. Dark,¹ ¹School of Surgical and Reproductive Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom

12:30 PM (242) Should Transplant Centres Retrieve Their Own Hearts or Can Others Do It?; J.S. Ganesh,¹ C.A. Rogers,¹ N.R. Banner,¹ R.S. Bonser,¹ ¹On Behalf of the Steering Group, UK
¹Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

12:35 PM (243) Equity Effects of Implementation of a New Lung Allocation Policy; R.T. Bustami,¹ T.E. Hulbert-Shearon,² S. Murray,² K.P. McCullough,¹ A.M. Rodgers,¹ R.A. Wolfe,² T. Egan,³ R.M. Merion,² ¹Research, SRTR/URREA, Ann Arbor, MI; ²Research, SRTR/University of Michigan, Ann Arbor, MI; ³Surgery, University of North Carolina, Chapel Hill, NC

1:15 PM-2:45 PM

CONCURRENT SESSION 29

New Horizons and Unexpected Dangers in Cardiac Transplantation (Salons G-L)

Moderators: Jayan Parameshwar, FRCP and G. William Dec, MD

1:15 PM (244) Heart Transplantation for Amyloidosis; C.G.A. McGregor,¹ B.S. Edwards,¹ R.J. Rodeheffer,¹ R.P. Frantz,¹ S.S. Kushwaha,¹ A.L. Clavell,¹ J.A. Dearani,¹ T.M. Sundt,¹ R.C. Daly,¹ ¹Mayo Clinic William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

1:30 PM (245) Heart Transplantation for Adults With Congenital Heart Disease: A UK National Study; J.S. Ganesh,¹ C.A. Rogers,¹ R.S. Bonser,¹ N.R. Banner,¹ ¹On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

1:45 PM (246) Orthotopic Heart Transplantation in Patients With Cardiac Amyloidosis; S.S. Sudhakar,¹ D.R. Bijmalangshu,¹ R.H. Falk,² T.R. Spitzer,¹ S.L. McAfee,¹ W.G. Dec,¹ D.G. Thomas,¹ R.J. Hajjar,¹ T.G. Wang,¹ T.E. MacGillivray,¹ J.C. Madsen,¹ M.J. Semigran,¹ ¹Massachusetts General Hospital, Boston, MA

2:00 PM (247) Correlation of Outcomes With C4d in Patients With Cardiac Allograft Dysfunction; S.E. Fedson,¹ A.M. Safley,² A.Y. Kim,¹ A.N. Husain,² A.S. Anderson,¹ ¹Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL; ²Department of Pathology, University of Chicago, Chicago, IL

2:15 PM (248) Thromboembolism in Heart Transplantation: Role of Prothrombin G20210A and Factor V Leiden; S.G. Miriuka,¹ L.J. Langman,² J. Evrovski,² S.E. Miner,¹ S. Kozuszko,¹ N. D'Mello,¹ B.Y. Wong,² D.H. Delgado,¹ H.J. Ross,¹ D.E.C. Cole,² ¹Internal Medicine, Toronto General Hospital; ²Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada

2:30 PM (249) Heart Transplantation in Patients With Marfan's Syndrome; C. Knosalla,¹ Y.-G. Weng,¹ R. Hammerschmidt,¹ O. Grauhan,¹ H.B. Lehmkuhl,¹ M. Dandel,¹ R. Hetzer,¹ ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

1:15 PM-2:45 PM

CONCURRENT SESSION 30

Outcomes Before and After Lung Transplantation (Salon ABF)

Moderators: Lianne G. Singer, MD, FRCPC and Reda Girgis, MB, BCh

1:15 PM (250) The Effect of Gender on Outcome in Human Lung Transplantation: The ISHLT Registry Experience;

M. Sato,¹ C. Gutierrez,² H. Kaneda,¹ M. Liu,¹ T.K. Waddell,¹ S. Keshavjee,¹ ¹Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada; ²Respiratory Medicine, Toronto General Hospital, Toronto, Ontario, Canada

1:30 PM (251) NT-proANP and BNP Predict the Risk of Death in Patients With Pulmonary Arterial Hypertension (PAH); S.M. Kawut, K.K. Berekashvili, E.M. Horn, A.C. Widlitz, E.B. Rosenzweig, R.J. Barst, ¹Department of Medicine, College of Physicians and Surgeons; ²Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY

1:45 PM (252) The Effect of Recipient's Age on Lung Transplant Outcome; C.A. Gutierrez,¹ S. Al-Faifi,¹ C. Chaparro,¹ T. Waddell,¹ D. Hadjilias,¹ L. Singer,¹ S. Keshavjee,¹ M. Hutcheon,¹ ¹Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada

2:00 PM (253) Evidence for Reduced SMAD Signalling in Diverse Forms of Pulmonary Arterial Hypertension (PAH); M.R. Southwood, C. Atkinson, S. Stewart, R.C. Trembath, N.W. Morrell, ¹Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom

2:15 PM (254) Gender and Body Mass Index (BMI) Are Associated With Poor Functional Status One Year Post Lung Transplant Independent of Effects on Early Mortality; Sager,¹ J.S. Kotloff,¹ Ahya,¹ Simcox,² Blumenthal,¹ Mendez,³ Bilker,³ Pochettino,⁴ Christie,³ ¹Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania Medical Center; ²Division of Respiratory Services, University of Pennsylvania Medical Center.; ³Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine; ⁴Division of Thoracic Surgery, University of Pennsylvania Medical Center, Philadelphia, PA

2:30 PM (255) Survival Benefit in Patients With End Stage COPD After Lung Transplantation; G. Winkler,¹ P. Jaksch,¹ S. Geleff,² M. Alber,¹ W. Klepetko,¹ ¹Cardiothoracic Surgery, General Hospital Vienna, University Vienna, Vienna, Austria; ²Clinical Pathology, General Hospital Vienna, University Vienna, Vienna, Austria

1:15 PM-2:45 PM

CONCURRENT SESSION 31

Aristotle's Corner (Salon E)

Moderators: Anne Keogh, MBBS, MD and Bruce R. Rosengard, MD, FRCS, FACS

1:15 PM (256) The Future of Tolerance; J.C. Madsen,¹ Cardiac Surgery, Massachusetts General Hospital, Boston, MA

1:30 PM (257) The X-Files of Immunosuppression (or What's Stronger in Transplant Medicine, Rationality or Irrationality?); A. Zuckermann,¹ Department of Cardio-Thoracic Surgery, Med-University of Vienna, Vienna, Austria

1:45 PM (258) Determination of the Differences in Cellular Three Dimensional Solvent Accessible Molecular Surfaces Generated by HLA Polymorphisms; Potential Role in Clinical Solid Organ Transplantation; O.E. Pajaro,¹ Thoracic Transplantation, Mayo Clinic, Jacksonville, FL

2:00 PM (259) Long-Term Outcome: What Do You Mean? J. Vanhaecke,¹ W. Droogne,¹ J. Van Cleemput,¹ W. Daenen,² Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium; ²Department of Cardiac Surgery, University Hospital Gasthuisberg, Leuven, Belgium

2:15 PM (260) Society's Self-Imposed Standards Infringe on Personal Liberty and Markedly Reduce Availability of Donor Organs; a Case for Self-Directed Heart Donation; D.S. Feldman,¹ D. Biniakiewicz,¹ C.V. Leier,¹ Department of Medicine/Division of Cardiology, The Ohio State University, Columbus, OH

2:30 PM (261) WITHDRAWN

1:15 PM-2:45 PM

CONCURRENT SESSION 32

Toward Tolerance and Experimental Cardiac Transplantation (Salon CD)

Moderators: Thomas D. Wekerle, MD and James F. George, PhD

1:15 PM (262) Selective CD28 Blockade by a Single-chain Fv Inhibits T Cell Proliferation and Prevents Acute Rejection in a Murine Model of Cardiac Allograft Transplantation; T. Zhang,¹ H. Zhou,¹ G. Wu,¹ R.M. O'Hara Jr.,² R.N. Pierson III,¹ A.M. Azimzadeh,¹ Division of Cardiac Surgery, University of Maryland, SOM and VAMC, Baltimore, MD; ²Wyeth Research, Cambridge, MA

1:30 PM (263) Overexpression of Neonatal Isoform of Cardiac Myosin in Donor Hearts Results in Prolongation of Graft Survival; M. Zwierzchniewska,¹ J. Robbins,² R.C. Robbins,¹ E.V. Fedoseyeva,¹ CT Surgery, Stanford University, Stanford, CA; ²Molecular Cardiovascular Biology, Children's Hospital, Cincinnati, OH

1:45 PM (264) Tolerance to Cardiac Allografts in Miniature Swine Using Donor-Specific Transfusions Combined With Cyclosporine but Not With Rapamycin; R. Hoerbelt,¹ T. Shoji,¹ A. Muniappan,¹ D.A. Guenther,¹ S.L. Houser,¹ J.S. Allan,¹ M. Bravard,¹ D.H. Sachs,¹ J.C. Madsen,¹ Surgery, Massachusetts General Hospital, TBRC, Charlestown, MA

2:00 PM (265) Heart and en-bloc Thymus Transplantation in Cynomolgus Monkeys; A. Muniappan,¹ D.R. Johnston,¹ D.A. Guenther,¹ T. Shoji,¹ S. Boskovic,¹ R. Hoerbelt,¹ S.L. Houser,¹ J.S. Allan,¹ K. Yamada,¹ T. Kawai,¹ J.C. Wain,¹ D.H. Sachs,¹ J.C. Madsen,¹ Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA

2:15 PM (266) Cytotoxic Hyporesponsiveness Is Associated with High IL-10 mRNA Expression in Immunosuppressed Cardiac Allograft Patients; E. Dijke,¹ J. Velthuis,¹ A. Balk,² S. Korevaar,¹ L. Maat,² W. Weimar,¹ C. Baan,¹ Internal Medicine, Erasmus MC; ²Thorax Center, Erasmus MC, Rotterdam, Netherlands

2:30 PM (267) Interleukin-10 Reduces Endothelium-Dependent T Cell Costimulation Through Upregulation of Suppressor of Cytokine Signaling-3 and Immunoglobulin-Like Transcript 3 and 4; C.A. Gleissner,¹ R. Klingenberg,¹ M.H. Konstandin,¹ S. Celik,¹ T.J. Dengler,¹ Department of Cardiology, University of Heidelberg, Heidelberg, Germany

2:45 PM-3:00 PM

Coffee Break (Ballroom Pre-Function)

3:00 PM-4:30 PM

CLOSING PLENARY SESSION (Salons G-L)

Moderators: Mark L. Barr, MD and John Dark, MB, FRCS

3:00 PM **Invited Lecture: Revisiting Listing Criteria for Heart**, Mandeep Mehra, MD, Oschner Medical Institutions, New Orleans, LA; Mariell Jessup, MD, University of Pennsylvania, Philadelphia, PA; Eduardo Gronda, MD, Instituto Clinico Humanitas, Milan, Italy

3:20 PM **Invited Lecture: Revisiting Listing Criteria for Lung**, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD

3:40 PM **Invited Lecture: Primary Graft Dysfunction Update**, Jason D. Christie, MD, University of

Pennsylvania, Philadelphia, PA

4:00 PM **DEBATE: Cell Therapy is a Myth**

PRO: Bruce R. Rosengard, MD, FRCS, FACS, Papworth Hospital Surgical Unit, Cambridge, United Kingdom

CON: Axel Haverich, MD, Hannover Medical School, Hannover, Germany

4:30 PM ADJOURN

EXHIBIT FLOOR PLANS

EXHIBITING COMPANIES	Booth #
Arrow International	108
Abbott laboratories	109
MedImmune, Inc.	112
Actelion	113
Home Solutions	114
Vitrolife, Inc.	115
ISHLT Registry	116
Ventracor Limited	117
United Network for Organ Sharing	118
MicroMed Technology, Inc.	208
Scios	212
Berlin Heart AG	216
Roche	300
XDx	312
Novartis	400
Thoratec Corporation	409
Chiron BioPharmaceuticals	412
Genzyme	413
Abiomed, Inc.	415
Fujisawa Healthcare, Inc.	500
World Heart Inc.	501
Therakos	505
Syncardia Systems, Inc.	507
Scanlan International, Inc.	508
Ceres Medical Systems, LLC	509
CHF Solutions, Inc.	510
Miller Pharmacal Group, Inc.	511
Vital Engineering	512
Medical Insight Research	513
Argon Medical Devices, Inc.	514
Elsevier	515
Haemoscope Corp	516
HRA Research	517

EXHIBITORS

Abbott Laboratories

200 Abbott Park Road

Abbott Park, IL 60064

Web site: www.abbott.com

Abbott Laboratories is a global organization committed to researching Acute Decompensated Heart Failure (ADHF).

Abiomed, Inc.

22 Cherry Hill Drive

Danvers, MA 01923

Website: www.abiomed.com

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS[®] 5000 Biventricular Support System and the AB5000[™] Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. In September 2004, ABIOMED applied for initial FDA market approval for the AbioCor Implantable Replacement Heart to treat a defined subset of irreversible end-stage heart failure patients under a Humanitarian Device Exemption

Actelion Pharmaceuticals

Argon Medical Devices, Inc.

1445 Flat Creek Road

Athens, TX 75751

Website: www.argonmedical.com

Argon Medical devices, Inc. manufactures and markets wide variety vascular products. Products offered includes Angiography Kits, Introducers, Micro-Introducers, Stainless Steel and Hydrophilic Nitinol Gude wires, Manifolds, Stopcocks, Pressure Lines, Monitor Lines, Control Syringes, Color Coded Medicine Syringes Endomyocardial Biopsy Forceps, Transducers, Pressure Monitoring Kits and Arterial Needles.

Arrow International

Hill & George Ave
Reading, PA 19610
Website: www.arrowinternational.com

The LionHeart™ LVAD is now CE marked and is the only fully implantable LVAD designed for destination therapy of heart failure patients. The LionHeart features pulsatile flow with transcutaneous energy transmission offering patient's hope and a good quality of life.

Astellas Pharma, Inc.
(Formerly Fujisawa Healthcare, Inc.)
3 Parkway North
Deerfield, IL 60015
Website: www.astellas.com

Berlin Heart AG
Wiesenweg 10
Berlin, Germany 12242
Website: www.berlinheart.com

INCOR® - implantable third generation axial flow LVAD system with unique contact free magnetically levitated impeller.
EXCOR® - extracorporeal pneumatically driven Uni/BiVAD system with a full range of pumps and cannulas for support of all patient sizes from newborn to adult.

Ceres Medical Systems, LLC
4665 Sweetwater Blvd
Suite 104
Sugar Land, TX 77479

CHF Solutions, Inc.
7601 Northland Dr.
Ste 170
Brooklyn Park, MN 55428
Website: www.chfsolutions.com

Aquapheresis enables predictable, mechanical isotonic solute removal with no clinically significant impact on electrolytes in volume overloaded patients. An advanced form of therapeutic apheresis with selective ultrafiltration, aquapheresis using the Aquadex system (CHF Solutions, Inc.) and its low extracorporeal blood volume (37 cc) and blood flow (20-40 cc/min) empowers a physician to select safe, predictable isotonic saline removal rates (10-500 ml/hour) using a variety of venous access sites (central, peripheral, midline, standard IV). Able to be performed in virtually any clinical setting, the safety, efficacy, and efficiency of the

Aquadex make aquapheresis the gold standard in salt and water removal.

Chiron BioPharmaceuticals

4560 Horton Street
Emeryville, CA 94608
Website: www.chiron.com

Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a difference in people's lives. The company has a strategic focus on cancer and infectious disease to develop products from its platforms in proteins, small molecules and vaccines. The company commercializes its products through three business units: BioPharmaceuticals, Vaccines and Blood Testing. For more information about Chiron, visit the company's website at www.chiron.com.

Elsevier

625 Walnut St
Suite 300
Philadelphia, PA 19106
Website: www.elsevier.com

Elsevier, a premier worldwide health science publishing company featuring the Saunders, Mosby, Churchill Livingstone, Butterworth Heinemann, and the Hanley-Belfus imprints, is proud to publish "The Journal of Heart and Lung Transplantation", the Official Publication of the International Society for Heart and Lung Transplantation.

Please visit us to browse our complete selection of publications in Transplantation, Surgery, and Cardiovascular Medicine including books, periodicals and software.

Genzyme

500 Kendall Street
Cambridge, MA 02478
Website: www.genzyme.com

Genzyme is a leader in the effort to address a range of unmet medical needs. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant and immune disease, cancer, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial research and development program focused on genetic diseases, immune system disorders, heart disease, and cancer.

Haemoscope Corp.

6231 W. Howard
Niles, IL 60714
Website: www.haemoscope.com

TEG® Hemostasis Analyzer: Point-of-care whole-blood instrument that provides a complete picture of all phases of patient hemostasis; delivers an analysis more comprehensive and complete in conventional, Isolated laboratory tests; helps clinicians make faster, more well-informed diagnoses for better treatment and clinical outcomes; reduces costs associated with decreased blood product and pharmaceutical use.

Home Solutions, Infusion Therapy

HRA Research

400 Lanidex Plaza
Parsippany, NJ 07054
Website: www.hraresearch.com

Our team of experienced interviewers will be distributing carefully developed questionnaires. We'll be gathering the answers to vital marketing and clinical questions-answers that can affect the introduction of new products or the continuation of existing health care products and services.

ISHLT Registry

700 North 4th Street
Richmond, VA 23219

The International Registry for Heart and Lung Transplantation provides on-going, current information on the worldwide thoracic organ transplantation experience. Additionally, we maintain the Mechanical Circulatory Support Device Database to collect data on the implantation and outcomes of patients receiving cardiac assist devices. The data, utilized for scientific study, contributes to the body of knowledge regarding thoracic transplantation and cardiac device management. Our goal is to identify overall best practices for improving cardiothoracic patient care.

This year the exhibit will make your center-specific information available for your review. In addition, members can view data screens from both the ISHLT Registry and the MCSDB Database and receive guidance on enrollment, training on submission of data and instructions for submitting special data requests.

Medical Insight Research

25 Burlington Mall Road, 6th Floor

Burlington, MA 07803

Medical Insight Research is an economic consulting firm focused on the pharmaceutical and biotechnology industry. They provide a variety of services including pricing research, product positioning, and launch planning.

MedImmune, Inc.

One MedImmune Way
Gaithersburg, MO 20878
Web site: www.medimmune.com

MedImmune, Inc. is dedicated to advancing science and medicine to help people live better lives. The biotechnology company is focused on pediatric infectious diseases, cancer and inflammatory diseases. CytoGam® (cytomegalovirus immune globulin intravenous (human) (CMV-IVIG) is indicated for prophylaxis associated with transplantation of the kidney, lung, liver, pancreas and heart.

MicroMed Technology, Inc.

8965 Interchange Drive
Houston, TX 77054
Web site: www.micromedtech.com

MicroMed, a leader in miniaturized implantable VADs, will present the DeBakey VAD® and the DeBakey VAD *Child*. Developed in collaboration with NASA, Drs. Michael DeBakey and George Noon, the DeBakey VAD is currently in pivotal trials across the US for evaluation as both BTT and Destination Therapy. The DeBakey VAD is 1/10 the size of pulsatile devices designed to be highly durable and provide full left ventricular support in a broad range of BSA. The DeBakey VAD *Child* is the only commercially approved (HDE) implantable VAD for children. They both have been awarded the CE mark for distribution in Europe.

Miller Pharmacal Group, Inc.

350 Randy Road, Ste. #2
Carol Stream, IL 60188
Web site: www.millerpharmaca.com

Miller Pharmacal features the oral magnesium supplement “MG Plus Protein.” Currently in use at many transplant centers (solid organ and BMT), “MG Plus Protein” treats and prevents the hypomagnesemia caused by immunosuppressants, without causing the GI disturbances common with magnesium oxide.

The diarrhea commonly caused by magnesium oxide complicates maintaining immunosuppressant levels; in addition to being a large quality-of-life for patients (and a

major cause of noncompliance).

“MG Plus Protein” is inexpensive, a 500-tablet bottle is available for \$31.00; a fraction of the cost of “Slow-Mag.” Professional samples and an indigent patient program are available.

Novartis Pharmaceuticals Corporation

One Health Plaza

East Hanover, NJ 07936

Web Site: www.Novartis/transplantation

Roche

PBC Congresses

Bldg 74/40.409

4040 Basel, Switzerland

Web site: www.roche.com

Scios, Inc.

6500 Paseo Padre Parkway

Fremont, CA 94555

Web site: www.hoovers.com

Scios Inc., a Johnson & Johnson biopharmaceutical company, is dedicated to changing the way

Heart failure is treated and is developing new and exciting therapeutics for cardiovascular disease, inflammatory disease and cancer. With its flagship product, Natrecor® (nesiritide), Scios proved that its winning combination of integrated research, clinical experience, and passionate commitment to patients with unmet medical needs can make a difference in the management of disease. Applying the same experience and commitment, Scios is advancing a new potential treatment for advanced chronic heart failure and is developing novel potential therapies in inflammatory disease and cancer for patients with unmet medical needs.

Scanlan International, Inc.

One Scanlan Plaza

Saint Paul, MN 55107

Website: www.scanlangroup.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Offering a wide array of Titanium Needle Holders, forceps and clamps and stainless steel instrumentation, including Resano forceps, Scanlan SUPER CUT™ and ULTRA SHARP® scissors, Scanlan DIAMOND DUST™ instrumentation. Scanlan offers a wide variety of custom modifications to accommodate surgeons' specific needs. Single-use products include SCANLAN® Surg-I-Loop® PLUS, single-use aorta/vein punch, A/C LOCATOR® and RADIOMARK® graft markers, Vascu-Stat® single-use

bulldog clamps, as well as SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers.

Scios, Inc.

6500 Paseo Padre Parkway
Freemont, CA 94555
Web Site: www.scios.com

Syncardia Systems, Inc.

1992 E. Silverlake Road
Tucson, AZ 85713
Website: www.syncardia.com

Thoratec Corporation

6035 Stoneridge Dr.
Pleasanton, CA 94588

Thoratec Corporation, the pioneer of and leader in ventricular assist devices (VADs) offers a full line of technologically advanced devices for the restoration of hemodynamics designed to meet the needs and provide a better quality of life for the widest range of patients experiencing heart failure. Only Thoratec offers both FDA approved implantable and paracorporeal ventricular assist devices for a full range of indications including postcardiotomy support, bridge to cardiac transplantation and Destination Therapy. Our HeartMate LVAS, Thoratec VAD and IVAD™ Systems are ideally suited for short to long term, left, right or biventricular support in patients of almost any size.

Therakos

437 Creamery Way
Exton, PA 19341
Web site: www.therakos.com

United Network for Organ Sharing (UNOS)

700 N. 4th Street
Richmond, VA 23219
Web site: www.unos.com

UNOS is a 501 (c) 3 non-profit, scientific, educational and charitable organization that oversees the national Organ Procurement and Transplantation Network (OPTN). Responsibilities include: facilitating organ donation through research, education and advocacy; managing the U.S. transplant waiting list matching donors to recipients; maintaining a database that monitors U.S. transplant recipients; and, through private, charitable funding working to increase organ availability and continuously improve the outcomes and quality of life of transplant candidates and recipients.

Ventricor Limited

126 Greville Street
Chatswood, NSW 2067 Australia
Website: www.ventracor.com

The VentrAssist™ LVAS Left Ventricular Assist System
The VentrAssist™ Left Ventricular Assist System (LVAS) has been developed as a solution for patients requiring circulatory support, be that as destination therapy or bridge to transplant. It is capable of delivering 10L/min at 120mmHg. The unique, hydrodynamically suspended “open flow rotor” eliminates poits of wear, local heating and flow disturbance which can lead to device failure and thrombus formation. In pre-clinical and clinical trialing the VentrAssist™ LVAS has shown exceedingly low levels of hemolysis. Its small size suits it for use in a wide range of patients.

Vital Engineering

330 Scaife Hall
200 Lathrop St
Pittsburgh, PA 15213
Web site: www.vitalengineering.com

Vital Engineering provides training and educational programs for physicians and other health care providers as well s on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnerships benefits to patients, clinicians, hospitals, and industry.

Vitrolife, Inc.

3601 S. Inca Street
Englewood, CO 80110
Web site: www.vitrolife.com

Perfadex is a colloid containing lightly buffered extracellular low K+ electrolyte solution for rapid cooling, perfusion and storage of organs in connection with transplantation. Perfadex is the gold standard in lung preservation.

World Heart Inc.

7799 Pardee Lane
Oakland, CA 94621
Web site: www.worldheart.com

WorldHeart, a worldwide pioneer and technology leader in mechanical circulatory support systems, is a global medical device company with offices in Oakland, California, Heesch, The Netherlands, and Ottawa, Canada. WorldHeart is currently focused on the development and commercialization of ventricular assist devices. Its Novarcor® LVAS, which has unprecedented reliability and durability, is well established in the marketplace. It is the first ventricular assist device to provide a recipient with more than 6 years of circulatory support and continues to hold the industry record for longest support on a single device, over 45 years.

WorldHeart recently acquired Medquest, developer of a magnetically levitated centrifugal rotary blood pump making WorldHeart the only company with small, silent, next-generation pulsatile and rotary systems under development, as well as having the most durable and reliable current-generation pulsatile device in the market today.

XDx

701 Gateway Blvd, Suite 100
South San Francisco, CA 94080
Web site: www.xdx.com

LINED NOTE PAGES

FUTURE ISHLT MEETINGS

November 11-12 , 2005
7th ISHLT Fall Education Meeting
Immediately Prior to the AHA Annual Meeting
Dallas, TX, USA

APRIL 5-8, 2006
ISHLT 26TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
Madrid, Spain

APRIL 25-28, 2007
ISHLT 27TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
San Francisco, CA